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ABBREVIATIONS
ABCB5: ATP-binding cassette, sub-family B, 
member number 5 
ALDH1: aldehyde dehydrogenase 1 
AML: acute myeloid leukemia 
BHD: Birt-Hogg-Dubé 
BMDC: bone marrow-derived cell 
BMP: bone morphogenetic protein 
BMPC: bone marrow-progenitor cell 
CAF: cancer associated fibroblast 
CA-IX: carbonic anhydrase-IX 
ccRCC: clear cell RCC 
CD105: Endoglin 
CD133: Prominin-133 
cfDNA: circulating free DNA 
CFS: cancer-free survival 
chRCC: chromophobe RCC 
c-MET: tyrosine-protein kinase Met 
CRC: colorectal carcinoma 
CSC: cancer stem cell 
CSS: cancer-specific survival 
CT: computed tomography 
CTC: circulating tumor cell 
ctDNA: circulating tumor DNA 
CTLA-4: cytotoxic T-lymphocyte-associated 
antigen 4 
CXCL8: CXC motif ligand 8 
CXCR4: CXC-chemokine receptor 4 
DC: dendritic cell 
DFS: disease-free survival 
ECM: extra-cellular matrix 
EGF: epidermal growth factor 
EGFR: EGF receptor 
EMT: epithelial-mesenchymal transition 
EPO: erythropoietin 
ERK: extracellular signal-regulated kinase 
EV: extracellular vesicle 
FACS: fluorescent-activated cell sorting 
FAK: focal adhesion kinase 
FGF: fibroblast growth factor 
FGFR: FGF receptor 
FISH: fluorescence in situ hybridization 
Glut1: glucose transporter 1 
GPCR: G protein-coupled receptor 
HA: glycosaminoglycan hyaluronan 
HCC: hepatocellular carcinoma 
HDAC1: histone deacetylase 1 
HGF: hepatocyte growth factor 
HIF: hypoxia-inducible factor 
HLA-G: human leukocyte antigen G 
HLRCC: hereditary leiomyomatosis RCC 
HRE: hypoxia-responsive elements 
HSP: heat shock family proteins 
IFNα: interferon-α 
IGF-1: insulin-like growth factor-1 
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IHC: immunohistochemistry 
IL-15: interleukin-15 
IL-1β: interleukin-1β 
IL-2: interleukin-2 
IL-6: interleukin-6 
IL-8: interleukin-8 
JAK: Janus kinase 
LDA: limiting dilution assay 
LOH: loss of heterozygosity 
MACS: magnetic beads-conjugated antibodies 
MAPK: mitogen-activated protein kinase 
MDSC: myeloid-derived suppressor cell 
MEK: mitogen-activated protein kinase kinase 
MET: mesenchymal-epithelial transition 
miRNA: microRNA 
MMP: matrix metalloproteinases 
MRI: magnetic resonance imaging 
MSC: mesenchymal stem cell 
mTOR: mammalian target of rapamycin 
MVB: multivesicular body 
n.s.: non-significant 
NF-kB: nuclear factor-kappa B 
NK: natural killer 
NSCLC: non-small-cell lung cancer 
NSG: NOD scid gamma
OCD: dissociated tumor cells 
OS: overall survival 
PCR: polymerase chain reaction 
PD-1: programmed death 1 
PDGF: platelet-derived growth factor 
PDGFR: PDGF receptor 
PD-L1: PD-1 ligand 
PHD: prolyl hydroxylase domain protein 
PI3K: phosphatidylinositol-3 kinase 
PKC: protein kinase C 
PLC: phospholipase C 
pRCC: papillary RCC 
RCC: renal cell carcinoma 
RFS: recurrence-free survival 
Rh123: Rhodamine 123 
RT-PCR: real time-PCR 
SCF: stem cell factor 
SDF1: CXC chemokine stromal cell-derived 
factor 1 
SDH-RCC: succinate dehydrogenase RCC 
siRNA: small interfering RNA 
SNP: single nucleotide polymorphism 
SP: side population 
STAT: signal transducers and activators of 
transcription 
TAM: tumor-associated macrophage 
TEM: transmission electron microscopy 
TGF: transforming growth factor 
TGFβ: transforming growth factor β 
TKI: tyrosine kinase inhibitor 
TMA: tissue microarray 
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TMA: tumor-associated macrophage 
TME: tumor microenvironment 
TNA: tumor-associated neutrophil 
TNFα: tumor necrosis factor α 
TNM: tumor, lymph nodes, metastasis 
TS: tuberous sclerosis 
UCH: ubiquitin C-terminal hydrolase 
   
VEGF: vascular endothelial growth factor 
VEGFR: VEGF receptor 
VHL: von Hippel-Lindau 
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ABSTRACT 
Renal cell carcinoma (RCC) represents the most common malignancy affecting the adult kidney. Accounting 
for 2 % of all cancers, RCC lays among the 10 most common cancers worldwide. In particular, clear cell renal 
cell carcinoma (ccRCC) is the most frequent RCC subtype. ccRCC is characterized by inactivation of the von 
Hippel-Lindau (VHL) tumor suppressor gene by chromosomal loss of one allele located at position 3p 
combined with a mutation on VHL on the second allele resulting in loss of heterozygosity (LOH). The protein 
pVHL is involved in many different biological processes, therefore, drugs targeting VHL downstream 
pathways are now standard therapies used for treating ccRCCs. However, these drugs show only moderate 
overall survival benefit and have significant side effects for patients. Recently, several additional tumor 
suppressor genes have been found frequently mutated in ccRCC such as genes involved in the chromatin-
remodeling process: SETD2, BAP1, PBRM1, JARID1c, TP53 and some other genes involved in PI3K-mTOR 
pathway: PIK3CA, MTOR and PTEN. Interestingly, phylogenic evaluation revealed these genes to be mutated 
together or separately in different tumor regions analyzed from the same primary ccRCC tumor. Additionally, 
comparison of multiple samples derived from the same ccRCC patient revealed 25 % higher similarity to 
unrelated ccRCC samples, indicating that ccRCC is characterized by extensive inter- and intra-tumor 
heterogeneity. Indeed, tumor heterogeneity is one of the major limitation in the treatment of epithelial 
tumors. Poor response is observed upon chemotherapy and radiotherapy in ccRCC patients, whereas 
targeted therapies such as TKIs are only palliative in advanced ccRCCs. It is becoming increasingly clear that 
genetic and epigenetic factors are not just the only two factors contributing to tumor heterogeneity. The 
tumor microenvironment, stroma cells, soluble molecules and extracellular vesicles (i.e. exosomes) play an 
important role in modulating metastatic properties and sensitivity of tumor cells to therapy. Moreover, 
cancer stem cells (CSCs) are recognized being the major cause of tumor recurrence and resistance to therapy. 
They are characterized by unlimited cell division, self-renewal, capability to differentiate into several cell 
types, and tumorigenicity. Therefore, the identification of a specific subpopulation of cells within a tumor 
ABSTRACT 
10 
that either initiate or maintain tumorigenesis is of utmost importance for understanding tumor biology and 
in the development of novel therapies. 
During my Ph.D. studies, I focused on the investigation of the clinical applicability of circulating tumor DNA 
(ctDNA) and exosomes as potential prognostic and diagnostic biomarkers showing that the development of 
non-invasive methods to detect de novo or to monitor already known tumor specific signatures continue to 
be a major challenge in renal cancer. Nevertheless, genomic investigation of exoDNA together with ctDNA 
might prove to successfully detect new mutations harboring during tumor progression and therapeutic 
intervention. Moreover, primary tumor cultures were exploited in order to dissect tumor heterogeneity in 
the context of a personalized medicine approach. We showed that patient-derived cultures are more 
accurate in retaining patient-specific molecular features compared to immortalized cell lines and, therefore, 
are a promising tool for translational cancer research studies. Finally, new biomarkers for renal cancer stem 
cells with potential therapeutic implications were investigated. IL-8/CXCR1 were found associated with 
cancer stem cell properties in vivo and in vitro representing a potential therapeutic target for renal cancer. 
Moreover, IL-8 and CXCR1 were found correlated with clinical prognosis in ccRCC patients. For this reason, 
targeting CSCs through IL-8/CXCR1 in combination with conventional chemotherapy agents and/or 
immunotherapy would be the next step towards overcoming tumor recurrence. In conclusion, understanding 
the mechanisms underlying tumor heterogeneity and cancer stem cell contribution to tumor progression, 
metastasis formation and therapy failure, together with the use of primary cell cultures, may ultimately 
promote the discovery of more accurate and reliable diagnostic and prognostic tools as well as provide the 
instruments for precise and patient-oriented therapeutic intervention. 
KURZFASSUNG 
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KURZFASSUNG 
Das Nierenzellkarzinom ist das häufigst auftretende bösartige Nierenkrebsleiden und wird in 2 % aller 
neudiagnostizierten Krebsfälle nachgewiesen. Somit steht das Nierenzellkarzinom an zehnter Stelle aller 
Krebsleiden weltweit. Das klarzellige Nierenzellkarzinoms ist des weiteren der häufigste Subtyp und ist durch 
die Inaktivierung des von Hippel-Lindau (VHL) Tumorsuppressorgens charakterisiert. Häufig ist die 
Inaktivierung des VHL Gens durch einen 3p-Allelverlust und einer weiteren Mutation auf dem zweiten Allel 
gekoppelt, was zu einem sogenannten ‘loss of heterozygosity’ (LOH) Genotyp führt. Das VHL Protein ist in 
vielen biologischen Prozessen involviert, welche durch verschiedene Inhibitoren reguliert werden können. 
Einige dieser Inhibitoren sind bereits zugelassene Standardtherapien, wobei leider nur bei einem kleinen 
Prozentsatz der Patienten ein verlängertes Gesamtüberleben nachgewiesen wurde. Kürzlich wurden im 
klarzelligen Nierenzellkarzinom nebst Mutationen im Gen VHL auch häufig genetische Alterationen in 
anderen Tumorsuppressorgenen (SETD2, BAP1, PBRM1, JARID1c, TP53) und in Genen der PI3K-mTOR 
Signalkaskade (z.B. PIK3CA, MTOR, PTEN) gefunden. Phylogenetische Analysen zeigten zudem, dass 
Mutationen in diesen Genen entweder zusammen oder einzeln in verschiedenen Regionen des ein und 
demselben Primärtumors auftreten können. Des Weiteren konnte gezeigt werden, dass Tumorproben von 
Patienten mit klarzelligem Nierenzellkarzinom untereinander sogar eine 25 % höhere Übereinstimmung der 
genetischen Alterationen aufwiesen, als mit einzelnen Metastasen und des Primärtumors von demselben 
Patienten. Dies lässt auf einen hohen Grad an inter- und intra- Tumorheterogenität im klarzelligen 
Nierenzellkarzinom schliessen. Dieser Fact ist auch gut vereinbar mit dem schlechten Ansprechen von 
Patienten mit einem klarzelligen Nierenzellkarzinom auf Chemo- und Radiotherapie und der nur palliative 
angewandten Therapien mittels TKIs. Zunehmend wird klarer, dass nicht nur genetische und epigenetische 
Faktoren zur Tumorheterogenität beitragen sondern auch die umliegenden Zellen, wie Stromazellen, oder 
zellfreie Moleküle und extrazelluläre Vesikel, wie Exosomen, welche das metastasierende Potential eines 
Tumors oder die Sensitivität gegenüber einer Therapie beinflussen. Zusätzlich rücken sogennante 
Krebsstammzellen weiter in den Fokus und werden haupsächlich für das erneute Auftreten eines Tumors 
nach Behandlung und dessen Resistenz verantwortlich gemacht. Krebsstammzellen sind durch unlimitiertes 
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Wachstum, Selbsterhaltung und Tumorgenität charakterisiert und können in verschiedene Zelltypen 
differenzieren. Deshalb ist es von grösstem Interesse eine solche Stammzellpopulation innerhalb der 
Tumormasse ausfindig zu machen, um die Tumorevolution besser zu verstehen und geeignete 
Behandungsoptionen anbieten zu können. 
Während meinem Ph.D. Studium fokussierte ich mich zuerst auf die klinische Anwendbarkeit von 
zirkulierender Tumor-DNA (ctDNA) und Exosomen als prognostische und prediktive Biomarker im klarzelligen 
Nierenzellkarzinom. Die Anwendung sollte einerseits zur Detektierung von schon bekannten Mutationen, 
welche bereits vor Therapiestart bekannt waren, genutzt werden. Andereseits sollte es aber auch möglich 
sein, neue sogenannte Resitenzmutationen nachzuweisen. Der Nachweis solcher Mutationen im klarzelligen 
Nierenzellkarzinom erwies sich als schwierig und wurde auch als solches publiziert (Corrò C. et. al., 2017: 
Detecting circulating Tumor DNA in renal cancer: An open challenge). Als zweites Haupziel meiner 
Dissertation vertiefte ich mich in die Etablierung und Analyse von primären Zelllinien, welche von 
Nierenzellkarzinom-Patienten stammten. Dieser Ansatz erlaubte es, gezielt die Tumorheterogenität zu 
untersuchen und mögliche personaliserte Therapien auszuarbeiten. Wir konnten zeigen, dass diese primären 
Patientenzelllinien das molekulare Profil besser erhalten als z.B. immortalisierte Zelllinien. Ein weiteres Ziel 
im Rahmen der Dissertation war, Stammzell-Biomarker im klarzelligen Nierenzellkarzinom zu finden und zu 
untersuchen. Dabei zeigte sich, dass Nierenkrebszellen, welche IL-8 und CXCR1 exprimierten zu einer 
Nischenpopulation gehörten, welche Stammzelleigenschaften aufwiesen. Demzufolge wäre eine 
Kombinationstherpaie von konventioneller Chemotherapie gekoppelt mit einer Immuntherapie ein 
möglicher nächster Schritt, um eine Therapie einzusetzten, welche die Wahrscheinlichkeit eines 
Wiederauftretens des Tumor verkleiner würde. Zusammengefasst erarbeitete ich in meiner Dissertation 
neue Einblicke in die Tumorheterogenität des klarzelligen Nierenzellkarzinoms, insbesondere in dessen 
Krebsstammzelleigenschaften, und wie diese sich auf die Tumorprogression, Metastasierung und 
Therapieansprechen auswirken können. Diese Ergebnisse bieten eine Möglichkeit neue und bessere 
Therapieansätze zu entwickeln, welche den Nierenzellkarzinom-Patienten helfen können.
INTRODUCTION 
13 
INTRODUCTION 
1. Renal Cell Carcinoma
Cancer is one of the leading cause of morbidity and mortality worldwide. Despite of the significant progress 
made in understanding and treating cancer in the last decades, cancer still represents a major public health 
problem (WHO factsheet 2017). In 2016, 1’685’210 new cancer cases and 595’690 cancer deaths are 
projected to occur in the United States (1). 
Cancer assembles a group of diseases engaging dynamic chances in the genome (2). Tumorigenesis is a multi-
step process, which involves the malignant transformation of normal cells into tumor cells. Cancer cells can 
grow beyond their usual boundaries, invade nearby tissues and spread to other organs forming metastases, 
which are the major cause of death (WHO factsheet 2017) (Fig. 1.1A). It is a complex phenomenon, which 
not only requires tumor cells to acquire sustaining proliferative signaling, evasion of programmed cell death 
(apoptosis), reprogramming metabolic pathways and activating tissue invasion and metastasis, but also 
involves all the cellular components neighboring tumor cells, and that contribute to the acquisition of another 
dimension of complexity by creating the “tumor microenvironment”. These hallmark traits are represented 
by evasion from the immune system, genome instability and inflammation (3) (Fig. 1.1B). 
Renal cell carcinoma (RCC), a malignant tumor affecting the adult kidney, accounts for 2 % of all cancers. 
Affecting 64’000 people every year with 20 % death incidence, RCC is among the 10 most common cancers 
worldwide (4) (Fig. 1.2). Arising from the renal tubular epithelial cell, RCC is the most frequent 
malignancy affecting the adult kidney (87 %), whereas the remainder are 11 % urothelial carcinomas of the 
renal pelvis and rare others (2 %) (5). Incidence and mortality rate of RCC have been raising in many countries, 
in particular in highly developed countries most likely due to risk factors prevalent in these areas like cigarette 
smoking, analgesic use, hypertension and obesity as well as a longer period of life (6,7). RCC occurs 
preferentially in men then in women with a ratio of approximately 2:1. The RCC incidence increases with age 
reaching a peak at 60-70 years of age. 
INTRODUCTION 
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Figure 1.1. Dissecting cancer.  Adapted from Hanahan D. and Weinberg R.A., “Hallmarks for cancer: the next 
generation”, Cell, 2011; and Saxena M. and Christofori G., “Rebuilding cancer metastasis in the mouse”, 
Molecular Oncology, 2013.  A) Schematic representation of the metastatic cascade. Proliferating tumor cells from 
the primary tumor disseminate into the blood circulation and colonize distant secondary sites initially forming 
micrometastases and, finally, outgrowing as a macroscopic mass. B) The hallmarks of cancer. 
Figure 1.2. Kidney cancer statistics. Adapted from Siegel R.L. et al., “Cancer statistics”, ACJC, 2016. 
INTRODUCTION 
15 
1.1 Renal cell carcinoma classification 
Morphologically RCCs are a very heterogeneous class of tumors. According to the WHO 2016 classification 
which combines histological and genetic characteristics and clinical implications, RCC can be subdivided into 
three different entities (WHO 2016; Fig 1.3). Clear cell renal cell carcinoma which is the most common 
subtype of RCC, representing up to 80 % of all RCCs; papillary renal cell carcinoma accounting for 10-15 %; 
and chromophobe renal cell carcinoma representing only 5 % of all RCCs. These tumor subtypes have 
different prognosis and response to novel therapies might be different (8). Five years survival for metastatic 
RCC is 12 % (9). The classification is continuously evolving and tumor entities can be differently grouped.  
The majority of RCC tumors occur in a sporadic form. However, 2-4 % of cases are associated with inherited 
tumor syndromes, such as von Hippel-Lindau (VHL) tumor syndrome, hereditary papillary RCC (HPRCC), Birt-
Hogg-Dubé (BHD) syndrome, hereditary leiomyomatosis RCC (HLRCC), succinate dehydrogenase RCC (SDH-
RCC), tuberous sclerosis (TS) and Cowden’s disease (10,11). Patients carrying germ line mutations in one of 
the predisposing genes to hereditary RCC are likely to develop renal cancers: VHL, MET, FH, BHD and HRPT2, 
TSC, TFE, SDH and PTEN. Each of these genes plays an essential role in pathways involved in cell metabolism 
leading to changes in proliferation and survival. 
1.1.1 Clear cell renal cell carcinoma 
Accounting for almost 80 % of all RCCs, clear cell renal cell carcinoma (ccRCC) is the most frequent and studied 
RCC subtype. It arises from the proximal tubular epithelial cells probably through dedifferentiation (12). The 
name clear cell RCC reflects the fact that this tumor entity is composed of cells contained within a delicate 
vascular system with clear or eosinophilic cytoplasm due to high lipid content which is lost during routine 
histological processing (12,13). The presence of necrotic areas and highly vascularized tumor stoma as well 
as sarcomatoid differentiation and tumor infiltrating lymphocytes are associated with tumor aggressiveness 
and poor prognosis (8). ccRCC frequently metastasize through the vena cava to lungs or through the 
urogenital tract to bone, liver and brain. Many patients present metastasis at the time of diagnosis, and 20 
% of them present with brain metastasis. Additionally, late metastasis can appear at 10 years of distance (8). 
INTRODUCTION 
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1.1.2 Papillary renal cell carcinoma 
Accounting for 10-15 % of all RCCs, papillary renal cell carcinoma (pRCC) represent the second most frequent 
malignancy affecting the adult kidney after ccRCC. It arises from the proximal tubular epithelial cells 
undergoing malignant transformation and formation of tubules and papillae (8,14). The 5 years survival rate 
for this tumor type lays around 90 % (13). Characteristic of pRCCs is the presence of bilateral or multifocal 
tumors accompanied by necrosis. Sarcomatoid differentiation is also seen in pRCC and correlates with poor 
prognosis (8). 
pRCC is characterized by trysomy or polysomy of chromosomes 3q, 7, 8, 12, 16, 17 and 20, and loss of Y 
chromosome. Treatment of pRCC is very similar to that of ccRCC. For localized pRCC radical nephrectomy or 
nephron-sparing surgery is applied. Anti-angiogenesis agents such as bevacizumab, sunitinib, and sorafenib 
are used in first-line therapy for metastatic pRCC. Temsirolimus, which targets the mammalian target of 
rapamycin (mTOR) receptor pathway, also appears to improve overall survival in patients with metastatic 
pRCC (14,15). 
Two morphological subtypes of pRCC have been identified. pRCC type I, also known as basophilic, is the major 
pRCC subtype accounting for 70 % of all pRCCs (8,16). It is characterized by a single layer of epithelial cells 
with scant cytoplasm covering the tubules. pRCC type II, also known as eosinophilic, is the least frequent 
pRCC subtype but more aggressive (poor prognosis) (16). It shows eosinophilic cytoplasm and pseudo-
stratified nuclei. 
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1.1.3 Chromophobe renal cell carcinoma 
Accounting for 5 % of all RCCs, chromophobes renal cell carcinoma (chRCC) is the third most frequent RCC 
subtype. It originates from the distal nephron. It is characterized by polygonal cells delineated by a prominent 
cell membrane and a transparent reticulated cytoplasm due to the high content of microvesicles. Some cells 
are irregular and multinucleate. Macroscopically, chRCC appears grey-brown. 
Contrary to ccRCC, chRCC occurs in patients with a wide age range and with a male:female ratio of 1:1. The 
mortality rate is less than 10 % and metastases affect lung, liver, and pancreas. Rarely occurring sarcomatoid 
differentiation is a sign of poor prognosis. 
chRCC harbors extensive chromosomal loss involving chromosome Y, 1, 2, 6, 10, 13, 17 and 21 (17). It has 
been proposed that chRCC may evolve from oncocytoma. Oncocytoma is a benign neoplasm (18). Moreover, 
mutations in TP53 tumor suppressor gene were found together with loss of heterozygosity around PTEN gene 
in 27 % of chRCCs (19). 
 
 
Figure 1.3. Renal cell carcinoma subtypes. In the upper panel are depicted the three most common RCC 
subtypes stained by H&E: A) clear cell renal cell carcinoma (ccRCC), B) papillary RCC type I and type II (C), D) 
chromophobe RCC (chRCC). In the lower panel frequencies and the gene of interest for each subtype is described. 
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1.2 Diagnosis, prognosis and therapeutic treatments 
Renal cancer is often asymptomatic in early stage and it is usually detected by chance during examination or 
illness. Clinical presentation of a palpable mass on the flank, pain in the abdomen, anemia, loss of weight and 
the presence of blood in the urine is very uncommon (20). However, the most common clinical signs may 
appear with the tumor growth. Following presentation of one or more of these symptoms, different tests are 
performed such as blood and urine test, ultrasound, computed tomography (CT) scan, magnetic resonance 
imaging (MRI), and finally biopsy. 
Determine tumor stage and grade is fundamental in order to stratify treatment options, and assess prognosis 
and survival. The most common staging system for kidney cancer is the TNM system introduced by the 
American Joint Committee on Cancer (AJCC), where “T” indicates tumor size, “N” describers whether the 
primary tumor has spread to the nearby lymph nodes, and “M” stands for presence of disseminated 
metastases (Table 1.1). Common metastatic sites include bone, liver, lung, brain, and distant lymph nodes 
(AJCC 6th edition 2017). According to the TNM values, the overall stage can be assigned (Table 1.1). 
Several grading systems for RCC have been discussed over the years. The Fuhrman system is based on the 
microscopic evaluation of the uniformity of the nuclear size, shape and nucleolar prominence (21,22). It was 
the most frequently used but it couldn’t be applied to chRCC and to the new entities (23). Therefore, a new 
grading system has been introduced by the WHO in 2016 (24). The new four-tired WHO/ISUP system defines 
tumors of grade 1-3 based on nucleolar prominence, whereas grade 4 is defined by the presence of nuclear 
pleomorphism, big tumor cells and sarcomatoid differentiation (25)(Table 1.2). 
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Table 1.1. Renal cancer staging. 
TNM classification 
T Information concerning the primary tumor 
TX Information not available 
T0 Primary tumor not detectable 
T1 Primary tumor confined to the kidney and no longer than 7 cm in size 
T1a Tumor size is no longer than 4 cm across 
T1b Tumor size is no longer than 7 cm across 
T2 Primary tumor larger than 7 cm but still confined to the kidney 
T2a Tumor size between 7 and 10 cm across 
T2b Tumor size larger than 10 cm 
T3 Tumor is growing into a major vain or in the tissue surrounding the kidney, but not in the 
adrenal gland or beyond the Gerota’s fascia 
T3a Tumor is growing into the renal vain or in the fatty tissue surrounding the kidney 
T3b Tumor is growing into the vena cava leading to the heart 
T3c Tumor has grown into the vena cava within the chest 
T4 Primary tumor has spread beyond the Gerota’s fascia 
N Information concerning regional lymph node involvement 
NX Information not available 
N0 No lymph node is involved 
N1 Tumor has spread to nearby lymph nodes 
M Information concerning the presence of metastasis 
M0 Tumor has not spread to other organs 
M1 Tumor has spread to other organs 
Staging classification 
Stage I 
T1 N0 M0 Primary tumor is no larger than 7 cm across. There is no lymph nodes or other 
organs involvement 
Stage II 
T2 N0 M0 Primary tumor is larger than 7 cm across. There is no lymph nodes or other 
organs involvement 
Stage III 
T3 N0 M0 Primary tumor is growing into a major vain but not in the adrenal gland or 
beyond the Gerota’s fascia. There is no lymph nodes or other organs 
involvement 
T1-3 N1 M0 Primary tumor can be of any size and it has spread to the nearby lymph nodes, 
but it has not spread beyond the Gerota’s fascia or to any other organ.  
Stage IV 
T1-4 N0-1 M1 Primary tumor can be of any size. It may or may not have spread to nearby 
lymph nodes, but it has spread to distant lymph nodes or other organs. 
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Table 1.2. Renal cancer tumor grade. 
Grading classification 
Grade I 
Nuclear size Nuclear outline Nucleoli 
10 mm Round, uniform Absent 
Grade II 
Nuclear size Nuclear outline Nucleoli 
15 mm Slightly irregular Small (400x magnification) 
Grade III 
Nuclear size Nuclear outline Nucleoli 
20 mm Markedly irregular Prominent (100x magnification) 
Grade IV 
Nuclear size Nuclear outline Nucleoli 
>20 mm Bizarre Large 
 
Treatment options depends on the staging of the tumor, on the tumor type, on the markers expressed by 
the tumor and on the patient’s age and general health (5). 
Curative surgical resection is the only effective therapeutic option for localized RCCs (5,26,27). Radical 
nephrectomy represents the method of choice for significantly big tumors (>pT2). It is achieved by removal 
of the entire kidney, perirenal fat and adrenal gland accompanied by lymph nodes dissection. Nevertheless, 
high cardiovascular events and mortality rate is associated with this method. Partial nephrectomy (nephron 
sparing) represents a less invasive technique which requires the removal of the tumor mass and the 
surrounding tissue (safe margins) without impairing the renal function. Nephron sparing nephrectomy 
applies to all pT1 tumors where the relationship between the tumor size and the rest of the kidney is less 
than 50 %. Both resections can be performed laparoscopically reducing periperative morbidity and the length 
of the hospitalization. If the renal tumors are not in close proximity to susceptible organs, thermal ablation 
can be an alternative option for selected patients (5). 
At the time of diagnosis, 3-22.5 % of the patients have nodal involvement, 20-35 % of the patients present 
tumor extension into renal veins, whereas 30 % of patients have already developed metastases and 50 % of 
those with localized disease will develop metastatic lesions. In these patients treatment is palliative to relief 
symptoms and concentrated on prolonging survival time and preserving the quality of life (94, 95). Local 
recurrence in the nephrectomy bed is 20-40 %. 
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Some patients may receive radiotherapy or chemotherapy before or after surgical resection of the tumor in 
to shrink the tumor size or further kill cancer cells, respectively (neo-adjuvant versus adjuvant therapy). 
Nevertheless, chemotherapy, radiotherapy and hormonal therapy showed a very little benefit to the patients 
(18). 
Due to the much higher prevalence of ccRCCs, very few clinical trials have been carried out considering other 
histological RCC subtypes. Therefore, most of the drugs have been developed based on ccRCC, and they are 
currently applied to all RCC patients. Treatment of advanced or metastatic RCC patients is achieved primarily 
by targeted therapy. Tyrosine kinase inhibitors (TKIs) play an important role in modulating growth factor 
signaling acting on epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth 
factor (PDGF), and vascular endothelial growth factor (VEGF) receptors (28). First line treatment of such 
patients relies on the usage of VEGF-inhibitors such as the VEGF-neutralizing antibody bevacizumab, the 
VEGF receptor antagonists sorafenib, sunitinib and pazopanib (29,30). Although pazopanib showed enhanced 
quality of life and safety advantages compared to sunitinib, it is still regarded as second treatment option 
against sunitinib (31-33). Interestingly, EGF-inhibitors showed to be ineffective in the treatment of RCCs. 
More traditional cytokine therapy includes interferon-α (IFNα) and interleukin-2 (IL-2) treatment, which is 
effective only for a small group of patients (34). 
Tumor angiogenesis is also stimulated by growth factors through the phosphatidylinositol-3 kinase (PI3K)-
AKT-mTOR signal transduction pathway. Agents targeting this pathway can also be expected to have 
antitumor activity (34). Therefore, second line treatment is managed by axitinib, everolimus and 
temsirolimus (35). Axitinib is a selective TKI for VEGFR-1, -2 and -3 (36). Whereas, everolimus and 
temsirolimus are mTOR inhibitors. Interestingly everolimus is also considered as third line treatment option 
(Table 1.3). 
Several approaches to immunotherapy are currently investigated for RCC patients such as vaccines, adoptive 
cell therapy and T-cell modulation (37,38). In this regard, the anti-CTLA-4 antibody (ipilimumab) prevents 
CD80 and CD86 from binding to CTLA-4 receptor and, thereby, promotes T-cell activation. Evidence also 
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shows that CTLA-4 antibodies can deplete regulatory T cells contributing to the activation of the immune 
system (38). Antibodies against programmed death 1 (PD-1, nivolumab) and its ligand PD-L1 (durvalumab 
and atezolizumab) have been developed and act by blocking the interaction between T-cells and cancer cells 
at the tumor site leading to the activation of the T-cell response (38). 
Despite all the progress made in the development of novel anti-cancer compounds, the management and 
treatment of RCC patients still remains a crucial aspect in the clinics. Improving the understanding of 
morphologic features and molecular genetics of renal cancers as well as the discovery of prognostic and 
predictive biomarkers will improve the identification of more efficient therapeutic strategies. 
 
Table 1.3. Therapeutic options for renal cancer. Adapted from Bukowski R.M. et al., “Pazopanib”, Nature 
Reviews, 2010 (39). 
  
Treatment Drug Target 
 
First line Bevacizumab 
Sorafenib 
Sunitinib 
Pazopanib 
Multiple RTKs 
(VEGFR, PDGFR) 
Second line Axitinib 
Everolimus 
Temsirolimus 
PI3K-AKT-mTOR 
Third line Different TKIs 
New agents: 
Cabozatinib 
Growth factors 
(EGF, FGF, PDGF, 
VEGF) 
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1.3 Biomarkers in renal cancer 
Diagnosis and classification of RCC subtypes can be usually accomplished by morphological evaluation of the 
tumor specimen. Occasionally, evaluation of immunohistochemical staining (IHC), which allow the detection 
of antigens expressed on tumor cells, may be used to verify unclear diagnosis. For instance, ccRCC shows 
reactivity for Vimentin, Cytokeratin, CD10, Pax2, and Carbonic anhydrase-IX (CA-IX); pRCC is positive for 
Vimentin, Cytokeratin, and CK7; whereas chRCC is positive for E-cadherin, CD117 and CK7 (40) (Table 1.4). 
Due to the high tumor heterogeneity which characterize RCCs, employment of such panel of markers is often 
speculative and limited. Besides immunohistochemistry other techniques are adopted such as molecular 
cytogenetics (41), fluorescence in situ hybridization (FISH) (42), gene expression profiling (43-45), single 
nucleotide polymorphism (SNP) array (46,47), methylation status, mutational analysis and proteomics (48). 
To date no prognostic and diagnostic biomarker is routinely used in the clinics. Several studies proposed new 
potential biomarkers for RCCs. However, most of them need further validation. Among them, the most 
significative are: VHL (49,50), HIF1α (51,52), CA-IX (52,53), survivin (54), Ki-67 (55), fascin (56), c-MET (57), 
family of the ligands B7-H (58,59), VEGF (60), CAF (46) and IL-8 (47,61). 
The majority of biomarkers require invasive procedure such as biopsies and surgical intervention. Blood and 
urine represent two valuable sources of cancer-derived molecules being proteins, nucleic acids, extracellular 
vesicles (EVs) and circulating tumor cells (CTCs). Detection of changes in the level of these molecules in the 
body fluids have been associated with tumor load and malignant progression, proposing these liquid biopsies 
as a novel prognostic, diagnostic and predictive tool for cancer patients. Additionally, the possibility to 
analyze the genetic content of CTCs and EVs as well as determine de novo mutations in the circulating tumor 
DNA (ctDNA) over time is regarded as an important step towards personalized medicine and treatment 
monitoring. 
The presence of nucleic acids circulating in the blood have been shown for the first time in 1948 by Mandel 
and Metais who discovered the presence of DNA and RNA in the plasma of healthy and diseased donors (62). 
After this study, several others have identified the presence of circulating free DNA (cfDNA) in the 
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bloodstream of patients and changes in the levels of these circulating nucleic acids have been associated with 
tumor load and malignant progression proposing these liquid biopsies as a novel prognostic, diagnostic, and 
predictive tool for cancer patients, including renal cancer (63-65). However, correlation of cfDNA levels to 
tumor stage and grade in renal cancer revealed discordant results (65-68). 
In particular, it has been shown that the amount of ctDNA shed by cancer cells represents up to 10 % of total 
cfDNA derived from blood in patients with advanced tumors (69). Thus, ctDNA opens the possibility to detect 
the mutational profile of a specific cancer during tumor evolution, metastasis formation and therapy. Indeed, 
different mutations have been identified in cfDNA of patients affected by colon, lung, ovarian and breast 
cancers (63,70-74). More recently, Bettegowda and co-workers detected ctDNA in more than 75 % of the 
patients with advanced pancreatic, ovarian, colorectal, bladder, gastro-oesophageal, breast, melanoma and 
head and neck cancers but in less than 50 % of patients presenting with renal and prostate cancers (75). In 
particular, the release of ctDNA was investigated in five ml of plasma derived from five metastatic RCC 
patients. Prior analysis of the tumor tissue revealed in one RCC patient a MET mutation, in one a HOOK2 
mutation, and in three a VHL mutation. When analysing the ctDNA, only one VHL mutation and the MET 
mutation were successfully detected (40 %). For the detection of VHL, the authors used PCR-ligation and for 
the detection of the MET mutation SafeSeqS. Both methods are highly sensitive with detection limits below 
1 % allele count. However, for both assays the mutation of interest has to be identified in the tumor tissue 
before analysis of the blood samples.  Therefore, the development of non-invasive methods to detect de 
novo or to monitor already known tumor specific signatures continue to be a major challenge in renal cancer. 
Table 1.4. Renal cancer subtype discrimination using immunohistochemical markers. 
RCC 
subtype 
IHC 
positive markers 
IHC 
negative markers 
ccRCC Vimentin, Keratin, 
CD10, Pax2/8, CA-IX, 
CK18 
CK7, Ksp-cadherin, E-
cadherin, CK19 
pRCC Keratin, CK7, Vimentin CD117, Ksp-cadherin 
chRCC E-cadherin, CD117, 
CK7 
Vimentin, CA-IX 
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1.4 Tumor heterogeneity in clear cell renal cell carcinoma 
Clear cell renal cell carcinoma is the most common RCC subtype. Inactivation of VHL tumor suppressor gene 
by mutation or promoter methylation has been found responsible for about 80 % of ccRCC cases (76). 
Characteristic for the majority of sporadic ccRCC is the chromosomal loss of one allele located at position 3p 
combined with a mutation on VHL on the second allele resulting in loss of heterozygosity (LOH) (77). In several 
cases amplification of chromosome 5q and loss of 14q were reported (78).  
Recently, several additional tumor suppressor genes have been found frequently mutated in ccRCC such as 
genes involved in the chromatin-remodeling process: SETD2 (16 %), BAP1 (15 %), PBRM1 (33 %), JARID1c (4 
%), TP53 (2 %) and some other genes involved in PI3K-mTOR pathway: PIK3CA (3 %), MTOR (6 %) and PTEN 
(4.3 %) (78-83). PBRM1, SETD2 and BAP1 are located on chromosome 3p suggesting they might be involved 
in large deletions together with VHL (84). Mutations in PBRM1 and BAP1 were mutually exclusive, whereas, 
mutations in PBRM1 and SETD2 were appearing together as well as individually (83). 
BAP1 encodes a nuclear deubiquitinase of the ubiquitin C-terminal hydrolase (UCH) family. Mutations in this 
gene promotes mTOR signaling activation. BAP1 mutations in ccRCC patients have been correlated to 
decreased cancer specific survival (85), overall survival (TCGA, 2013), and lower recurrence free survival (80). 
Additionally, BAP1 loss of expression assessed by immunohistochemistry correlated with lower overall 
survival (86). 
The PBRM1 gene encodes the polybromo BAF180 protein. PBRM1 loss induces cytoskeleton remodeling, cell 
mobility and cell proliferation via inhibition of the cyclin-dependent kinase inhibitor p21 (79). Loss of PBRM1 
expression correlates with high tumor grade, late tumor stage and worse patient outcome (87). However, 
patients carrying a mutation only in the PBRM1 gene showed favorable clinical outcome compared to BAP1-
mutant (82). 
SETD2 has been found linked to DNA mismatch repair, microsatellite instability and DNA methylation in 
ccRCCs (78). However, the role of SETD2 in ccRCC is still unclear (79). SETD2 was shown to be a potential 
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prognostic biomarker for overall survival and progression-free survival prediction in patients with metastatic 
renal cell carcinoma receiving targeted therapy as well as in non-metastatic RCCs (88,89). 
According to their significance, mutations can be classified into driver and passenger mutations. Driver 
mutations are implicated in tumor initiation and progression, whereas passenger mutations are transitory 
(90). Interestingly, these genes have been found to be mutated separately or together in the same primary 
ccRCC in different tumor regions analyzed (91). Comparison of multiple samples derived from the same ccRCC 
revealed in 25 % a higher similarity to unrelated ccRCC samples (92) (Fig. 1.4). These findings hint to a high 
degree of parallel evolution of tumor subclones in ccRCC resulting in tumor heterogeneity, which opens the 
discussion about tumor stem cells and the metastatic-initiating tumor cell population. 
 
 
Figure 1.4. Intra-tumor heterogeneity. Adapted from Gerlinger M. et al., “Intratumor Heterogeneity and 
Branched Evolution Revealed by Multiregion Sequencing”, The New England Journal of Medicine, 2012. A) 
Different regions and metastatic sites were resected and analyzed by whole exome sequencing. B) Phylogenic 
evaluation revealed mutations in VHL, SETD2, BAP1 and in the mTOR pathway appearing together or separately 
in different tumor regions analyzed from the same primary ccRCC tumor. At the same time, comparison of multiple 
samples derived from the same ccRCC patient revealed 25 % higher similarity to unrelated ccRCC samples. 
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1.5 VHL and HIFs 
The VHL gene encodes for two proteins by alternative splicing. The full length isoform p-VHL30, so-called 
because of a molecular weight of 30 KDa, consists of 213 amino acids and it is localized in the cytoplasm. On 
the other hand, p-VHL19 consists of 160 amino acid residues and it is equally distributed between the 
cytoplasm and the nucleus. 
P-VHL is part of the E3 ubiquitin ligase complex containing elongin B, elongin C, Cul2 and Rbx1 (93). The VHL 
protein contains two domains: the α domain is responsible for binding to elongin C triggering the formation 
of the complex, the β domain is responsible for the binding to HIFα (94). 
In presence of normal oxygen tension (normoxia), this complex binds to the α subunit of the heterodimeric 
transcription factor hypoxia-inducible factor (HIF) leading to polyubiquitination and proteosomal 
degradation (76). Under low oxygen levels (hypoxia), HIFα is not hydroxylated on the proline residues (Pro-
402 and Pro-564), therefore, it escapes the recognition by p-VHL,  dimerizes with HIFβ, translocates into the 
nucleus, and by binding to the hypoxia-responsive elements (HRE) transcriptionally activates genes involves 
in metabolism, angiogenesis, cell migration, resistance to apoptosis and cytoskeletal remodeling (95). These 
genes are VEGF, PDGF, EGFR, transforming growth factor α (TGFα), c-Met, Cyclin D1, glucose transporter 1 
(GLUT1), CA-IX, and erythropoietin (EPO) (35) (Fig. 1.5). 
All the mutations found in VHL compromise the ability to either suppress HIF or bind to the complex. 
Interestingly, nonsense and frameshift mutations abrogate p-VHL, whereas missense mutations may have 
different effects (77). Nevertheless, pVHL-deficiency alone is not sufficient to initiate tumor formation (96), 
and therefore, VHL status was not found correlated with the clinical outcome in ccRCC patients (97-100). 
Recently, it was shown that out of the remaining 8 % VHL wt ccRCC cases, 42 % harbor biallelic inactivation 
of the elongin B gene (TCEB1). 
There are three HIFα family members (HIF1α, HIF2α, HIF3α) and two HIFβ family members (HIF1β, HIF2β). 
The α subunit is oxygen sensitive, whereas the β subunit is constitutively expressed (76). The HIF proteins are 
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members of the basic helix-loop-helix PAS family of DNA-binding transcription factors. Both HIF1α and HIF2α 
have two dedicated transcriptional activation domains that can activate transcription when bound to DNA. 
The core sequence of the HRE recognized by HIF is 5’-RCGTG-3’, where R stands for purine. Both HIF1 and 
HIF2 share common but also distinct transcription patterns. HIF1 drives the expression of genes involved in 
apoptosis and metabolism acting as a tumor suppressor gene (101). HIF2 activates genes involved in cell 
proliferation and angiogenesis. For this reason, it was suggested that HIF2 is more oncogenic than HIF1. HIF1α 
has been found involved in early lesions, whereas HIF2α plays an important role in malignant progression 
and metastasis formation (102). 
Finally, the protein pVHL is involved in many other different biological processes, such as organization of 
extracellular matrix and microtubules (93), cell polarity, inhibition of NF-kB activity (103), maintenance of 
chromosome stability (104), differentiation, and growth arrest (105). 
Drugs that inhibit specifically members of the VHL-HIF-VEGF pathway are now standard therapies used for 
treating ccRCC cases (35,93)(Fig. 1.5). However, these drugs show only moderate overall survival benefit and 
have significant side effects for patients. Therefore, development of new prognostic and diagnostic markers 
are needed. 
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Figure 1.5. The pVHL-HIF axis. Adapted from Clark P.E., “The role of VHL in clear-cell renal cell carcinoma and 
its relation to targeted therapy.”, Kidney International, 2009. Under normoxia conditions HIFα subunits are 
hydroxylated by a member of the PHDs protein family, which leads to E3 ubiquitin ligase complex formation and 
HIF1α and HIF2α are targeted for proteasomal degradation. During hypoxia or loss of functional pVHL, HIFα 
subunits are stabilized and HIF target genes are transcribed. Drugs that inhibit specifically members of the VHL-
HIF-VEGF/mTOR pathway are now standard therapies used for treating ccRCC cases. 
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2. Cancer stem cells 
In particular, intra-tumor and inter-tumor heterogeneity is one of the major limitation in the treatment of 
epithelial tumors (106). Two different tumor models have been proposed playing a role in tumor 
development, progression and tumor heterogeneity. The cancer stem cell (CSC) model or hierarchical model 
proposes that tumor growth and propagation is driven by a small subpopulation of cells with 
pluriproliferative features (107,108). According to this model, a pool of CSCs can only be maintained by cells 
that have both stem cell potential and the ability to give rise to progeny with self-limited proliferative capacity 
(109). The clonal evolution model or stochastic model implies the presence of a tumor cell population, 
derived from a normal cell that underwent malignant transformation known as cell-of-origin or tumor 
initiating cells, carrying different mutations which are accumulated during time and then selected under 
different selective pressure (110). 
Genetic and epigenetic factors are not just the only two factors contributing to tumor heterogeneity. Tumor 
heterogeneity is in fact, further enhanced by clonal variation and tumor microenvironment (TME) (111). 
Therapy itself may act as selection mechanism that shapes tumor evolution. More recently, a unifying model 
of clonal evolution applied to CSCs has been proposed by Kreso et al., whereby CSCs can acquire mutations 
and generate new stem cell branches contributing to tumor heterogeneity (108) (Fig. 2.1). 
Therefore, the identification of a specific subpopulation of cells within a tumor that either initiate or maintain 
tumorigenesis is of utmost importance for understanding tumor biology and in the development of novel 
therapies. 
CSCs are a small population of neoplastic cells within a tumor presenting characteristics reminiscent of 
normal stem cells. In particular, they are capable to give rise to all the cell types present in the tumor tissue 
which they derive from (differentiation). They are characterized by unlimited cell division, maintenance of 
the stem cell pool (self-renewal), give rise to tumor and metastasis in vivo (tumorigenicity), resistance to 
therapies and recurrence. These cells divide asymmetrically resulting in a CSC identical to the parental cell 
and on the other hand to a more differentiated cell responsible for establishing the tumor bulk. 
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Dick and co-authors performed the first experimental study on CSCs in 1994. They isolated CD34+/CD38- cells 
from acute myeloid leukemia (AML) patients and showed they could initiate AML in vivo upon transplantation 
into NOD/SCID mice (112). Subsequently, several others have showed the presence of CSCs in colorectal 
cancer, breast cancer, glioblastoma, melanoma, lung cancer, liver and prostate cancer (113-122). Growing 
evidence suggests that renal cancer, as many other solid tumors, possesses a rare population of cells capable 
of self-renewal that contribute to metastasis and resistance to therapy. So far, many studies tried to identify 
biomarkers in order to isolate CSC populations in RCC (123-127). Some of these markers are CD105, ALDH1, 
OCT4, CD133 and CXCR4, which have been found specifically expressed in CSC and cancer stem-like cells 
derived from RCC (Table 2.1). 
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Figure 2.1. Model of tumorigenesis. This figure illustrates three models of tumorigenesis. The clonal evolution 
model or stochastic model which implies the presence of a tumor cell population carrying multiple mutations 
which is transformed over time by selective pressure resulting in tumor heterogeneity and progression. The CSC 
model or hierarchical model which proposes that tumor growth and propagation is driven by a small 
subpopulation of cells with pluriproliferative features namely CSCs. More recently, a unifying model 
characterized by high tumor heterogeneity, plasticity and complexity has bene proposed. According to this 
model CSCs can acquire mutations and generate new stem cell branches, on the other hand, tumor cells in the 
non-CSC subpopulation can undergo EMT and acquire CSC-like features contributing to tumor heterogeneity. 
Moreover, tumor microenvironment and therapy add another layer of complexity. 
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Table 2.1. Summary of putative CSC markers. 
Sample Assay Putative 
marker of the 
study 
Positive 
markers 
Negative 
markers 
CSC features Reference 
769P side population ABCB1 ABCC1, 
ABCG2 
clonogenic, tumorigenicity, 
resistance to chemo and 
radiotherapy 
Huang et al. 
(128) 
786O sphere formation assay CD73 
 
tumorigenicity, resistance 
to radiotherapy 
Song et al. 
(129) 
786O flow 
cytometry 
Rh123 
  
spheroids in soft agar, 
proliferation, 
differentiation, 
tumorigenicity, resistance 
to radiotherapy 
Lu et al. 
(130) 
786O, 
769P, 
A704, 
Caki1, 
Caki2 
 
Flow 
cytometry 
USP21 ALDH  sphere formation, 
clonogenic, proliferation, 
invasion 
Peng et al. 
(131) 
ACHN  side population ALDH1 CD105, 
CD133 
sphere formation, self-
renewal, tumorigenicity 
Ueda et al. 
(126) 
ACHN, 
Caki1 
sphere formation assay Oct4, Nanog, 
LIN28, KL4, 
Zeb1, Zeb2, N-
cadherin, 
Vimentin, CD44, 
CD24 
miR17 sphere formation, self-
renewal, differentiation, 
tumorigenicity 
Lichner et al. 
(132) 
ACHN, 
Caki1 
flow 
cytometry 
CD105 CD105, Oct4, 
Nanog, CD90, 
CD73 
CD24, 
CD34, 
CD11, 
CD19, 
CD45 
spheroids in soft agar, 
hanging drops 
Khan et al. 
(133) 
ACHN, 
Caki1 
MACS 
 
CD133+/CD24+, 
Oct4, Notch1, 
Notch2, 
Jagged1, 
Jagged2, DLL1, 
DLL 4 
 self-renewal, invasion and 
migration, tumorigenicity, 
resistance to chemotherapy 
(sorafenib and cisplatin) 
Xiao et al. 
(134) 
ACHN, 
Caki1, 
SMKTR2, 
SMKTR3, 
RenCa 
 
side population DNAJB8 
 
tumorigenicity Nishizawa et 
al. (135) 
ACHN, 
Caki2 
 
flow 
cytometry 
ALDH1 Oct4, Nanog, Pax2 self-renewal, clonogenic, tumorigenicity 
Caki1, 
Caki2, 
786O, 
769P 
 
sphere formation assay CXCR4 
 
sphere formation, 
tumorigenicity 
Micucci et 
al. (136) 
HEK293T sphere formation assay ALDH+, CD44, β-
catenin, Notch1, 
Survivin, 
Vimentin, N-
cadherin, Zeb1, 
Snail, Slug 
CD24 sphere formation, 
resistance to radiotherapy 
Debeb et al. 
(137) 
RCC 
xenograft 
sphere formation assay CD133/CXCR4 sphere formation, 
tumorigenicity, resistance 
to chemotherapy 
Varna et al. 
(127) 
RCC26, 
RCC53 
flow 
cytometry 
CXCR4 CXCR4, CD24, 
CD29, CD44, 
CD73, Nanog, 
Oct4, Sox2 
CD90, 
CD105, 
CD133, 
CXCR1, 
sphere formation, 
tumorigenicity, resistance 
to chemotherapy 
Gassenmeier 
et al. (138) 
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Vimentin, 
β-catenin 
RCCs flow 
cytometry 
CD105 CD105, CD44, 
CD90, CD73, 
CD29, Nanog, 
Oct4, Vimentin, 
Nestin 
CD133 sphere formation, 
clonogenic, differentiation, 
tumorigenicity 
Bussolati et 
al. (139) 
RCCs flow 
cytometry 
CD133+/ 
CD34- 
CD73, CD44, 
CD29, 
Vimentin 
 non tumorigenic Bruno et al. 
(140) 
RCCs flow 
cytometry 
CD133+/ 
CD24+ 
CTR2, Nanog, 
Oct4, Sox2 
CD105, 
CD90 
resistance to chemotherapy Galleggiante 
et al. (141) 
RCCs side population CD133 
 
spheroids in soft agar, 
differentiation 
Addla et al. 
(142) 
RenCa 
  
DNAJB8 
 
side population, sphere 
formation, tumorigenicity 
Yamashita 
et al. (143) 
SK-RC-42 sphere formation assay Oct4, Nanog, 
BMI, β-catenin 
MHC-II, 
CD80 
sphere formation, 
tumorigenicity, resistance 
to radio and chemotherapy 
Zhong et al. 
(144) 
 
2.1 Cancer stem cell markers 
2.1.1 CD105 
Among those, CD105 (Endoglin) is a transmembrane glycoprotein encoded by the endoglin gene located on 
chromosome 9q34. This protein is composed of two constitutively phosphorylated subunits of 95 KDa each, 
forming a 180 KDa homodimeric mature protein (145). CD105 is an accessory protein of the TGFβ complex. 
Upon activation of the TGFβ complex, the binding of endoglin results in the activation of Smad proteins 
regulating cell proliferation, migration, differentiation and angiogenesis (146). Endoglin is predominantly 
expressed in endothelial cells where it is activated by hypoxia and TGFβ stimulation, whereas it is decreased 
by tumor necrosis factor α (TNFα)(147). In breast, prostate and gastric cancer, CD105 was present in 
endothelial cells forming the immature tumor vasculature. 
CD105 was shown to be expressed on a ccRCC subpopulation representing <10 % of the tumor mass. These 
cells isolated my magnetic sorting showed potent capability to grow as spheres and initiate tumors and 
metastasis recapitulating the histological pattern in mice (124,139). CD105+ cells expressed mesenchymal 
markers CD44, CD90, CD29, CD73 and Vimentin; embryonic stem cell markers Oct3/4, Nanog and Nestin and 
embryonic renal marker Pax2 (139). However, CD105+ cells did not express CD133 also known as human 
tubular progenitor cell marker (148). CD105+ CSCs were able to differentiate into epithelial and endothelial 
cells and generate CD105- cells. Additionally, IHC of tumoral CD105 was found positively correlated to nuclear 
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grade and tumor stage, whereas endothelial expression negatively correlated with clinicopathological 
features (149). Interestingly, CD105+ CSCs released microvesicles/exosomes containing pro-angiogenic 
mRNAs (VEGF, FGF, MMP2 and 9) that triggered angiogenesis and promoted the formation of a premetastatic 
niche in vivo (124). EVs derived from renal CSCs impaired T cell activation and dendritic cell differentiation 
by the human leukocyte antigen G (HLA-G) promoting escape from the immune system (150). 
Nevertheless, the use of CD105 as a renal CSC marker was questioned in many studies where also CD105- 
cells showed CSC-like features (129). 
2.1.2 CD133 
Prominin-1 (CD133) is a transmembrane glycoprotein of 865 amino acids (120 KDa) encoded by the gene 
PROM1 on chromosome 4p15 (151). The protein consists of an N-teminal extracellular domain, five 
transmembrane domains with two large extracellular loops, and a cytoplasmic tail (152). Phosphorylation of 
CD133 results in the activation of PI3K/AKT signaling pathway (153,154). Hypoxia, mTOR inhibition and TGFβ1 
were shown to increase CD133 expression in lung cancer, pancreatic cancer and hepatocellular carcinoma 
(HCC). Interestingly, Oct4 and Sox2 have been found binding the promoter region of CD133 inducing its 
activation in lung cancer cell lines. 
CD133+ cancer cells were able to form spheres, give rise to tumors in vivo, and exhibit chemoresistance 
properties in colorectal carcinoma, HCC, lung cancer, glioblastoma, pancreatic cancer and ovarian cancer. On 
the contrary, sorted CD133+ cells from RCC patients did not show tumorigenic capability in vivo although they 
expressed stem cell markers such as CD44, CD29, Vimentin, and Pax2 (148). When co-transplanted with renal 
carcinoma cells, CD133+ progenitors significantly enhanced tumor development and growth. The same result 
was obtained using CD133+ cells derived from normal kidney tissue (140). Of note, CD105+ cells did not 
express CD133, suggesting that CD133+ cells may represent renal resident adult progenitor cells. 
Interestingly, CD133+/CD24+ cells derived from ACHN or Caki1 RCC cell lines displayed sphere formation 
capability, enhanced invasion and migration properties, high colony formation efficiency in soft agar, and 
resistance to sorafenib and cisplatin (134).  
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Another interesting publication identified CD133 and CXCR4 coexpressing CSCs in spheres derived from RCC 
xenografts and tumor tissues. Increased expression of these markers was found in RCC patients after sunitinib 
treatment (127). However, the coexpressing cells increased only from 4 % to 8 % in average of total cells in 
the spheres investigated upon treatment. Nevertheless, whether the CD133 and CXCR4 positive or negative 
cells had detectable levels of CD105 was not assessed. Additionally, the gene expression profile as well as the 
tumorigenic potential of the spheres was not deciphered. 
Lastly, CD133 expression was found strongly correlated with nuclear HIF1α in RCC patients (155,156). CD133 
mRNA levels in blood showed to be useful for identifying metastasis, predicting recurrence, and stratifying 
the patients into different risk groups for possible adjuvant treatment (157). Nevertheless, CD133 expression 
analyzed by IHC in RCC patients was inconsistent and varied among different studies (146,158). 
2.1.3 CD44 
CD44 is a transmembrane glycoprotein of 85 KDa (742aa) encoded by the gene CD44 located on chromosome 
11. CD44 consists of 20 exons. Exons 1-17 are responsible for different regions of the extracellular domain, 
whereas exons 18-20 are responsible for the cytoplasmic tail. CD44 has more than 20 isoforms due to RNA 
alternative splicing, giving rise to different proteins in different cancer subtypes. It is involved in many 
different biological processes such as cell-cell interaction, cell adhesion, migration, proliferation, 
differentiation and angiogenesis (159). CD44 transcription was found activated by Wnt and β-catenin 
signaling pathway. It increases secretion of cytokines such as interleukin-8 (IL-8), TNFα and interleukin-1β (IL-
1β). 
CD44 binds primarily to the extracellular glycosaminoglycan hyaluronan (HA), promoting homing of CSCs in 
many tumor types. CSCs synthetize HA to attract tumor-associated macrophages (TAMs) in CSC niches. 
Stromal cells will in turn produce growth factors that regulate stem cell activity (159). Enhanced CD44 
expression was observed in RCC cell lines after co-culture with macrophages. This effect was the result of the 
activation of NF-kB pathway by the TNFα derived from TAMs (160). TNFα enhanced migration and invasion 
of ccRCC cells together with down-regulation of E-cadherin expression and upregulation of matrix 
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metalloproteinase 9 and CD44 expression (161). Knockdown of CD44 increased sensitivity to doxorubicin in 
hepatic cancer cells. Monoclonal antibodies against CD44 are now in clinical trial for patients affected by 
AML. 
Spheres derived from HEK293T, ACHN, Caki-1 and 786O renal cancer cell lines as well as CD105+ cells isolated 
from RCC specimens showed the presence of a CD44+ population having self-renewal properties, sphere 
formation capability and resistance to therapy (130,132,137). 
Moreover, CD44 expression was found correlated with Fuhrman grade, tumor stage, histological type, and 
poor prognosis in RCC patients (162). Upregulation of TNF-α together with CD44 was associated with primary 
tumor stage, distant metastasis, and poor treatment outcome (146,161). Therefore, CD44 expression may 
serve as a predictor of the number of metastases sites in RCC (158). 
2.1.4 CD24 
CD24 is a small cell surface protein molecule. It is composed by only 27 amino acids, and its molecular weight 
ranges between 20 and 70 KDa depending on the glycosylation. CD24 is encoded by the CD24 gene located 
in the chromosome 6q21. CD24 is expressed in a wide variety of cell types, including hematopoietic cells 
(163). Nevertheless, it is preferentially expressed in progenitor/stem cells. CD24 is an important maker for 
cancer diagnosis and prognosis in breast, non-small cell lung, colon, ovarian and prostate cancer (163,164). 
High CD24 expression was observed in CSCs derived from the RCC cell line Caki2 (165). Nevertheless, CD24 
expression together with the CSC marker CD44 showed contrasting results. CD24 expression was found 
correlated to tumor grade, overall survival and disease-free survival in RCCs suggesting its prognostic 
significance (164). 
2.1.5 CXCR4 
The CXC-chemokine receptor 4 (CXCR4 or CD184) is a seven transmembrane G protein-coupled receptor 
(GPCR) on the cell membrane. It is encoded by the CXCR4 gene located on chromosome 2q22. CXCR4 
selectively binds to the CXC chemokine stromal cell-derived factor 1 (SDF1 or CXCL12) leading to the 
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activation of a variety of biological processes such as stemness, survival, proliferation, migration, 
angiogenesis and differentiation (166). A number of signaling pathways are involved in the signal 
transduction. For instance, PLC/MAPK, PI3K/AKT, JAK/STAT and the Ras/Raf pathway. 
CXCR4 was found expressed in many different tumor tissues. It has been shown in breast, small cell lung 
cancer and neuroblastoma that CXCR4+ cells migrate towards tissues expressing high levels of SDF1 to 
metastasize (167,168). Therefore, CXCR4/SDF1 is involved in cell to stroma interaction creating a permissive 
niche for metastasis (146). 
CXCR4+ cells derived from RCC cell lines (RCC26 and RCC53; Caki1, Caki2, 786O and 769P) expressed high 
levels of stem cell-associated genes, resistance to therapy (TKI) and showed high capability to form spheres 
in vitro and tumors in vivo. Additionally, CXCR4 expression correlated with the tumorigenic potential in the 
cell lines. Inhibition of CXCR4 by ADM3100 or small interfering RNA (siRNA) impaired tumor formation 
(136,138). Moreover, overexpression of Notch1 upregulated CXCR4 in ACHN and Caki1 cell lines promoting 
SDF1 induced chemotaxis in vitro (134). 
Interestingly, loss of pVHL in ccRCCs as well as hypoxia showed increased CXCR4 and MMPs expression 
indicating HIF1α may be responsible for expansion of the CXCR4 population (169).Varna and co-authors 
showed that CD133+/CXCR4+ cells coexpressed HIF1α and were located in perinecrotic areas in RCCs (127). 
Moreover, hypoxia promoted CD133+/CXCR4+ cells tumorigenicity. HIF2α was shown to be involved in the 
expansion of CXCR4+ CSCs in four RCC cell lines (136). 
High mRNA levels of CXCR4 in primary tumors from RCC patients with localized disease predicted shorter 
survival. Analysis of 2’673 RCC patients by meta-analysis revealed CXCR4 overexpression correlated to worse 
overall survival (OS), cancer-free survival (CFS) and disease-free survival (DFS) (170). 
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2.1.6 ALDH1 
Aldehyde dehydrogenase 1 (ALDH1) is an enzyme involved in the alcoholic pathway. It catalyzes 
dehydrogenation of aldehydes to carboxylic acids. It has also been reported its role in stem cells through the 
retinoid signaling pathway. It is encoded by the ALDH1 gene located in the chromosome 9q21.   
ALDH1 plays an important role in cellular differentiation, proliferation, mobility, embryonic development and 
organ homeostasis(126). ALDH1 has been identified as a CSC marker many tumor types including breast, 
prostate and bladder (171,172). Its prognostic significance in RCC is still unclear (173), although ALDH1 was 
found correlated with tumor grade in RCC by Ozbek and co-authors (174). High expression of ALDH1 was 
found in the side population (SP) derived from the RCC cell line ACHN compared to the non-SP. Analysis of 
the ALDH1+ cells revealed enhanced ability to sphere formation, self-renewal, tumorigenicity and high 
expression of stemness genes compared to ALDH1- cells. Moreover, drug treatment or hypoxia increased the 
ALDH1+ cell population (126). 
2.1.7 ABCB5 
The drug efflux transporter ABCB5 (ATP-binding cassette, sub-family B, member number 5), is an integral 
membrane glycoprotein encoded by the gene ABCB5 located in the chromosome 7p21. It is composed of 812 
amino acids for an overall molecular weight of 90 KDa. This protein is involved in the transport of small ions, 
sugar, peptides and organic molecules across the plasma membrane (175).  
ABCB5 has been found overexpressed in CSCs in melanoma, liver and colorectal cancers. Moreover, it has 
been found associated with tumor progression, chemotherapy resistance and recurrence (176). 
ABCB5+ cells showed self-renewal and tumorigenic potential as well as differentiation capacity in vivo. 
Moreover, ABCB5 controls IL-1β secretion which, in turn, stimulates IL-8 production by ABCB5- cells present 
in the tumor bulk. IL-8 activates CXCR1 expressed by the ABCB5+ cells through paracrine and autocrine 
signaling (176). 
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2.1.8 Others 
DNAJB8 is part of the heat shock family proteins (HSP40) that regulate chaperone activity. It is encoded by 
the gene DNAJB8 located in chromosome 3q21. DNAJB8 is commonly expressed by the testis. Recently, 
Nishizawa et al., showed that DNAJB8 is expressed in different cancer cells including RCCs (135). In particular, 
the expression of DNAJB8 correlated with the SP compartment, and overexpression of the protein increased 
SP cells. Interestingly, DNAJB8 immunization completely abolished tumor formation in mice, indicating that 
DNAJB8 can be a target for immunotherapy (135). 
MicroRNAs (miRNAs) are non-coding small RNA molecules (~22 nucleotides) involved in regulating gene 
expression by translational repression, mRNA cleavage, and deadenylation. The role of miRNAs in CSCs has 
been described for different tumor types (177). Six miRNAs involved in TGFβ and Wnt signaling pathways 
showed the most significant variations in expression by RT-PCR between spheres and parental cells derived 
from two metastatic RCC cell lines, ACHN and Caki1. Among those, miR17 was significantly downregulated in 
Caki1 and ACHN spheres. Upon miR17 inhibition sphere formation was enhanced. This result showed that 
TGFβ signaling plays an important role in renal CSCs and that miR17 impairs the signaling cascade by targeting 
TGFβ receptor 2 (132). 
Galleggiante et al. isolated a subpopulation of cancer cells expressing CD133 and CD24 from 40 RCC samples. 
This population showed stem cell properties such as self-renewal, differentiation, tumorigenicity and 
expression of stemness-related transcription factors (141). CD133+/CD24+ cells appeared to be more 
undifferentiated compared to tubular adult renal progenitor cells. Interestingly, these cells also expressed on 
the cell membrane the amino acid transporter CTR2 which was found involved in resistance to cisplatin (141). 
Rhodamine 123 (Rh123) is a fluorescent dye that permeates the cell membrane and accumulates in the 
mitochondria proportionally to the mitochondrial membrane potential (178). 786O cells were stained with 
Rh123 and sorted by flow cytometry into two population: Rh123high and Rh123low. Rh123high exhibited high 
proliferative activity, differentiation, resistance to radiation, tumorigenic potential and spheroid formation 
in soft agar, indicating Rh123 as an alternative method to isolate CSCs (130). Moreover, spheres derived from 
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786O cell line expressed high levels of CD73 together with Rh123. CD73+ cells expressed high levels of 
stemness-related transcription factors. These cells were resistant to radiotherapy and were able to initiate 
tumors in vivo (129). 
2.2 Cancer stem cell isolation techniques 
Stemness traits can be acquired via genetic, epigenetic modification as well as interaction with the tumor 
microenvironment. This entire process has to be considered reversible, plastic and dynamic. All these 
mechanisms contributing to cellular plasticity render difficult to discover unique biomarkers. In fact, CSC 
markers are not unique across tumor types. Several studies have shown that non-CSCs can acquire CSC-like 
properties under certain conditions. At the same time, CSCs display different stemness features depending 
on the microenvironment, and these features may be transient. For this reason, different approaches for CSC 
isolation have been developed over the years (Fig. 2.2). 
Antigen-based methods require labelling of the cells based on the expression of specific markers. These 
include magnetic beads-conjugated antibodies (MACS) (179,180), fluorescent-activated cell sorting (FACS) 
(181,182), and side population (SP) analysis (183,184). However, dissociation of the tumor tissue into single 
cell suspension may damage surface antigens limiting the isolation of CSCs exploiting the use of cellular 
markers (183). In addition, no generally applicable markers are known so far, thus, characterization of 
putative CSC markers is often based on functional assays (148). 3D culture systems based on the use of 
scaffolds which recapitulate spatial organization and cell-matrix interactions as well as scaffold-free 
(anchorage-independent) methods are commonly employed in stem cell studies. These methods 
comprehend spheroid (185,186) and organoid cultures (187-189), sphere formation assay (144,182,186) and 
hanging drops (190,191), respectively. 
Finally, in order to evaluate tumorigenic potential of a tumor cell population expressing CSC features, cancer 
cells are serially transplanted into immunocompromised mice (serial tumor transplantations) at low cell 
density (limiting dilution assay, LDA). Cancer cells capable to develop tumors repeatedly and to recapitulate 
the histological features and heterogeneity of the parental tumor are defined as CSCs (106). 
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Figure 2.2. Identification and isolation of cancer stem cells. Several potential CSC markers are here depicted. 
CD105, TβR, CD133, CD44, CD24, CXCR4 and ABCB5 are some of the most studied membranous CSC markers. 
Whereas, miRNAs, DNAJB8, ALDH1 stand out among the intracellular CSC markers. Based on these markers, FACS 
and MACS have been adopted as isolation methods for the separation of CSCs from other tumor cells. More 
recently, other techniques exploiting CSC properties have been developed with the aim to discover potentially new 
biomarkers such as sphere assay, spheroid and organoid formation and hanging drops. 
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3. Tumor microenvironment and cancer stem cells 
It is becoming more important that tumor microenvironment, stroma cells, soluble molecules (i.e. cytokines 
and chemokines) and extracellular vesicles play an important role in modulating metastatic properties and 
sensitivity of tumor cells to therapy by promoting stem cell features (192). 
The tumor microenvironment is composed of extra-cellular matrix (ECM), cancer-associated fibroblasts 
(CAFs), endothelial and immune cells. ECM is composed of collagen, proteoglycans and all the non-cellular 
components present in the tissues. The ECM exerts its effect through so called mechano-transduction. 
Differential matrix stiffness and geometry are transmitted through cell contacts to the cytoskeleton and cells 
change their behavior according to such stimuli. YAP/TAZ, transcriptional coactivators of the Hippo pathway, 
were shown to be sensors and mediators of these mechano-stimuli enhancing CSC features. Moreover, an 
increased ECM stiffness can act as physical barrier blocking therapeutic agents. 
CAFs arise from multiple sources including tissue-resident fibroblasts, mesenchymal stem cells and 
endothelial cells. Compared to normal fibroblasts they exhibit high proliferative capacity, enhanced ECM 
production, release of matrix metalloproteinases (MMPs) and release of other mediators of intercellular 
communication such as SDF1, interleukin-6 (IL-6), VEGF, EGF, FGF, PDGF, and hepatocyte growth factor 
(HGF). Hence, CAFs stimulate stemness via activation of Wnt and Notch pathways (193). MMPs also 
contributes to Wnt signaling and stemness (194). 
Mesenchymal stem cells (MSCs) are adults stem cells involved in promoting cancer cell proliferation, 
angiogenesis, metastasis and immune escape (195). MSCs induce stemness in cancer cells through NF-kB 
signaling pathway by secreting SDF1, IL-6 and IL-8 and producing BMP antagonists (196). 
Lastly, the microvasculature surrounding the tumor is important component that supports cancer growth. 
And it is also a factor that determine dormancy. CSCs can transdifferentiate into endothelial cells and support 
their growth forming a niche. Stem cell niches are often localized in hypoxic region. 
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Approximately 1-1.5 % of the human genes are regulated by HIFs (137). Studying the role of HIFs and the 
pseudo-hypoxic condition in RCC has always been crucial to fully understand RCC tumorigenesis, and yet this 
process remains still unclear. 
It has been observed that hypoxia and enhanced expression and activity of HIF1 and HIF2 in cancer 
stem/progenitor cells and their progeny frequently occur during disease progression and metastases, and 
may induce the expression of several genes involved in self-renewal, survival, metabolism, angiogenesis, 
invasion, migration and resistance to therapy. Gene products involved in these pathways are Oct3/4, Nanog, 
Sox2 (189) (190) (191), Snail, Twist, VEGF, TGFβ, CXCR4 and EMT-associated molecules (192). 
At the same time, the sustained stimulation of EGFR, insulin-like growth factor-1 receptor (IGF-1R), stem cell 
factor (SCF) receptor KIT, TGFβRs, Notch and their downstream signaling elements such as PI3K/Akt/mTOR 
may lead to an enhanced activity of HIFs creating a positive feedback loop. 
Chronic exposure to elevated oxidative stress is sufficient to induce malignant transformation in kidney 
epithelial cells (HK2) through acquisition of stem cell characteristics such as CD44, CD24, CD133, ALDH1, Oct4, 
Nanog, E-cadherin, Vimentin, β-catenin, and Snail (193). Antagonistic effect of HIF1/2 towards c-Myc and 
TP53 appear to influence RCC development and progression. HIF1α antagonizes c-Myc activation, slowing 
down cell cycle and protecting CSCs from DNA damage and enhancing stemness features. In addition, Snail 
has been reported to reduce the expression of p53 by formation of the Snail-histone deacetylase 1 (HDAC1)-
p53 complex which leads to p53 proteasomal degradation (194). 
In the tumor, tumor microenvironment is characterized by chronic inflammation, which support tumor cell 
proliferation and progression (196). Tumor-associated macrophages (TMAs), tumor-associated neutrophils 
(TANs) and myeloid-derived suppressor cells (MDSCs) are recruited in the tumor milieu by cancer cells 
secreting cytokines and chemokines. These cells contribute to immunosuppression by secreting TGFβ, 
inflammatory cytokine and other factors, which maintains chronic inflammation. Additionally, TAMs and 
MSCs can produce exosomes, involved in promoting multidrug resistance and niche preparation. 
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The most common inflammatory molecules (i.e. IL-6, IL-8, TGFβ, NF-kβ, TNFα, and HIF) present in the tumor 
microenvironment during chronic inflammation activate downstream pathways such as TGFβ signaling, 
canonical and non-canonical Wnt, growth factor-receptor tyrosine kinase, and ECM-integrin signaling 
pathway which overlap with the process of epithelial-mesenchymal transition (EMT) (196). The EMT is a 
biological process that allows polarized epithelial cells to assume mesenchymal phenotype which includes 
enhanced migratory capacity, invasion and cell survival (197). The EMT program is often activated reversibly 
and partial EMT characterized by concomitant expression of epithelial and mesenchymal markers represent 
one of the most frequent state of a tumor cell. One of the characterizing features of a stem cell is the 
expression of mesenchymal markers. Interestingly, tumor cells in the non-CSC compartment can 
spontaneously undergo EMT changes and acquire CSC-like phenotype and surface marker expression. 
In conclusion, all these processes undergoing in the TME such as inflammation, hypoxia, angiogenesis and 
EMT contribute to maintenance of the CSC fate by acting on the most known pathways regulating CSCs: Wnt, 
SHH, Notch, TGFβ, and growth factor-receptor tyrosine kinase (RTK) (Fig. 3.1). 
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Signaling 
pathway 
CSCs Angiogenesis Inflammation EMT Hypoxia 
RTK + + + + + 
Notch + +  + + 
TGFβ/BMP + + + + + 
Wnt +  + + + 
NF-kB +  + +  
Hedgehog +   +  
 
Figure 3.1. Cancer stem cell signaling pathways. Stemness is determined by the activation of several signaling 
pathways. Many of these pathways overlap with some of the biological processes acting during tumor progression. 
Hence, inflammation, hypoxia, angiogenesis and EMT contribute to maintenance of the CSC properties. 
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3.1 Exosomes 
Exosomes are small membrane vesicles (40-100 nm) of endocytic origin formed within multivesicular bodies 
(MVBs) secreted by most of the cell types in response to hypoxia, change in pH and oxidative stress (198-
201). The exact mechanism of formation and secretion of these EVs is not fully clarified. RAB1A, RAB5A, RAB7, 
and in particular RAB27A, were found involved in exosomes secretion in melanoma cell lines (202). Exosomes 
contain functional nucleic acids (mRNAs, microRNAs and DNA), proteins and lipids (200,203). The exosomal 
protein content may vary depending on the cellular origin of the parental cells. These proteins include 
adhesion molecules, trafficking molecules, cytoskeleton molecules, chaperones, enzymes and signal 
transduction proteins (204-207). Released EVs may remain in close proximity to the place of origin or enter 
biological fluids and reach distant sites (208). Exosomes have been found in various biological fluids including 
blood, urine, breast milk and saliva (192). It has been shown that exosomes are involved in many different 
signaling processes related to intercellular communication, protein secretion pathway, immune system 
function, cancer progression and treatment failure (201,209). They may interact with target cells directly, by 
transferring receptors or delivering proteins and genetic information to other cells (208). They can be isolated 
from body fluids or culture supernatant by differential ultracentrifugation, immunoprecipitation or ELISA 
according to the surface marker expression (199). The top five oncogenic proteins found expressed in 
exosomes are CD9, HSPA8, CD63, GAPDH, and CD81 (210-212). Importantly, exosomes also contain Alix and 
TGS101, which are involved in formation of MVBs (195). 
Interestingly, cancer patients displayed an increased exosome content in the body fluids compared to healthy 
donors (213). Exosomes have been found also involved in the pathogenesis of Alzheimer disease by spreading 
β-amyloid peptides to the surrounding cells (214). 
Accumulating evidence shows that exosomes are mediators of metastasis contributing to the generation of 
the metastatic niche by exchange of molecules stimulating angiogenesis, modulating stromal cells, and 
remodeling ECM. Tumor-derived exosomes promote education and mobilization of bone marrow-derived 
cells (BMDCs) such as MSCs, mesenchymal stromal cells, dendritic cells (DCs) and bone marrow-progenitor 
cells (BMPC), that support angiogenesis, invasion and migration (202,215,216). Exosomes from highly 
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metastatic melanoma cell lines increased metastatic behaviors of primary tumors in mice by educating 
BMDCs through MET (202). They were also found to stimulate endothelial signaling promoting angiogenesis, 
preparation of the lymph nodes niche and acceleration of metastasis (217,218). 
Interestingly, cancer cells and stem cells seem to shed increased numbers of exosomes compared to other 
cell types (219). CSC-derived exosomes have been found involved in promoting angiogenesis in xenograft 
mice with renal cancer (124,220) and metastatic niche formation in lung carcinoma (221). Moreover, they 
enhanced invasion, migration and tumorigenic properties of cancer cells in colorectal cancer, breast cancer 
and glioblastoma (212,222-225). Several studies have shown that a cross-talk between CSCs and the tumor 
microenvironment indeed exist, thereby, not only CSCs may secrete exosomes which are taken up by other 
cells to model the tumor microenvironment in a favorable manner, but also cancer cells or stromal cells may 
shed exosomes to affect CSC fate (226). For instance, fibroblast-derived exosomes were found involved in 
promoting CSC features in vitro and in vivo. 
At the same time, exosomes play important roles the normal immune system as well as in tumor 
immunomodulation (201). Exosomes can negatively regulate T cells and natural killer (NK) cells. An increased 
number of exosomes was detected in patients with poor prognosis and resistance to chemotherapy (208). 
Exosome release has been found enhanced upon chemotherapy. In gastric cancer exosomes induced chemo-
resistance in vitro and in vivo by activation of the calcium/calmodulin-dependent protein kinases and the 
Raf/MEK/ERK kinase cascade in association with enhanced expression of multidrug resistance associated 
proteins (227). 
Exosomes can bind the antibody directed against specific receptors expressed by tumor cells reducing its 
efficacy as well as export anticancer drugs. On the other hand, exosomes have been explored as a vehicle to 
deliver miRNAs and drugs to cancer cells, perhaps exploiting the expression of tumor-specific markers on 
their membrane and the homing capacity (195). To date, exosomes are extensively used in regenerative 
medicine. In conclusion, exosomes represent a valuable tool to investigate cancer pathogenesis and to 
provide new insights into cancer diagnostics and therapeutics. 
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4. IL-8/CXCR1-2 
CXCL8 (CXC motif ligand 8 or IL-8), represents one of the major chemokines associated with the promotion 
of neutrophils and inflammatory response (228). IL-8 is undetectable under physiological state but it is rapidly 
induced by inflammatory cytokines such as TNFα and IL-1β as well as by hypoxia and hormones (229,230). IL-
8 belongs to the CXC chemokines family. It is encoded by the gene IL-8 located in chromosome 4 q12-q21. 
Initially produced as a 99 aa protein, it is rapidly cleaved to form a 72 aa (8-10 KDa) active form. Previous 
studies have demonstrated that IL-8 is involved in proliferation and survival of neoplastic cells. IL-8 is also 
associated with apoptosis, multidrug resistance, angiogenesis and metastasis-related tissue remodeling. 
Interestingly, IL-8 promotes the recruitment of bone marrow-derived MSCs to the tumor region, which 
support angiogenesis and tumor aggressiveness (231). For instance, kidney cancer cells were capable to 
secrete IL-8 and activate Akt signaling pathway via CXCR2 in MSCs inducing homing of MSCs (232). 
Additionally, activated MSCs efficiently recruited CXCR2+ neutrophils to the tumor region. The interaction 
between neutrophils and tumor cells resulted in elevated metastasis-related genes by tumor cells in breast 
cancer and lymphoma (233,234). IL-8 was also found recruiting macrophages in RCC (235). 
Dimerization of IL-8 is necessary for the receptor binding. IL-8 interacts with CXCR1 and CXCR2 with different 
affinities to mediate several cellular responses. CXCR1 receptors can be activated only by binding of IL-8, 
whereas CXCR2 is activated in response to multiple chemokines, neutrophil-activating peptide and 
granulocyte chemotactic protein 2 (230). CXCR1/2 are members of the GPCR family which contains seven 
transmembrane domains. They are encoded by the genes IL8RA and IL8RB located in chromosome 2q33-q36. 
CXCR1/2 have recently been demonstrated to be associated with CSC populations as well as proliferation, 
migration and invasion in certain type of human cancers such as breast, prostate, colon and pancreatic 
cancers (236-239). 
In particular, a recent study on pancreatic cancer showed that positive CXCR1 but not CXCR2 expression 
correlates with metastasis and poor survival rate in patients (236). Further, IL-8 increased sphere formation, 
migration and invasion, and these effects could be reversed by CXCR1 blockade. CXCR1 stimulation by 
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applying exogenous IL-8 increased the SP fraction, the expression of ABC transporters and decreased drug 
sensitivity in HCC (228). On the other hand, CXCR2 was found playing a critical role in tumor growth and 
metastasis formation in colon cancer (239). Ginestier et. al. developed a strategy to target breast CSCs using 
either CXCR1-specific antibodies or repertaxin. Repertaxin, a small molecule blocking CXCR1/2, was able to 
specifically target breast cancer xenografts retarding tumor growth and reducing metastasis (238). 
Additionally, ABX-CXCL8 treated mice exhibited significant reduction in tumor growth, angiogenesis and 
metastasis in bladder and melanoma xenograft models (229,240). 
The drug efflux transporter ABCB5 identifies CSCs in various cancers. Its expression is associated with clinical 
disease progression and tumor recurrence. Interestingly, the drug efflux transporter ABCB5 has been found 
functionally involved in the regulation of IL-8/CXCR1 signaling through IL-1β in melanoma cells and has 
therefore been associated with cancer stem-like cells, clinical disease progression and tumor recurrence 
(176). The correlation between IL-8 and ABC transporters has been proposed in ovarian and colon cancer as 
well (228). 
CXCL8 acts through several signaling pathways (Fig. 4.1). IL-8 activates PI3K followed by phosphorylation of 
Akt resulting in increased angiogenesis, cell migration and proliferation (230). IL-8 signaling also regulates 
MAPK signaling through PI3K in neutrophils and via EGFR resulting in Ras-GTPase activation in ovarian and 
lung cancers (241-243). It also stimulates PLC signaling which in turn induces the phosphorylation of protein 
kinase C, and promotes migration by increasing Ca+ concentration and regulating actin cytoskeleton (229). 
IL-8 has been shown to promote activation of EGFR and VEGFR promoting downstream activation of MAPK 
cascade (230). IL-8 is positively correlated with an increased phosphorylation of Src-kinases and focal 
adhesion kinase (FAK) in cancer cells which contributes to cell proliferation, cell survival and 
chemoresistance. Moreover, the Rho-GTPases may promote phosphorylation of Src and FAK with further 
impact on downstream transcriptional factors (229). IL-8 signaling induces β-catenin nuclear translocation 
and HIF1α in prostate cancer (244). 
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High IL-8 levels in blood samples correlated with shorter progression free survival in patients non-small-cell 
lung cancer (NSCLC) and colorectal carcinoma (CRC) (239,245). IL-8 confers resistance to EGFR inhibitors by 
inducing stem cell properties in lung cancer (245). In ccRCC, increased IL-8 expression was associated with 
sunitinib resistance in vitro and in vivo (61). Moreover, increased expression of IL-8 is a potential independent 
adverse prognostic biomarker for cancer-specific survival (CSS) and recurrence-free survival (RFS) in patients 
with ccRCC after nephrectomy (246). 
Nevertheless, the role of the IL-8/CXCR1 axis in ccRCC pathogenesis and CSC properties is currently unknown. 
 
Figure 4.1. IL-8 signaling pathways. Adapted from Liu Q. et al., “The CXCL8-CXCR1/2 pathways in cancer”, 
Cytokine & Growth Factors Reviews, 2016; and Waugh D.J.J. and Wilson C., “The interleukin-8 pathway in cancer 
“, Clinical Cancer Research, 2008. The diagram illustrates the major signaling pathways of IL-8 including PI3K or 
PLC, promoting activation of Akt, PKC calcium mobilization and MAPK singaling cascade. In addition, IL-8 activates 
member of the RhoGTPase family with effects on FAK/Src (dashed lines). 
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4.1 Cancer stem cell-targeted therapies 
Several therapeutic agents have been proposed targeting CSCs based on molecular mechanisms that regulate 
stem cell features. Interleukin-15 (IL-15) induced loss of the stem cell makers, tumorigenicity and sphere 
formation capability via differentiation of CD105+ cells from human RCC. Differentiated CD105+ CSCs became 
sensitive to chemotherapy (247-249). A phase I clinical trial on IL-15 is ongoing for melanoma and metastatic 
RCC patients (NTC01021059, http://clinicaltrails.gov/). As previously discussed, CSCs activate PI3K/Akt/mTOR 
singling pathway. Therefore, mTOR inhibitors have been proposed as potential therapeutic agents against 
CSCs. However, contrasting results have been reported in the literature so far. Bone morphogenetic protein 
2 (BMP2) has been shown capable to inhibit tumorigenicity of CSCs in osteosarcoma and renal cancer (250). 
However, no clinical trial involving BMP2 is registered for cancer patients. Among the agents targeting IL-
8/CXCR1-2 axis (Fig. 4.1), a clinical phase II study using repertaxin in combination with chemotherapy in 
metastatic triple negative breast cancer is running (FRIDA, http://clinicaltrials.gov/). Targeting CXCR1/2 using 
orally active small molecule antagonist (SCH-527123, SCH-479833) inhibited human colon liver metastasis by 
diminished angiogenesis and increased apoptosis. However, there was no difference in primary tumor 
growth (251). Navarixin blocks CXCR2 signaling inhibiting tumorigenesis in xenograft models of breast cancer, 
CRC, and melanoma (252). Moreover, the administration of humanized antibodies against IL-8 (ABX-IL8) has 
shown to attenuate the growth of bladder cancer and melanoma in xenograft models (230). A strategy using 
small interfering RNA has been shown to suppress ovarian tumor xenografts (253). Although IL-8 expression 
has been described associated with the multidrug resistance ABC transporters, conventional chemotherapy 
itself has been shown to induce IL-8 expression and secretion by cancer cells increasing the level of autocrine 
and paracrine IL-8 signaling. Thus, targeting IL-8 in combination with conventional chemotherapy agents 
and/or immunotherapy would be the next step towards overcoming tumor recurrence. Several other 
strategies have been proposed to target CSCs, which have not been experimented on RCC so far. They include 
targeting ABC transporters, CSC surface markers, inhibiting CSC related signaling pathways and delivering 
CSC-specific therapeutics (146). 
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OBJECTIVES OF THE STUDY 
5. Objectives of the study 
The project I have been carrying out during my Ph.D. focuses on understanding the mechanisms underlying 
tumor heterogeneity and cancer stem cell contribution to tumor progression, metastasis formation and 
therapy failure, which may ultimately promote the discovery of more accurate and reliable diagnostic and 
prognostic tools as well as provide the instruments for precise and patient-oriented therapeutic intervention. 
As an outline of the whole project, the workflow depicted in the figure 5.1 was established with the aim to 
address the following questions: 
1. Liquid biopsies as a potential diagnostic and prognostic tool for ccRCC patients; 
2. Dissecting tumor heterogeneity and personalized medicine using primary cultures; 
3. Identifying new biomarkers for renal cancer stem cells with potential therapeutic implications. 
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Figure 5.1. Dissecting tumor heterogeneity and cancer stem cell properties in clear cell renal cell 
carcinoma. Experimental workflow where liquid biopsies, patient-derived models and the investigation of cancer 
stem cell properties will lead to a better understanding of tumor heterogeneity and, therefore, RCC pathogenesis 
and therapeutic interventions. Mass spectrometry workflow adapted from Giesen C. et al., “Highly multiplexed 
imaging of tumor tissues with subcellular resolution by mass cytometry”, Nature Methods, 2014 (254).
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RESULTS 
6. Results 
In the following section, I will present three manuscripts I have completed during my Ph.D. work aiming to 
understanding tumor heterogeneity and cancer stem cell properties in clear cell renal cell carcinoma. 
6.1 Liquid biopsies as a potential diagnostic and prognostic tool for ccRCC patients 
6.1.1 Detecting circulating tumor DNA in renal cancer: An open challenge 
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Background: Detection of circulating tumor DNA (ctDNA) in blood of cancer patients is regarded as an important
step towards personalizedmedicine and treatment monitoring. In the present study, we investigated the clinical
applicability of ctDNA as liquid biopsy in renal cancer.
Methods: ctDNA in serum and plasma samples derived from ccRCC and colon cancer patients as well as ctDNA
isolated from RCC xenografts with known VHLmutation status was investigated using next generation sequenc-
ing (NGS). Additionally, a Taqmanmutation speciﬁc assaywas used for speciﬁc VHLmutation detection in blood.
Results: In our study, we successfully identiﬁed KRASmutation in colon cancer patients. We also conﬁrmed the
presence of speciﬁc VHL mutations in ctDNA derived from RCC xenografts indicating the capability of renal
tumors to release DNA into the blood circulation. However, we could not detect any VHL mutation in plasma
or serum samples derived from nine ccRCC patients. To increase the sensitivity, a VHLmutation speciﬁc Taqman
assay was tested. With this approach, the pVHL mutation p.Val130Leu in exon 2 in one patient was successfully
detected.
Conclusion: These data suggest a reduced tumor DNA shedding and an increased clearance of the tumor DNA
from the circulation in renal cancer patients independently of tumor size, metastases, and necrosis. This implies
that highly sensitive detection methods for mutation calling and prior knowledge of the mutation are required
for liquid biopsies in ccRCC.
© 2017 Published by Elsevier Inc.
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1. Introduction
The presence of nucleic acids circulating in the blood have been
shown for the ﬁrst time in 1948 by Mandel and Metais who discovered
the presence of DNA and RNA in the plasma of healthy and diseased do-
nors (Mandel and Metais, 1948). After this study, several others have
identiﬁed the presence of circulating free DNA (cfDNA) in the blood-
stream of patients and changes in the levels of these circulating nucleic
acids have been associated with tumor load and malignant progression
proposing these liquid biopsies as a novel prognostic, diagnostic, and
predictive tool for cancer patients, including renal cancer (Esposito et
al., 2014; Fleischhacker and Schmidt, 2007; de Martino et al., 2012).
However, correlation of cfDNA levels to tumor stage and grade in
renal cancer revealed discordant results (de Martino et al., 2012; Feng
et al., 2013; Perego et al., 2008; Jung et al., 2010).
In particular, it has been shown that the amount of circulating tumor
DNA (ctDNA) shed by cancer cells represents up to 10% of total cfDNA de-
rived fromblood inpatientswith advanced tumors (Schwarzenbach et al.,
2011). Thus, ctDNA opens the possibility to detect the mutational proﬁle
of a speciﬁc cancer during tumor evolution, metastasis formation and
therapy. Indeed, different mutations have been identiﬁed in cfDNA of
patients affected by colon, lung, ovarian and breast cancers (Esposito et
al., 2014; Kukita et al., 2013; Forshew et al., 2012; Diehl et al., 2008;
Schwarzenbach et al., 2008; Hashad et al., 2012). More recently,
Bettegowda and co-workers detected ctDNA in N75% of the patients
with advanced pancreatic, ovarian, colorectal, bladder, gastro-esophageal,
breast, melanoma and head and neck cancers but in b50% of patients
presenting with renal and prostate cancers (Bettegowda et al., 2014). In
particular, the release of ctDNAwas investigated in 5ml of plasmaderived
from ﬁve metastatic RCC patients. Prior analysis of the tumor tissue
revealed in one RCC patient aMETmutation, in one a HOOK2mutation,
and in three a VHLmutation. When analyzing the ctDNA, only one VHL
mutation and the MET mutation were successfully detected (40%). For
the detection of VHL, the authors used PCR-ligation and for the detection
of the METmutation SafeSeqS. Both methods are highly sensitive with
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detection limits below 1% allele count. However, for both assays the mu-
tation of interest has to be identiﬁed in the tumor tissue before analysis of
the blood samples. Therefore, the development of non-invasive methods
to detect de novo or to monitor already known tumor speciﬁc signatures
continue to be a major challenge in renal cancer.
Renal cell carcinoma (RCC), a malignant tumor affecting the adult
kidney, is among the 10 most common cancers, affecting around
64,000 people every year with 5% death incidence (Siegel et al., 2012).
Nearly half of all patients with RCC die within 5 years of diagnosis and
5-year-survival for those with metastatic disease is 5–10% (Moch et
al., 2000). This is mainly due to the fact that RCC is characterized by
asymptomatic manifestation in early stage and a poor response to ra-
diotherapy and chemotherapy in metastatic stage, making this tumor
type very difﬁcult to diagnose and treat (Baldewijns et al., 2008; Moch
et al., 2016). In particular, clear cell renal cell carcinoma (ccRCC) is the
most common type of RCC (Baldewijns et al., 2008; Moch et al., 2016).
Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene by
mutation or promoter methylation has been found responsible for
about 80% of ccRCC cases (Sato et al., 2013; Nickerson et al., 2008;
Gnarra et al., 1994; Latif et al., 1993; Zhang and Yang, 2012). The
majority of sporadic ccRCCs are characterized by chromosomal loss of
one allele located at chromosome 3p combined with a mutation in VHL
on the second allele (Beroukhim et al., 2009; Rechsteiner et al., 2011).
In the present study, the amount of cfDNA will be exploited as a
possible biomarker for ccRCC. We aimed to identify parameters which
might increase the presence of ctDNA such as tumor size or necrosis.
Additionally, ultra-deep next-generation sequencing and Taqman
mutation speciﬁc PCR assay will be employed to detect speciﬁc tumor
mutations in ctDNA, i.e., the tumor suppressor gene VHL, next to normal
cfDNA with high sensitivity.
2. Materials and methods
2.1. Ethics statement
This study was conducted in strict accordance with the recommen-
dations in the Swiss regulations on animal welfare and experimenta-
tion. The protocol was approved by the Ethics committee of the Zurich
Cantonal Veterinary Ofﬁce (license 06/2013).
2.2. Cell lines
The RCC cell lines A-498, HEK293, and SLR26, were purchased from
ATCC-LGC Standards (Manassas, VA). The cell lines were additionally
authenticated by IdentiCell. Cells were cultured using Dulbecco's Modi-
ﬁed Eagle Medium (Sigma) containing 10% vol/vol dialyzed fetal calf
serum (FCS) and 2 mM glutamine and they were split when reaching
80% conﬂuence.
2.3. Study cohort and sample collection
Peripheral blood (5 ml) was collected from nine consecutive ccRCC
patients shortly before surgery with a written informed consent of the
patients. None of the patients received treatments before surgery. In
parallel, tissue specimens derived from the partial or radical nephrecto-
my were ﬁxed and embedded in parafﬁn and evaluated by one pathol-
ogist (H.M.). Tumorswere histologically classiﬁed and graded according
to the World Health Organization classiﬁcation (Moch et al., 2016).
Tumor staging was performed according to the current TMN system.
The research protocol was approved by the local commission of ethics
(KEK-ZH-Nr. 2011-0072).
In addition, plasma from four colon cancer patientswith tumor stage
IV was kindly provided by our collaborators Dr. T. Winder and Dr. G.
Prager (PASSION-trail, NCT02119026).
2.4. Processing of blood
Peripheral blood (5 ml) was collected in serum (BD Vacutainer,
Plymouth, UK) or EDTA-containing tubes (BD Vacutainer, Plymouth,
UK) and processed immediately at 3500 rpm for 15 min at 4 °C after
collection. Serum and plasma samples were stored at−80 °C.
2.5. Circulating free DNA extraction
Circulating free DNA (cfDNA) was extracted from 1 ml of serum or
plasma EDTA using the QIAamp Circulating free DNA Kit (Qiagen,
Hilden, Germany) according to the manufacturer's instructions. CfDNA
concentrationwas thenmeasured using aﬂuorometric assay (High Sen-
sitivity dsDNA Assay, Qubit, Thermo Fisher Scientiﬁc/Life Technologies,
Zug, Switzerland). Additionally, DNA fragment distribution was ana-
lyzed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Basel,
Switzerland) in order to determine the quality of the DNA extracted
and the DNA fragment size.
2.6. Next-generation sequencing
Sequencing libraries of cfDNA samples were constructed with the
Ion AmpliSeq library preparation Kit 2 according to manufacturer's in-
structions. A human speciﬁc gene target set of primers (Cancer Hotspot
Panel (CHP2), Life Technologies) including BRAF, KRAS and VHL was
used in the ampliﬁcation process. The libraries were then quantiﬁed
by qPCRwith the Ion Library Quantitation kit (Thermo Fisher Scientiﬁc)
and amplicon distribution analyzed using the Agilent 2100 Bioanalyzer.
Subsequently, the libraries were diluted to 12 pM, mixed and used for
template preparation (Ion One Touch™ 200 Template Kit v2, Ion PI
Template OT2 200 Kit v3 or Ion PI Hi-Q OT2 200 Kit; Thermo Fisher
Scientiﬁc). The template Ion Sphere Particles (ISPs) were then enriched,
loaded on an Ion 318 Chip v2 or Proton chip and sequenced on the Ion
Torrent PGM System (Ion PGM Sequencing 200 Kit v2; Thermo Fisher
Scientiﬁc) or Proton platform (Ion Proton Sequencing 200 Kit v3 or
Ion Pi Hi-Q Sequencing 200 Kit; Thermo Fisher Scientiﬁc).
2.7. Sequence alignment and mutation detection
The sequences were aligned to the human genome hg19
(GRCh37.p5). The RefSeq for VHL was NM198156.4. The sequencing
run performance evaluation, the mutation detection (variant calling)
and the data analysis were performed using the Ion Torrent Browser
and Ion Reporter Software 4.2 using default settings of the integrated
analysis workﬂows(Thermo Fisher Scientiﬁc). Filter criteria for variant
calling included variant allele read count N10× and total coverage
N50×. All variants were inspected using the Broad Institute's Integrated
Genome Viewer (IGV).
2.8. Xenograft
SCID-beige mice (10 weeks old) were maintained in a speciﬁc
pathogen-free facility (Prof. I. Frew, license 06/2013, LASC Irchel Facility,
Zurich University, Switzerland). Mice were subcutaneously injected with
theA-498 cell line (5×106 cells) in BDMatrigel GFR (BDBiosciences) and
euthanized when the tumor size reached 1 cm3. Blood from mice was
collected, tumors were excised and the DNA isolated. Part of the tumor
tissue was used for histological preparation and evaluation.
2.9. PCR-speciﬁc mutation detection
The Taqman mutation detection assay kit (Cat #4465804) was
purchased from Applied Biosystems (Foster city, CA, USA) in order to
detect the mutation c.388GNC p.Val130Leu located in the exon 2 of
the VHL gene.
256 C. Corrò et al. / Experimental and Molecular Pathology 102 (2017) 255–261
A mutation speciﬁc primer was used to detect either the wt or the
mutated DNA template. The assay was performed according to the
manufacturer's instruction in 10 μl reaction volume and run on an ABI
ViiA7 Real-Time PCR machine (Applied Biosystems). T138 DNA was
derived from human tumor tissue as described by Rechsteiner and co-
workers (Rechsteiner et al., 2011) and was used as a negative control
in the Taqman assay.
2.10. Sanger sequencing
The PCR ampliﬁcation was performed with the same DNA as was
used for library preparation for next-generation sequencing (Table
S9). The sequencing run was performed as previously described
(Rechsteiner et al., 2013). Sanger sequencing data was analyzed by
Sequencher 5.1.
2.11. Statistical and computational analyses
Student's t-test was performed using SPSS Statistics 22 (IBM).
P-values b 0.05 were considered statistically signiﬁcant.
3. Results
3.1. ctDNA in renal cancer patients
Plasma and serum samples were collected from nine consecutive
ccRCC patients. Presence of metastases at diagnosis, tumor stage and
tumor necrosis was analyzed retrospectively. These factors potentially
increase the probability to detect ctDNA in the blood (Table S1).
The total cfDNA extracted from either serum or plasma ranged from
9.3–48.6 ng with a concentration of 0.31–1.62 ng/μl (Table S2). More-
over, the cfDNA fragment length was determined using the Bioanalyzer
and resulted in ~170 bp for all nine samples which was similar to the
fragment length detected in the plasma-derived cfDNA isolates from
colon cancer patients and xenografts. CfDNA and genomic DNA isolated
from the corresponding primary tumor tissue (FFPE) of the ccRCC cases
was then ampliﬁed using the Cancer Hotspot Panel (CHP2) and se-
quenced on the PGMplatform. The sequencingmetrics are summarized
in the supplementary Table S3.
We identiﬁed six different VHL mutations in the DNA derived from
the nine primary tumors of ccRCC patients (67%) which was in line
with ccRCC frequency described in previous studies (Rechsteiner et al.,
2011; Brugarolas, 2014). Three ccRCC patients (#P78; #P163 and
#P172) were wild-type for VHL. #P68 (primary tumor) showed the
VHLmutation c.345insC/p.Leu116ProfsX15 located in exon 2 with 15%
variant frequency. In #P69 (primary tumor) two VHLmutations were
detected in exon 2 with 10% variant frequency. In #P84 (primary
tumor) the VHLmutation c.300_315del16/p.Leu101AlafsX26 located in
exon 1was presentwith 6% variant frequency,whereas #P115 (primary
tumor) showed the VHL mutation in exon 2 c.345CNG/p.His115Gln
with 25% variant frequency (Table 1). Moreover, we could identify the
VHL mutation c.578insA/p.Asp193LysfsX63 in exon 3 in #P155 and, in
the same exon, #P159 showed the following mutation: c.488TNC/
p.Leu163Pro. These data were conﬁrmed by Sanger sequencing
(Fig. 1), but we could not identify the same VHL mutations in the
corresponding cfDNA derived from serum or plasma of ccRCC patients
although having a sequencing depth at these speciﬁc locations ranging
from 7880 to 10,895×. To increase the sensitivity ofmutation detection,
a second sequencing run was performed on the Proton platform using
the same NGS-libraries as used on the PGM platform. Again, no single
read with the appropriate mutation was detected.
The sequencingmetrics for the Proton run are aswell summarized in
the supplementary Table S4.
3.2. ctDNA detection in colon cancer patients
Since no VHL mutation was detected in cfDNA derived from VHL-
mutated renal cancer patients, a proof-of-concept study with four colon
cancer patients was initiated to determine whether we could detect
ctDNA in general. The total cfDNA extracted from the colon cancer pa-
tients ranged from 12.3–87 ng with a concentration of 0.41–2.90 ng/μl
(Table S5). Moreover, the size of the DNA fragments was determined
using Bioanalyzer and yielded ~170 bp in all the samples (Fig. S1a–d).
Subsequently, cfDNA samples were ampliﬁed using the CHP2 and se-
quenced on the PGM platform. The performance of the sequencing run
and the sequencing metrics are summarized in Table S6. Different muta-
tions in the KRAS gene were detected in three out of four samples ana-
lyzed. In particular, in patient #1 (#P1) the KRAS mutation c.TNC/
p.Ala146Thr in exon 4was detected with 8% variant frequency. In patient
#2 (#P2) nomutation was identiﬁed. Patient #3 (#P3) showed the KRAS
mutation c.GNT/p.Gln61His located in exon 3with 12% variant frequency
and the KRASmutation c.ANC/p.Gly12Val in exon 2 was revealed with
33% variant frequency in patient #4 (Table 2). As a control, patient #4
(KRAS p.Gly12Val) was successfully veriﬁed using Sanger sequencing.
These results indicate that tumor speciﬁc mutations can be detected
in cfDNA derived from plasma samples in colon cancer patients below
the detection limit of Sanger sequencing (10% variant allele frequency,
internal communication) using our NGS workﬂow presented here.
3.3. ctDNA detection in renal cancer xenografts
A second proof-of-concept study was started to test whether renal
cancer cells shed ctDNA per-se and whether mutations in VHL may be
detected in vivo. Therefore, SCID-beige mice (10 weeks old) were sub-
cutaneously injected with the renal cancer A-498 cell line (5 × 106
cells) in BD Matrigel GFR. One mouse (A2) obtained one injection and
another (A3) two injections into each ﬂank. When the tumor size
reached 1 cm3 (approx. after 7 weeks) around 800 μl of blood was
collected from each mouse and ~300 μl of plasma was obtained it. As a
control, blood was collected from a non-xenografted SCID-beige
mouse littermate (C2). After the collection of the blood, xenograft
tumors were excised (Fig. S2) and part of the tumor tissue was used
for histological preparation and evaluation and part was used for DNA
isolation.
Table 1
Tumor mutation detection on DNA extracted from FFPE.
Patient Mutation detected Total reads Reads for the wt Reads for the variant % wt % variant
#68 c. 345insC p.Leu116ProfsX15 exon 2 9867 8355 1492 85% 15%
#69 1) c.354CNT p.wt 1) 22,664 1) 20,303 1) 2360 90% 10%
2) c.388GNC p.Val130Leu exon 2 2) 22,778 2) 20,445 2) 2301
#78 WT (by Sanger sequencing) n.a. n.a. n.a. n.a. n.a.
#84 c.300_315del16 p.Leu101AlafsX26 exon 1 31 29 2 94% 6%
#115 c.345CNG p.His115Gln exon 2 11,058 8283 2748 75% 25%
#155 c.578insA p.Asp193LysfsX63 exon 3 (by Sanger sequencing) n.a. n.a. n.a. n.a. n.a.
#159 c.488TNC p.Leu163Pro exon 3 (by Sanger sequencing) n.a. n.a. n.a. n.a. n.a.
#163 WT (by Sanger sequencing) n.a. n.a. n.a. n.a. n.a.
#172 WT (by Sanger sequencing) n.a. n.a. n.a. n.a. n.a.
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Subsequently, cfDNA was isolated and its concentration was mea-
sured (Table S7). The total cfDNA extracted ranged from 8 to 12.1 ng
with a concentration of 0.266–0.402 ng/μl. Interestingly, no differences
were observed in cfDNA amount between control and xenograft mice
when normalized to the amount of plasma used as input.
cfDNA and DNA derived from xenografted tumor tissue were
extracted and then ampliﬁed using the human speciﬁc gene target set
from theCHP2 which includes VHL. Subsequently, the amplicons were
enriched and sequenced on the PGM platform. As a control, DNA de-
rived from the A-498 cell line, which was used for injection, was ampli-
ﬁedwith the CHP2 and sequenced in parallel.We successfully identiﬁed
the VHLmutation (c.426_429delTGCA/p.Val142fsX14located in exon 2)
in the cfDNA of mice (Fig. 2a), in the DNA derived from the correspond-
ing xenograft tumors (Fig. 2b), and in the A-498 cell line (Fig. 2a). The
sequencing metrics are summarized in the supplementary Table S8.
NGS of the xenografted tumor tissues revealed the presence of the
mutation of interest with N98% frequency, whereas in the cfDNA the
mutation was detected with 100% frequency in the mouse A2 and in
the mouse A3 with 3.5% variant frequency (Table 3).
These results indicate that the subcutaneously growing renal cancer
A-498 cell line can release its DNA in the tumor microenvironment and
in the blood circulation in mice and that our NGS approach delivers
reliable results using VHLmutations as a biomarker.
3.4. Mutation speciﬁc qPCR
Since our concept studies have validated and proven that ctDNA
with VHLmutations from renal cancer cells may be used as biomarker,
we tested whether the ctDNA detection in our renal cancer patient co-
hort was missed due to the sensitivity of our NGS workﬂow. Therefore,
a mutation speciﬁc qPCR was performed which has a detection limit of
b1%. For this experiment, patient #69 was selected because of the point
mutation c.388GNC/p.Val130Leu in VHL for which a commercial kit was
available. In this kit a VHLwild-type (wt) assay was included as control.
To determine assay speciﬁcity and sensitivity, DNA extracted from
HEK293 (wt at location c.388G) was ﬁrst tested using different amounts
of DNA input concentration (1.25 ng, 5 ng, 10 ng, 20 ng). The ct
values ranged from 38.5–35.7 for the mutation speciﬁc assay and from
26.0–21.7 for the wt assay with R2 = 0.95 and R2 = 0.99, respectively
(Fig. 3a). The limit of detection (LOD) of a realmutationwith themutation
speciﬁc probewas therefore set to ct=38.49when using 1.25 ng as input
for the mutation and ct = 25.06 for the reference. As additional controls,
Fig. 1. VHL next generation sequencing vs Sanger sequencing. Output data for deep sequencing of DNA derived from primary tumor tissue of ﬁve ccRCC patients. The electropherogram
highlights the same mutation identiﬁed by Sanger sequencing.
Table 2
Circulating tumor DNA detection in colon cancer patients.
Patient Mutation detected Total reads Reads for the wt Reads for the variant % wt % variant
#1 KRAS c.TNC/p.Ala146Thr exon 4 2666 2437 227 91.4% 8.5%
#2 No mutation was detected / / / /
#3 KRAS c.GNT/p.Gln61His exon 3 4876 4267 601 87.5% 12.3%
#4 KRAS c.ANC/p.Gly12Val exon 2 3490 2344 1144 67% 33%
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the SLR26 cell line (VHLc.389TNA/p.V130A), and T138 tissue (VHL
c.388GNT/p.V130F) were included as negative controls whereas DNA
derived from the patient's primary tumor was added as positive control.
We could successfully identify the mutation in 1.25 ng input DNA
derived from the primary tumor tissue (2−dct = 0.3; p-value: 0.0001;
Fig. 3b) and the cfDNA (3.8 × 10−4; p-value: 0.04). Moreover, we could
discriminate between the speciﬁc mutation (c.388GNC:3.8 × 10−4) and
anothermutation (c.389TNA: 2.3 × 10−6; p-value: 0.004) in the adjacent
nucleotide after normalization. Additionally, we could discriminate
between the speciﬁc mutation (c.388GNC: 3.8 × 10−4) and another
mutation (c.388GNT: 8.4 × 10−5; p-value: 0.009)at the same position
but involving another nucleotide.
These results show the higher sensitivity of the mutation speciﬁc
qPCR compared to our NGS approach, which is, however, only possible
with prior knowledge of a speciﬁc mutation.
4. Discussion
In this study, we could not detect VHLmutations in plasma or serum
samples derived from nine ccRCC patients using next-generation
sequencing, whereas we identiﬁed four speciﬁc KRAS mutations in
cfDNA derived from four colon cancer patients. Importantly, we con-
ﬁrmed that renal cancer is capable to shed ctDNA into the blood circula-
tion by detection of speciﬁc VHLmutations in cfDNA derived from RCC
Fig. 2.Next generation sequencing of the xenografts. a) Output data for sequencing of DNA derived fromxenografted tumor tissue andDNAderived directly fromA-498 cell line. b) Output
data for sequencing of cfDNA isolated from plasma of corresponding xenograft mice.
Table 3
Circulating tumor DNA detection in xenografted mice.
ID Mutation detected Total reads Reads for the wt Reads for the variant % wt % variant
Tumor tissue
A-498 cell pellet c.426_429delTGCA p.Val142fsX14 exon 2 2593 22 2571 0.85% 99.25%
A2 c.426_429delTGCA p.Val142fsX14 exon 2 2808 36 2772 1.28% 98.72%
A3L c.426_429delTGCA p.Val142fsX14 exon 2 1624 30 1594 1.84% 98.16%
A3R c.426_429delTGCA p.Val142fsX14 exon 2 1547 8 1539 0.51% 99.49%
cfDNA
C2 / 1839 1839 / 100% /
A2 c.426_429delTGCA p.Val142fsX14 exon 2 97 / 97 / 100%
A3 c.426_429delTGCA p.Val142fsX14 exon 2 9600 9266 334 96.5% 3.5%
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xenografts. We successfully identiﬁed such a speciﬁc VHLmutation in
the plasma sample of one ccRCC patient using a highly sensitive Taqman
mutation detection assay.
The physiological role of kidneys and the high vascularization of
ccRCC suggest a high likelihood to release ctDNA from the cancer cells
into the blood circulation. However, Bettegowda and co-workers
(Bettegowda et al., 2014) have shown that renal cancer represents
one of the tumor types with the lowest ctDNA shedding. ctDNA was
found in only two out of ﬁve patients (40%). In their study, cfDNA was
extracted from 5 ml of plasma derived from ﬁve metastatic RCC
patients. In three out of ﬁve cases (60%), VHLmutations were present
in prior analyzed tumor tissue. Only one VHL mutation was detected
subsequently in cfDNA using a highly sensitive PCR-ligation approach
(Bettegowda et al., 2014). In our analysis, nomutation in ctDNA derived
from nine ccRCC patients was detected by NGS.
Several other studies have tried to correlate the presence and the
amount of cfDNA to tumor stage and grade in renal cancer with discor-
dant results (de Martino et al., 2012; Feng et al., 2013; Perego et al.,
2008; Jung et al., 2010). However, none of them investigated the pres-
ence of VHLmutations in cfDNA. In these studies, cfDNA valueswere de-
termined using housekeeping genes in qRT-PCR. RCC patients showed
signiﬁcantly higher cfDNA concentrations compared to healthy donors.
Feng and co-workers analyzed 18 metastatic ccRCC patients showing
that plasma cfDNA levels were signiﬁcantly decreased upon sorafenib
treatment and these levels positively correlate with TNM stage and
Fuhrman grade (5). Further, cfDNA concentrations after eight to
24 weeks of treatment were able to predict remission, stable disease
or progression (5). On the contrary, de Martino et al. and Perego et al.
did not ﬁnd any signiﬁcant association between these parameters
after having analyzed serum and plasma samples derived from 112
and 39 ccRCC patients, respectively (4,6). These groups also observed
decreased cfDNA levels after nephrectomy (4,6). In our study, cfDNA
levelsweredetermined using aﬂuorometric assay (Qubit) and no corre-
lation was found between cfDNA levels and tumor stage, presence of
metastases and necrosis.
In contrast to RCC, ctDNA is readily detectable in colon cancer pa-
tients. ctDNA was found in N50% of the cases (Diehl et al., 2008;
Schwarzenbach et al., 2008; Bettegowda et al., 2014; Frattini et al.,
2006; Diehl et al., 2005), suggesting that the release of DNA into blood
is common among colon cancer patients. The concept of liquid biopsies
is therefore a very promising clinical tool for patients with colorectal
cancer. Our ﬁndings are in line with these results, as we also detected
KRASmutations in three out of four patients (75%). Importantly, KRAS
mutations in colon cancer were reported by our NGS analysis workﬂow
without knowing the mutation status i.e., to be present in the primary
tumor. Thus, our workﬂow allows the identiﬁcation of unknownmuta-
tions presenting ‘de novo’. This could be especially important after
targeted therapy, because this approach is not restricted to monitor
known mutations from primary tumor tissues.
In order to investigate the capability of RCC tumors to release ctDNA
in the blood, the RCC cell line A-498 was subcutaneously injected into
SCID mice. The analysis of the ctDNA release in vivo conﬁrmed the pos-
sibility to detect speciﬁc RCCmutations in heterotopic xenografts. These
results conﬁrmed that RCC cells are able to release ctDNA into tumor
microenvironment and blood circulation. Interestingly, a speciﬁc VHL
mutationwas found in the ctDNAof oneRCCpatient bymutation specif-
ic PCR (qPCR), indicating that this method has higher sensitivity than
NGS. The patient with this VHL mutation had low tumor stage and no
tumor necrosis, suggesting that qPCR could be applied also in patients
with low tumor burden. Unfortunately, mutation-speciﬁc PCR does
not allow a broadmutation screening since each PCR has to be designed
for a speciﬁc location and nucleotide change. The same is truewhen ap-
plying BEAMing or ddPCR technologies which are methods that have
even higher detection sensitivities. The detection limit of these tech-
niques lies below 1% allele count (Kukita et al., 2013; Diehl et al.,
2005; Kinde et al., 2011). Bettegowda and co-workers used plasma
volumes ﬁve times greater than in our approach in combination with
a highly sensitive detection method, which requires a known mutation
status of the patient's tumor tissue (PCR-ligation). This underscores the
limitations of liquid biopsies in clinical settings for renal cancer patients
because this approach is limited to patientswith knownmutation status
from primary tumor tissue.
It is tempting to speculate that ccRCC might have lower tumor
shedding in general compared to other tumor types i.e., colon cancer.
One could argue that speciﬁc mutationswere detected in the RCC xeno-
grafts because ctDNA was isolated after collection of blood samples by
complete bleeding of the animal. Further, RCC tumor cells were growing
subcutaneously at the injection side which is not the physiological
location of this tumor type. In addition, ctDNA is usually subjected to a
high clearance and the half-life of ctDNA has been shown to be from
few minutes to some hours (Fleischhacker and Schmidt, 2007). This
could be even more pronounced in renal cancers where ctDNA might
be easily excreted into the urine without entering the blood circulation.
In summary, highly sensitive detectionmethods and prior knowledge of
the mutation are required for liquid biopsies in renal cancer, limiting
their applicability in the clinics.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yexmp.2017.02.009.
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Fig. 3.Mutation speciﬁc qPCR. a) The HEK293 cell line (wt at location c.388G) was used as
negative control in order to determine the sensitivity and speciﬁcity of the assay. Different
concentrations of DNA (1.25 ng, 5 ng, 10 ng, 20 ng) were tested. The ct values ranged from
38.5–35.7 for the mutation speciﬁc assay and from 26.0–21.7 for the wt assay with R2 =
0.95 and R2 = 0.99, respectively. b) Normalized values for all the ﬁve samples in 1.25 ng
input DNA are reported in the ﬁgure which shows the detection of the mutation of
interest in the DNA derived from tumor tissue in #P69. The limit of detection (LOD)
calculated in Fig. 3a for 1.25 ng input DNA is highlighted in red.
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Supplementary table S1: ccRCC patient characteristics. 
Patient Tumor 
Grade 
Tumor 
Stage 
Presence of 
metastasis 
and tumor 
necrosis 
Tumor 
Dimension 
(cm) 
VHL Mutation Status 
#68 4 pT3a Yes 
necrosis 
8.5 c.345insC/p.Leu116ProfsX15 
exon 2 
#69 3 pT1b No 6.7 c.354C>T/p.wt 
c.388G>C/p.Val130Leu 
exon 2 
#78 1 pT3a No 6.0 wt 
#84 3 pT2b Yes 
necrosis 
10.5 c.300_315del16/p.Leu101AlafsX26 
exon 1 
#115 4 pT3a No 10.5 c.345C>G/p.His115Gln 
exon 2 
#155 3 pT3a No 9.5 c.578insA/p.Asp193LysfsX63 
exon 3 
#159 3 pT1b No 0.55 c.488T>C/p.Leu163Pro 
exon 3 
#163 3 pT3a, V1 No 8 wt 
#172 4 pT3a Yes 9.5 wt 
 
Supplementary table S2: cfDNA isolation from serum and plasma samples derived from ccRCC patients. 
Patient Serum [cfDNA] ng/µl Total [cfDNA] ng 
#68 1 ml 0.950 28.5 
#69 1 ml 0.633 19.0 
#78 1 ml 1.07 32.2 
#84 1 ml 0.967 29.0 
#115 1 ml 1.62 48.6 
 Plasma EDTA   
#155 1 ml 0.310 9.3 
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#159 1 ml 0.420 12.6 
#163 1 ml 0.482 14.5 
#172 1 ml 0.394 11.8 
 
Supplementary table S3: Sequencing metrics from the PGM platform in ccRCC patients. 
Patient Mapped Reads On Target Mean Depth Uniformity 
Primary Tumor Tissue 
#68 1,933,729 98.22% 8,465 94.08% 
#69 1,612,613 92.98% 6,555 97.63% 
#78 n.a. n.a. n.a. n.a. 
#84 64,119 90.77% 254.4 98.65% 
#115 2,252,690 96.70% 10,895 99.73% 
cfDNA 
#68 n.a. n.a. n.a. n.a. 
#69 2,270,554 83.89% 8,408 99.99% 
#78 n.a. n.a. n.a. n.a. 
#84 2,709,445 84.51% 10,164 99.58% 
#115 1,880,043 93.41% 7,880 99.41% 
#155 n.a. n.a. n.a. n.a. 
#159 n.a. n.a. n.a. n.a. 
#163 n.a. n.a. n.a. n.a. 
#172 n.a. n.a. n.a. n.a. 
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Supplementary table S4: Sequencing metrics from the PROTON platform in ccRCC patients.  
Patient Mapped Reads On Target Mean Depth Uniformity 
cfDNA 
#68 17,749,598 87.20% 847 71.00% 
#69 69,658,394 84.10% 245,786 95.48% 
#78 39,884,838 95.34% 2,252 87.79% 
#84 n.a. n.a. n.a. n.a. 
#115 84,252,873 93.34% 334,688 96.44% 
#155 5,806,973 94.69% 338 93.57% 
#159 5,117,607 91.67% 277 91.39% 
#163 32,682,145 93.00% 1,864 91.01% 
#172 34,848,264 95.76% 2,091 91.47% 
 
Supplementary table S5: cfDNA isolation from plasma samples derived from colon cancer patients. 
Patient Plasma EDTA [cfDNA] ng/µl Total [cfDNA] ng 
#1 1 ml 0.410 12.3 
#2 1 ml 0.656 19.7 
#3 1 ml 0.887 26.6 
#4 1 ml 2.9 87 
 
Supplementary table S6: Sequencing metrics from the PGM platform in colon cancer patients. 
Patient Mapped Reads On Target Mean Depth Uniformity 
#1 1,325,090 85.67% 4,983 99.90% 
#2 743,225 92.94% 3,067 99.99% 
#3 912,307 89.64% 3,700 99.79% 
#4 1,748,642 79.75% 6,079 99.05% 
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Supplementary table S7: cfDNA isolation from plasma samples derived from heterotopic xenografts. 
ID Tumor Volume Blood Volume Plasma EDTA [cfDNA] ng/µl Total [cfDNA] ng 
C2 No tumor 700 µl 280 µl 0.266 8.00 
A2 1 cm3 800 µl 400 µl 0.402 12.1 
A3 L: 1 cm3 
R: 0.5 cm3 
800 µl 350 µl 0.352 10.6 
 
Supplementary table S8: Sequencing metrics from the PGM platform in RCC xenografts. 
ID Mapped Reads On Target Mean Depth Uniformity 
Tumor Tissue 
A-498 
cell pellet 
668,443 97.43% 3,001 97.14% 
A2 771,817 97.43% 3,435 97.36% 
A3L 494,383 97.52% 2,193 98.74% 
A3R 464,635 97.60% 2,074 97.56% 
cfDNA 
C2 374,999 48.44% 151.2 9.48% 
A2 103,009 53.52% 663.8 27.9% 
A3 950,057 69.08% 2,365 50.3% 
 
Supplementary table S9: Sanger sequencing primer characteristics. 
 
Exon 1 2 3 
Primer 
forward 
5′-cgagcgcgcgcgaagactac-3′ 5′-accggtgtggctctttaaca-3′ 5′-gagaccctagtctgtcactgag-3′ 
Primer 
Reverse 
5′-gaccgtgctatcgtccctgc-3′ 5′-tcctgtacttaccacaacaacctt-3′ 5′-tcatcagtaccatcaaaagctg-3′ 
Size 
267bp 215bp 277bp 
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6.1.2 The dual function of exosomes in modulating cancer stem cell activities and improving the 
clinical applicability of liquid biopsies. 
 
In our study, exosomes were isolated from seven RCC cultures under normoxia and hypoxia conditions (48 
and 72 h) by differential ultracentrifugation. For hypoxic treatment, cells were cultured at 0.2 % of oxygen in 
an INVIVO2 hypoxia workstation 300 (Ruskin Technology, Bridgend, UK). As expected, isolated exosomes 
ranged between 40 and 100 nm in size (Fig. 6.1.2A). Normal kidney epithelial HK2 cell line was used as a 
control to compare tumor-derived RCC cultures with. Whereas, Burkitt’s lymphoma cell line Raji was used as 
internal positive control as it was previously shown secreting high levels of exosomes (255). 
Enhanced exosome secretion was observed under hypoxia condition in A498, 786O, 769P, ACHN, RCC4, Raji, 
SLR21 and SLR23 cell lines (Fig. 6.1.2B), indicating that environmental stress induces exosome release by 
cancer cells to communicate with neighboring cells. As proof of principle, protein expression of HIFs and HIF-
target genes was evaluated in Raji cell line by Western blot. High expression of HIF1α was observed upon 
hypoxia induction at 48 and 72h (Fig. 6.1.2C). At the same time, enhanced levels of CAIX and Glut1 were also 
observed (Fig. 6.1.2C). Considering that, exosomes contain functional nucleic acids (mRNAs, microRNAs and 
DNA), proteins and lipids (200,203); the exosome content was determined by exosomal protein 
quantification using BCA protein assay and Qubit protein assay. Protein content ranged between 14.6 µg/ml 
and 45.2 µg/ml under normoxia, whereas under hypoxia between 22.2 µg/ml and 70.7 µg/ml. Subsequently, 
exo-DNA quantity and quality was determined using Bioanalyzer and the fluorimetric Qubit dsDNA high 
sensitivity assay. Exosomes contained DNA fragments of about 300 bp in size, meaning no further processing 
(i.e. fragmentation) should be generated prior NGS (Fig. 6.1.2D). Moreover, no sign of DNA degradation or 
contamination by other nucleic acids was observed upon DNA extraction (Fig. 6.1.2D). In order to isolate 
exoDNA, the exosome suspension was treated with DNAse1 which digests cfDNA or DNA bound to the cell 
membrane. Afterwards, DNAse1 activity has been inactivated by adding EDTA and heating up to 70 °C for 10 
minutes. Exosome membranes were digested by proteinase K and exoDNA extracted using the QIAamp 
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Circulating free DNA Kit. The DNA content in the exosomes ranged between 0.4 ng/µl and 0.5ng/µl (Fig. 
6.1.2E), indicating it can be used for NGS analysis of the genomic content. 
As a next step, exoDNA will be exploited as a potential diagnostic and prognostic biomarker in the liquid 
biopsy setting next to the cfDNA, and as a tool to investigate tumor heterogeneity and RCC pathogenesis by 
genomic, transcriptomic, and proteomic analysis of the exosome content derived from in vitro cultures of 
RCC tumor cells (cell lines and primary cultures), and CSC subpopulations, as well as, in vivo tumor xenografts 
during tumor progression and upon therapeutic intervention. Ultimately, the information retained by the in 
vitro and in vivo tumor modelling will reflect and correlate to the clinicopathological features of the ccRCC 
patients. 
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Figure 6.1.2 A) Representative transmission electron microscopy (TEM) showing exosomes isolated from RCC 
cultures. The exosome size ranged between 40 and 100 nm. B) Hypoxia induces exosome release in all the cell 
line analyzed except for the normal kidney epithelial cell line HK2. An increased in the exosome content up to 
three fold was observed. No further enhancement in the exosome secretion was observed over 48h hypoxia 
incubation. C) As expected, western blot analysis of HIF1α and HIF-target genes CAIX and Glut1, revealed increased 
expression levels upon hypoxia incubation at 48h and 72h. D) exoDNA was successfully extracted from the 
exosomes without degradation or contamination by other nucleic acids as shown by the elecropherogram. ExoDNA 
exhibited a molecular size of around 300 bp (gel-like image), meaning no further processing (i.e. fragmentation) 
should be generated prior NGS.
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6.2 Dissecting tumor heterogeneity and personalized medicine using primary cultures. 
6.2.1 Cancer tissue biobanking at the next level: Establishing patient-derived renal cancer cell 
cultures as a resource for research and precision medicine 
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One sentence summary:  19 
Generation of patient-derived 2D and 3D renal cancer cell models as an integrative addition to 20 
routine tissue biobanking has the potential to provide more relevant tools for cancer research and 21 
ultimately advance precision medicine. 22 
   23 
Abstract 24 
 25 
Drug discovery screens and applied cancer studies often fail to translate into new cancer therapies 26 
because they rely on the use of immortalized cell lines that inadequately represent fundamental 27 
biological aspects of primary tumors. In order to provide more accurate renal cancer models for 28 
research and personalized medicine, we have extended routine tissue biobanking with patient-29 
derived cancer cell cultures from tumor nephrectomies sent to pathology for diagnostic purposes. 30 
We generated 2D and 3D cell cultures from renal cell carcinoma (RCC) surgical specimens and 31 
employed targeted sequencing, fluorescence in situ hybridization (FISH), cytology and 32 
immunohistochemistry (IHC) profiling to validate resemblance of these cell models to their 33 
respective primary tumors. Analysis of the mutational landscapes of four RCC-derived monolayer 34 
cell cultures over several passages revealed that genetically distinct subclones of the primary 35 
tumor were retained in the corresponding cell culture but were subject to clonal selection. We 36 
further explored the benefits of RCC cell models by comparative drug screening across different 37 
cell models. To conclude our findings, we suggest a general workflow for living cell biobanking 38 
from cancer tissue. The integration of 2D and 3D cell models into a comprehensive tissue biobank 39 
platform has the potential to satisfy the growing need for more relevant cancer models. It will 40 
provide a resource for scientists aiming to generate in vitro cell models that more closely resemble 41 
human cancers and are therefore suitable tools to advance pre-clinical drug development and 42 
precision cancer treatment. 43 
 44 
  45 
Introduction 46 
 47 
Despite the significant progress made in understanding and treating cancer in the last decades, 48 
this disease is still one of the leading causes of mortality worldwide accounting for 8.8 million 49 
deaths in 2015 (WHO Cancer Fact Sheet February 2017). At this scale, cancer-associated 50 
mortality is not only a health-related issue but also has significant economic impact. Consequently, 51 
the identification of novel therapeutic strategies and predictive biomarkers is still one of the most 52 
crucial aspects of pre-clinical and translational cancer research. Recent advances in sequencing 53 
technologies and the increasing feasibility of genomic tumor profiling have triggered a substantial 54 
rise in the development of anti-cancer compounds targeting specific genomic alterations. Yet, the 55 
average number of new drugs approved for cancer therapy has declined at the same time (1, 2). 56 
A major reason for the failure to translate promising drug candidates from the bench to the bedside 57 
can certainly be attributed to the inadequate use of model systems for human cancer research. 58 
Particularly in vitro cancer drug discovery screens have largely relied on monolayer cultures of 59 
immortalized cell lines, which often fail to recapitulate fundamental biological features of human 60 
tumors (3). Establishing patient-derived cell (PDC) cultures is one of the most promising strategies 61 
to overcome many of the disadvantages of using transformed cell lines. PDC models are 62 
potentially more accurate in reflecting patient-specific molecular features and are amenable to a 63 
variety of experimental applications making them essential tools for translational studies. 64 
Recently, three-dimensional (3D) cell culture formats have gained attention in disease modelling 65 
(4, 5). They are considered superior in retaining cell-cell and cell-matrix interactions, which more 66 
closely mirrors the architecture of human tissues and impacts on cellular behavior and drug 67 
response (6). However, a better understanding about phenotypic and molecular features of 68 
different PDC models and to what extend these represent the original human tumor is required to 69 
determine their optimal applications. 70 
 71 
As human PDC models will constitute important tools for predicting clinical treatment outcome and 72 
allow for individualized drug testing, they hold a particular promise for cancer patients with an 73 
unfavorable prognosis and a limited number of treatment options. Renal cell carcinoma (RCC) is 74 
a one of the cancer types that is associated with very high mortality and even novel treatment 75 
modalities using targeted therapy have failed to deliver a cure (7, 8). One reason for this 76 
shortcoming may stem from the fact that RCC is a diverse disease with significant 77 
pathophysiological and molecular heterogeneity (9, 10). The most frequent histologic subtype of 78 
RCC is the clear cell variant, accounting for about 70 - 80 % of adult RCCs (11, 12). Clear cell 79 
RCC (ccRCC) is characterized by the biallelic loss of the von Hippel Lindau (VHL) gene (13). To 80 
date, pre-clinical studies and screening programs of potential anti-cancer drugs have usually 81 
employed immortalized ccRCC cell lines, which represent inadequate platforms for drug discovery 82 
(3, 14, 15). Therefore, ccRCC patients may particularly benefit from the development of 83 
biologically relevant in vitro tumor models for the assessment of therapeutic alternatives. 84 
 85 
Here we describe the development of a comprehensive biobanking platform that has evolved from 86 
our extensive routine sample collection of biospecimens from human tumors. We outline a protocol 87 
for processing human surgical specimens and explore the feasibility of growing patient-derived 2D 88 
and 3D tumor cell models generated as an integrative addition to human tissue biobanking and 89 
patient care. We illustrate how PDC models can be validated in terms of their resemblance to the 90 
primary tumor and how comprehensive tissue biobanking can be utilized as a tool to bridge the 91 
gap between successful pre-clinical studies and success in clinical trials. Moreover, we also 92 
highlight challenges and pitfalls that may hamper the implementation of patient-derived cancer 93 
cell models. Our findings will serve as a resource for scientists aiming to overcome many of the 94 
disadvantages of using transformed cell lines for cancer research thus significantly advancing pre-95 
clinical disease modelling and early stage drug development.  96 
97 
Results 98 
Generation of a living biobank of PDC cultures from RCC 99 
The macroscopic and microscopic examination of surgical specimens and biopsies is the core of 100 
the diagnostic workflow carried out by pathologists. Tissue specimens are routinely archived as 101 
FFPE blocks, the gold standard material for histological and immunohistochemistry analysis (16-102 
18). With the advent of molecular pathology, we have established a complementing collection of 103 
fresh frozen cancer and adjacent normal tissue, which is a valuable asset for the use of –omics 104 
technologies (e.g. genomics, transcriptomics, epigenomics, metabolomics and proteomics) on 105 
human tissues. Recently, we have further extended our tumor tissue biobanking strategy by 106 
establishing primary cell cultures derived from surgical specimens of malignant human tumors 107 
(Figure 1). Such PDC models are amenable to a wide variety of molecular biology assays including 108 
high-throughput -omics and drug screens as well as the generation of PDX- and immune-oncology 109 
models. Even though our cell culture biobank receives a wide variety of tumors, our initial study 110 
focused on RCC. Surplus fresh RCC tumor tissue from human surgical specimens was sent to 111 
the cell culture biobank subsequent to pathological review. Frequently, the majority of the resected 112 
tissue was required for diagnostic procedures, which have priority over biobanking and research 113 
(Figure 1). Only for a subset of the renal tumor cases, we were able to obtain enough tumor 114 
material that allowed for the generation of PDC cultures. Over a period of three years, we acquired 115 
62 renal tumor samples. In 69.4 % (43/62 cases) we successfully established PDC cultures and 116 
expanded them to confluence for at least three passages. Upon entering the biobank workflow, 117 
primary tumor tissue was mechanically disaggregated and enzymatically digested with 118 
Collagenase A in order to obtain single cell suspensions (Suppl. Figure 1A). The size of tumor 119 
pieces we received ranged from approximately 0.5 - 8 cm3 yielding 100 000 to several millions of 120 
single cells (Suppl. Figure 1B). Dissociated cells were plated into Collagen I-coated cell culture 121 
dishes and maintained in K1 medium supplemented with 0.5 % fetal calf serum and Epinephrine 122 
which sustained primary cell viability (19, 20). In some instances, single cell suspensions of tumor 123 
cells were directly used for the formation of 3D PDC models or subjected to functional assays. 124 
Dissociated primary cancer cells were cryopreserved whenever enough material was available.  125 
 126 
Validation of PDC monolayer cultures from RCC 127 
From our initial cohort, we expanded 36 RCC PDC monolayer cultures to yield cell pellets suitable 128 
for formalin-fixation, paraffin-embedding (FFPE) and in situ analysis. We used these samples to 129 
construct a tissue and cell culture microarray (T/CMA), in which cylinders from surgical tumor 130 
samples were placed side-by-side to the corresponding cell cultures (Figure 2A and B). Using the 131 
T/CMA, we assessed whether PDC cultures resembled the corresponding patients’ primary 132 
tumors. When evaluating haematoxylin and eosin (HE)-stained sections, we found that histological 133 
features were rarely retained during FFPE-processing of cultured cells (Figure 2B). We therefore 134 
performed immunohistochemical analyses using eight markers commonly used in RCC 135 
diagnostics (Table 1 and Suppl. Table 1). Pax8 (Paired box 8) is a transcription factor expressed 136 
only in epithelial cells of the adult kidney (glomerular parietal epithelial cells, renal collecting ductal 137 
cells, atrophic renal tubular epithelial cells) and in about 90 % of renal cell neoplasms (21, 22). 138 
Indeed, 94 % (33/35) of cell cultures we derived from renal tumors were positive for Pax8 thereby 139 
recapitulating the positive staining of the primary tumors (Table 1 and Suppl. Table 2). Pax8 was 140 
not expressed in the primary angiomyolipoma, but was present in the corresponding PDC culture 141 
indicating that incongruity existed in some cases. Regardless of the passage number, all RCC-142 
derived cultures retained high expression of cytokeratins confirming their epithelial nature. 143 
Cytokeratin 7 (CK7), which has proven useful in the diagnosis of chromophobe and papillary RCCs 144 
(23, 24), displayed positivity in both the primary tumor and the corresponding PDC cultures in four 145 
out of five papillary RCC and in one chromophobe RCCs. In several PDC cultures, CK7 appeared 146 
to be upregulated while the corresponding primary tumor showed only little or no CK7 expression 147 
indicating that CK7 may be expressed during in vitro cell growth. Vimentin, a marker often 148 
observed in clear cell and papillary RCCs but rarely in chromophobe RCC and oncocytoma (25), 149 
stained positive in 11 of the 25 primary ccRCC and all papillary RCC cases on the T/CMA. 150 
Interestingly, Vimentin was positive in all but one PDC cultures, independent of the expression in 151 
the primary tumor, suggesting differential regulation during cell culturing similarly to CK7. All 152 
primary ccRCCs, one clear cell papillary RCC and two of five papillary RCCs showed positive 153 
immunostaining for CD10, a protein strongly expressed in podocytes and proximal tubular cell 154 
brush borders of the healthy kidney as well as in clear cell and papillary RCCs (25). Positive CD10-155 
staining was retained by 81 % (21/26) of the ccRCC- and clear cell papillary RCC-derived cell 156 
cultures. Interestingly, CD10 was slightly upregulated in all papillary RCC-derived cell cultures 157 
regardless of its expression status in the primary tumor. PDC cultures were further analyzed for 158 
the expression of Carboanhydrase 9 (CAIX), which is known to be expressed in the majority of 159 
ccRCCs and in a subset of papillary RCCs but not in normal renal cells (26). Of the 25 primary 160 
ccRCC and one clear cell papillary RCC samples displaying positive CAIX staining, 72 % of the 161 
corresponding cell cultures retained the immunophenotype (18/26). It is important to note that the 162 
two PDC cultures that did not retain Pax8 expression also failed to display matching CAIX staining 163 
when compared to the primary tumor. Only one primary papillary RCC showed expression of 164 
CAIX, which was not recapitulated by the corresponding cell culture. The RCC antibody generated 165 
against a crude microsomal fraction of proximal tubules from the normal human kidney (27) 166 
showed positive IHC staining in all but one ccRCCs and all papillary RCC but was negative in 167 
chromophobe RCCs and other neoplasms of the kidney. However, none of the PDC cultures 168 
displayed RCC positivity indicating that this marker was not suitable for cell culture validation. The 169 
c-kit proto-oncogene (CD117) was expressed in both primary chromophobe RCCs of the T/CMA 170 
as well as in the oncocytoma. None of the corresponding cell cultures retained CD117 expression 171 
casting doubt on the resemblance of the cultures to the primary tumors. Notably, for one patient 172 
of our cohort, papillary RCC type I with overexpression of c-Met was diagnosed as part of the 173 
clinical workflow. Our subsequent analysis confirmed that c-Met overexpression was preserved in 174 
the corresponding cell culture (Suppl. Figure 2A) verifying the resemblance between primary 175 
tumor and the cell culture derived thereof. 176 
Taken together, the analysis of Pax8, and Cytokeratin expression by IHC proved most useful in 177 
validating the renal epithelial origin of PDC cultures. CK7, Vimentin and in some instances even 178 
CD10 were found to be upregulated in the PDC culture regardless of their expression status in the 179 
primary tumor. Therefore, we found them of limited value for the validation of patient-derived cell 180 
cultures. In a number of cases, kidney cancer-specific markers such as CAIX or c-Met could 181 
confirm that the neoplastic phenotype of the tumor cells was retained during culturing. Our results 182 
suggest that IHC analysis can be a suitable tool to verify the origin of cell types, although frequently 183 
it did not provide sufficient information to distinguish renal cancer cells from normal epithelial 184 
kidney cells. 185 
 186 
Genotypic validation of known driver mutations is a more reliable method to exclude that PDC 187 
cultures contain predominantly benign epithelial cells. The most frequent histologic subtype of 188 
RCC, the clear cell variant, is characterized by a biallelic loss of the von Hippel Lindau (VHL) gene, 189 
which can occur by mutation, deletion or promotor methylation (13). We screened the primary 190 
ccRCC tumor samples of our cohort by targeted sequencing and found that 19 of the 25 ccRCCs 191 
carried a mutation in VHL (exons 1-3) (Table 1). Targeted sequencing of VHL in the corresponding 192 
cell cultures revealed that 68 % of samples (13/19) harbored the same VHL mutations as the 193 
primary tumor at various passage numbers. The remaining six PDC cultures (Patients 10, 12, 14, 194 
15, 19 and 20) displayed no VHL mutation within the detection limit of Sanger sequencing (10 % 195 
of mutated alleles in a heterogeneous population, (28)) thus revealing incongruity with the 196 
genotype of the primary tumor. Interestingly, both VHL mutations present in the clear cell papillary 197 
RCC primary tumor could be verified in the cell culture derived thereof. Somatic copy number 198 
alterations, particularly deletions affecting chromosome 3, are another hallmark of ccRCC that can 199 
be exploited for the comparison between primary tumors and corresponding cell cultures (29, 30). 200 
In the six VHL-wildtype ccRCC cases (Patients 3, 4, 16, 18, 22 and 24), we analyzed cytogenetic 201 
abnormalities on chromosome 3 by FISH (Figure 2C and Suppl. Figure 2B). Our results revealed 202 
that in all six cases 60 – 80 % of the tumor cells displayed either loss of the entire chromosome 3 203 
or deletion of the short arm of chromosome 3 (3p loss). These cytogenetic aberrations were 204 
recapitulated by each of the cell cultures derived from those tumors indicating their resemblance 205 
to the original tumors. 206 
As a result, using VHL sequencing and FISH analysis of chromosome 3 in primary tumors and 207 
PDC cultures, we could verify that 77% (20/26) of clear cell and clear cell papillary RCC-derived 208 
cell cultures matched the primary tumor on the genetic level. Interestingly, our IHC results 209 
indicated that from the six PDC cultures for which the VHL mutation could not be confirmed, one 210 
also did not display Pax8 expression (Patient 12) and four did not retain CAIX and/or CD10 211 
expression (Patients 12, 14, 15 and 19). This implies that these markers are the most useful for 212 
the validation of the neoplastic properties of ccRCC-derived cell cultures.  213 
 214 
Characterization of mutation spectra during ccRCC-PDC culturing 215 
For our subsequent analysis, we focused on three representative ccRCC-derived cultures and 216 
one that was generated from a ccRCC metastasis of the adrenal gland (Figure 3A). Cellular 217 
morphologies of the cultures established from fresh tumor tissue are depicted in Figure 3B. 218 
Importantly, VHL mutations of the primary tumors and the metastasis were retained in all cultures, 219 
as were the IHC profiles (Figure 3B and Suppl. Figure 3A, B, C and D). It is worth noting that unlike 220 
the other patient-derived cell cultures, cells obtained from the ccRCC metastasis (Patient A) have 221 
not undergone senescence to date and keep proliferating past passage 25.  222 
To gain insights into genotypic changes associated with culturing of PDCs, we assessed the 223 
mutation spectra of primary ccRCCs and cell cultures by next generation sequencing (NGS). We 224 
successfully obtained tumor specific genomic profiles for the complete coding sequence of 409 225 
cancer genes using the Ion Ampliseq Comprehensive Cancer Panel (CCP) for primary tumors as 226 
well as from the PDC cultures at different passages for each of the four patients described. 227 
Genomic alterations were highly concordant between primary patient samples and the 228 
corresponding cell cultures (Suppl. Figure 3E). Notably, concordance was higher between 229 
samples originating from the same patient than between cell cultures derived from different 230 
patients excluding genetic adaptation due to culture techniques. Besides the VHL driver mutations 231 
identified by targeted Sanger sequencing, primary tumors and corresponding cell cultures 232 
exhibited non-silent somatic mutations in well-known ccRCC-associated genes like PBRM1, 233 
SETD2 and BAP1 (13). Additionally, we identified several mutations in the primary tumor that were 234 
not only retained but enriched during PDC serial passaging (Figure 3C). Genes we found to be 235 
mutated in that manner included FLT3, ERBB3, ERCC2, PAX3, DST, KMT2D and SRC. However, 236 
the overall diversity of mutations present in the primary ccRCCs and the ccRCC metastasis 237 
diminished during in vitro cell growth. A significant number of mutations observed in the primary 238 
tumor were not detected in the corresponding cell cultures or were only present in early passages. 239 
Loss of tumor-specific variants appeared lower when comparing patient-derived cell cultures to 240 
dissociated fresh primary tumor cells (patients B and C). When FFPE tissue of the original tumors 241 
was used as a reference (patients A and D), the apparent loss of variants observed during serial 242 
cell culture was higher. This was likely due to formalin-induced sequencing artefacts or sampling 243 
discrepancies (31). Genetic adaptation of the cell cultures seemed limited and often variants that 244 
appeared after passaging of patient-derived cells were categorized as “low confidence” during the 245 
analysis. We therefore concluded that subclones with distinct mutational profiles coexisted within 246 
the tumor and were subject to clonal selection during cell culture of the primary material.  247 
 248 
Drug profiling in patient-derived 2D and 3D cancer models 249 
Human PDC models can be utilized to predict clinical treatment outcomes by individualized drug 250 
testing. In ccRCC patients with low grade or localized disease, targeted therapy is administered 251 
only when the tumor relapses and metastasizes. To preserve PDCs until patients require drug 252 
treatment, we stored them in liquid nitrogen. Importantly, none of the four patients described here 253 
(Figure 3A) have received systemic therapy and none of them have experienced a relapse yet. 254 
Nevertheless, we reactivated a subset of their samples for a proof-of-principle study. 255 
Cryopreserved dissociated and passaged cells were thawed and put into culture. Some samples 256 
failed to regrow due to reduced cell viability upon thawing illustrating the inherent risk associated 257 
with cryopreservation. We successfully regenerated PDC cultures from frozen cells for patient A 258 
and confirmed the VHL mutation. Consequently, we determined a cell doubling time of 259 
approximately four days (Suppl. Figure 4A). For cells derived from patient B, the culture we 260 
reconstituted from frozen dissociated or passaged cells did not recapitulate the VHL mutation of 261 
the original tumor and the cell culture established from fresh cells.  262 
Three-dimensional cancer cell models are considered to more accurately mirror the complex 263 
spatial organization of tumor tissue in vivo (6). Here, we used cells cryopreserved after tissue 264 
dissociation or 2D growth to test their capacity of forming microtissues using the hanging drop 265 
technology (hereafter referred to as “microtissues”) (32). Dissociated primary as well as passaged 266 
frozen cells developed stable aggregates within three days under the condition that exogenous 267 
normal human dermal fibroblasts (nHDF) were supplied at a ratio of 1:20 (Figure 4A). Microtissues 268 
reached a final size of about 100-200 μm in diameter. Characterization by IHC revealed that 269 
expression of cytokeratins, Pax8 and CAIX was retained in the microtissues derived from patient 270 
A but only in a small subset of cells from patient B (Figure 4A). Likewise, we used cryopreserved 271 
dissociated primary and passaged cells to establish tumor organoids grown in matrigel (hereafter 272 
referred to as “organoids”) using a workflow that has been described previously (33). Overall, we 273 
noted that proliferation of ccRCC cells in matrigel was slow and required supplementing the cell 274 
culture medium with additional growth factors and epinephrine (refer to Material and Methods). 275 
Cells derived from the ccRCC of patient A formed only small organoids consisting of few cells 276 
(Figure 4B). Organoids generated from dissociated ccRCC cells from patient B developed readily 277 
but contained a mixture of morphologically distinct entities. Further characterization of cells from 278 
organoids by cytology revealed the presence of multiple nuclei, large nucleoli and clear vacuoles 279 
all of which are suggestive of malignancy (Figure 4B). A detailed summary of benefits and 280 
limitations of the 2D and 3D cell models used in this study is given in table 2. 281 
As cell models derived from cells of patient A best represented the primary tumor, we utilized 282 
these to examine drug responses to a panel of agents used to treat locally advanced and 283 
metastatic ccRCC (34). Overall, the correlation between drug sensitivity was high across different 284 
PDC models (Figure 4C). Three-dimensional PDC models showed a slightly higher sensitivity 285 
towards the targeted agents than the monolayer culture. Remarkably, 2D and 3D models derived 286 
from this particular patient responded only modestly to any of the therapeutics. Severe cytotoxicity 287 
was only induced by high doses of sunitinib, albeit in all PDC models. Treatment with high doses 288 
of everolimus caused significant cell death in microtissues and was reflected by changes in their 289 
morphology (Suppl. Figure 4 B). Similarly, treatment with high doses of sunitinib caused extensive 290 
disruption of microtissue morphology. A decrease of microtissue size was also detected after 291 
treatment with pazopanib and carbozantinib but failed to translate into a perceivable reduction of 292 
signal in the cell viability assay (Figure 4C).  293 
 294 
  295 
Discussion 296 
The increasing understanding of the remarkable complexity of human malignant tumors has 297 
triggered the emergence of a new paradigm for medical care in which treatment is tailored to 298 
patient-specific cancer subtypes. Part of this development has been the growing interest in using 299 
biospecimen collections and ultimately PDCs as model systems for translational research and 300 
drug profiling (5, 33, 35). In this article, we focused on renal cancers describing a platform enabling 301 
us to generate and incorporate patient-derived cancer cell models into a comprehensive tissue 302 
biobanking strategy as an integrative addition to patient care.  303 
While primary tumor cells isolated from surgical RCC specimens represent the most relevant in 304 
vitro disease model, their direct use presents several challenges: With early detection and 305 
permanently optimized surgical interventions, the availability of such specimens becomes 306 
increasingly limited. Due to the priority of diagnostic procedures, relinquishing sufficient amounts 307 
of primary tissue for research purposes is restricted. The expansion of cells derived from primary 308 
RCC tissue by culturing techniques can circumvent this problem but requires stringent validation 309 
in order to ensure that the cultures are viable, retain important molecular features of the primary 310 
tumor and are not contaminated with non-tumor or stromal cells that can outcompete the cancer 311 
cells during growth (36, 37). Targeted sequencing of the VHL driver mutation and analysis of 312 
chromosome 3 by FISH enabled us to confirm the resemblance of 20 out of 26 patient-derived 313 
ccRCC and clear cell papillary RCC cell cultures to their respective primary tumors resulting in a 314 
validation success rate of 77 %. Since such characteristic molecular features are relatively rare or 315 
yet unknown in the remaining RCC subtypes, we evaluated the expression of a RCC-specific 316 
panel of IHC markers for all cases (38). We concluded that contamination of mesenchymal cells 317 
was not a primary concern but in accordance with previous reports, we observed that benign 318 
epithelial kidney cells could efficiently grow under cell culture conditions (5, 37). According to our 319 
results, IHC alone was often not reliable in confirming the malignant phenotype of the cultured 320 
cells.  321 
One of the main advantages of PDC cultures may be its ability to more adequately represent the 322 
mixed heterogeneous cell populations of the primary tumor. In PDC cultures, non-silent, somatic 323 
variants were highly correlated with those found in the original tissue. The VHL driver mutations 324 
as well as subsets of mutations commonly found in ccRCC were not only maintained but also 325 
enriched during serial passaging of cell cultures. In contrast to data reported for xeno-326 
transplantation of human tumor cells into immunodeficient mice, PDC in vitro cultures were hardly 327 
permissive for new variants to arise (39). Our findings therefore reflect the capacity of PDC 328 
cultures to capture a subset of sub-clonal populations. As our data also indicates that clonal 329 
selection is an ongoing process during in vitro cell growth, early passages should resemble the 330 
original tumor more closely in terms of genetic cellular heterogeneity. In order to preserve the 331 
original, most heterogeneous populations of tumor and associated cells, we cryopreserve 332 
dissociated tumor cells before culturing whenever possible. We perceive that PDC models will be 333 
utilized for various translational cancer studies in the context of personalized medicine. Since 334 
primary cell cultures usually become senescent after a few passages, both applications may 335 
require temporary storage of early-passage cells for later use (i.e. biobanking). However, cultures 336 
generated from frozen cells did not always display the VHL driver mutation of the primary tumor 337 
and the original cell culture making it essential to validate newly established cultures again. 338 
Lastly, we sought to explore the utility of patient-derived ccRCC models for sensitivity testing 339 
against a number of clinically approved drugs. Two-dimensional cell culture models are sometimes 340 
considered too simplistic for such experiments because they fail to recapitulate important aspects 341 
of spatial interactions and structural organization of human tumors (32, 33, 40, 41). As drug 342 
responses may ultimately vary depending on the cell culture assay conditions, we additionally 343 
generated 3D microtissues and multicellular spheroid models from PDCs. Success rates for the 344 
generation of 2D and 3D cultures varied greatly with no one model being more effective for the 345 
majority of the cases. The efficacy of a panel of targeted drugs used to treat metastatic ccRCC 346 
was comparable across 2D and 3D RCC cell culture models. In contrast to a study carried out with 347 
breast cancer cell models, we did not observe increased drug resistance in 3D models (42). 348 
Treatment with the targeted agents used in this study rather resulted in a slightly higher cytotoxicity 349 
in the 3D cell models compared to the monolayer cell culture. Taken together, patient-derived 350 
short-term 2D cell cultures represented the original ccRCC and allowed for in vitro screening at a 351 
reasonably large scale and moderate cost. Patient-derived 3D cell models were associated with 352 
considerably higher costs and their inherent complexity presented additional experimental 353 
challenges. Importantly, RCC microtissues and 2D cell cultures required only a few weeks while 354 
3D organoid cultures needed approximately two to three months of propagation to produce drug-355 
sensitivity data. Microtissues were unsuitable for expanding the limited amount of primary cell 356 
material whereas monolayer cell cultures and organoids could be cultured for several passages 357 
to facilitate biobanking of PDCs. Additional advantages and disadvantages of the cell culture 358 
models used in this study are summarized in table 2. 359 
A biobank should potentially fulfill requirements for a variety of research questions of the 360 
biomedical community. Provided that sufficient primary tumor tissue is available, it is advisable to: 361 
(i) cryopreserve dissociated tumor cells, (ii) generate 2D and 3D models for propagation of limited 362 
primary cell material, (iii) preserve and store living passaged cells for later use, and (iv) implement 363 
stringent, tumor type specific validation criteria (Figure 5). This demonstrates that collecting a well-364 
characterized cohort of representative PDC samples must be a collaborative effort and will require 365 
significant resources. In conclusion, our results indicate that RCC-derived cell models, validated 366 
and characterized in the context of diagnostic tissue collections, can be employed for drug profiling 367 
and might provide important information to direct ccRCC treatment decisions. Even though, more 368 
thorough analysis may be required before such cell models can be implemented in routine clinical 369 
procedures, PDC cultures represent a valuable resource for translational cancer studies and can 370 
provide key rationales for designing clinical trials in order to identify novel therapeutic options. 371 
 372 
  373 
Materials and Methods 374 
 375 
Ethics Statement 376 
All tissue samples were made available by the Tissue Biobank of the Institute of Pathology and 377 
Molecular Pathology, University Hospital of Zurich, Switzerland. The local ethics commission 378 
approved this study (KEK-ZH-Nr. 2011-0072 and KEK-ZH-Nr. 2014-0614) and all patients gave 379 
written consent. 380 
 381 
Specimen Procurement and tissue processing 382 
Renal tumors and neoplasms were surgically resected and underwent routine tissue processing 383 
and rapid sectioning for diagnostic purposes and biobanking (including formalin fixation and 384 
paraffin embedding, snap freezing of fresh tumor and normal tissue). A pathologist with 385 
specialization in uropathology (H. Moch) reviewed all tissue specimens. Tumors were 386 
histologically classified and graded according to the WHO classification (43). If available, 387 
additional fresh tissue samples macroscopically identified as cancer from adjacent areas were 388 
placed into sterile 50-ml conical tubes containing transport media (RPMI (Gibco) with 10 % FCS 389 
(Gibco) and Antibiotic-Antimycotic® (Gibco)) and stored at 4 °C. Tissue samples were further 390 
processed within 24 hrs. 391 
Tissue specimens were rinsed with PBS and finely cut into small fragments using a scalpel. 392 
Consequently, samples were enzymatically digested in a TBS/Collagenase A-mix containing a 393 
surplus of Ca2+ for 2-3 hrs at 37 °C.  The slurry was passed through a 70 µm cell strainer to remove 394 
large fragments and centrifuged at 1000 rpm for 5 min. The Collagenase A digestion was stopped 395 
by incubating the pellet in 1 ml Stop solution (50 mM Tris, 150 mM NaCl, 10 mM EDTA) for 5 min 396 
at room temperature. Cells were washed once with PBS and erythrocytes were lysed by incubating 397 
the cells in ACK buffer (150 mM NH4Cl, 10 mM KHCO3, 100 mM EDTA) for 2 min. After a final 398 
wash with PBS, the viability of the dissociated cells was evaluated by trypan blue dye exclusion. 399 
Appropriate amounts of cell suspension were resuspended in freezing medium (FCS containing 400 
10 % DMSO) for long-term storage in liquid nitrogen. 401 
 402 
Generation of monolayer primary cell cultures 403 
Dissociated cells (fresh or frozen) were resuspended in K1n medium (Dulbecco's Modified Eagle 404 
Medium: Nutrient Mixture F-12 (DMEM:F12, Gibco) with 0.5 % FCS (Gibco), Antibiotic-405 
Antimycotic® (Gibco), 2.5 µg/ml insulin (Sigma), 0.625 ng/ml Prostaglandin E1 (PGE1, Cayman 406 
Chmical), 26 pM 3,3,5, Triiodthyronine (T3, Sigma), 2.5 µg/ml transferrin (TF, Sigma), 50 pM 407 
sodium selenite (SS, Sigma), 25 nM Hydrocortisone (HC, Sigma), 10 µg/ml EGF (Thermo Fisher) 408 
and 0.5 µg/ml epinephrine (Sigma)) and transferred into collagen I-coated cell culture dishes 409 
(Corning) for culture in a humidified incubator at 37 °C with 5% CO2. The medium was replaced 410 
no earlier than 5 days after initial plating and subsequently every three to four days. Cells were 411 
expanded by passaging and aliquots were regularly frozen in liquid nitrogen for biobanking 412 
purposes. 413 
 414 
Generation of 3D tumor organoids 415 
Generation of tumor organoids was performed as described previously (33). In brief, an 416 
appropriate amount of dissociated cells was resuspended in a small volume of 3D media 417 
(Advanced Dulbecco’s modified Eagle medium (Gibco) with 1X Glutamax (Gibco), B27 418 
supplement (Gibco), Antibiotic-Antimycotic (Gibco), 1.25 mM N-Acetylcysteine (Sigma), 50 ng/mL 419 
Mouse Recombinant EGF (Thermo Fisher), 20 ng/mL Human Recombinant FGF-10 (Thermo 420 
Fisher), 1 ng/mL Recombinant Human FGF-basic (Thermo Fisher), 10 µM Rock inhibitor Y-27632 421 
(Selleck Chemical Inc), 500 nM A-83-01 (Tocris Bioscience), 10 µM SB202190 (Selleck Chemical 422 
Inc), 10 mM Nicotinamide (Sigma), 1 µM PGE2 (Sigma), 2.5 µg/ml insulin (Sigma), 0.625 ng/ml 423 
Prostaglandin E1 (PGE1, Cayman Chmical), 26 pM 3,3,5, Triiodthyronine (T3, Sigma), 2.5 µg/ml 424 
transferrin (TF, Sigma), 50 pM sodium selenite (SS, Sigma), 25 nM Hydrocortisone (HC, Sigma), 425 
0.5 µg/ml epinephrine (Sigma), Noggin and RSpondin (conditioned media, self-made) and mixed 426 
with a 1:1 - 1:2 volume of growth factor reduced Matrigel (Corning). Drops of cell 427 
suspension/Matrigel were distributed in a cell culture plate and allowed to solidify for 30 min at 428 
37°C, upon which 3D media was added to cover the drops. The media was replaced every five to 429 
seven days. Organoids at approximately 300 to 500 µm were passaged by incubation with TrypLE 430 
Express (Gibco) for up to 30 min in a water bath at 37°C. The trypsin was then inactivated by 431 
adding at least three volumes of DMEM containing 10 % FBS and the cells were pelleted by 432 
centrifugation at 1000 rpm for 5 min. Cell pellets were washed once with 3D media to remove 433 
residual FBS. Single cells and small cell clusters were re-plated according to the procedure 434 
described above.  435 
 436 
Generation of 3D tumor microtissues  437 
3D culture by microtissue formation was performed in hanging drop cultures using GravityPLUS™ 438 
plates (InSphero) as described previously (32). Cells were seeded at a density of 1000-2000 cells 439 
per drop and co-cultured with normal human dermal fibroblasts (nHDF) at a ratio of nHDF to 440 
primary tumor cells of 1:20. After successful spheroid formation, microtissues were transferred 441 
into GravityTrap™ ULA plates (InSphero) for further processing.  442 
 443 
Histological and Immunohistochemistry (IHC) analysis 444 
Formalin-fixed paraffin-embedded (FFPE) cell pellets from 2D cell cultures were prepared as 445 
previously described (44). FFPE cell pellets and corresponding FFPE primary RCC specimens 446 
were used to construct T/CMA according to the procedure described in (17). Microtissues were 447 
collected in 1.5 ml tubes and washed once with PBS. Consequently, they were fixed in 4 % para-448 
formaldehyde for 1 hr at 4 °C. Fixed microtissues were collected in the tip of a 1.5 ml microtube, 449 
embedded in 2 % agarose (Amresco®, Solon) and covered with PBS. For paraffin-embedding, 450 
the agarose plugs were taken out of the microtubes and the tip containing the microtissues was 451 
cut and placed in formalin for 12-14 hrs, followed by gradual dehydration. Finally, the plugs were 452 
embedded in paraffin (microtissues facing downwards) in order to facilitate sectioning. Cytological 453 
smears of 3D organoid cultures were prepared as previously described (45) and immediately wet-454 
fixed in Delaney solution. The Papanicolaou (Pap) stain was performed for cytopathological 455 
evaluation. Sections (2 µm) were prepared from FFPE specimens and were stained with 456 
haematoxylin and eosin (HE) for histological evaluation. For IHC, sections (2 μm) were transferred 457 
to glass slides followed by antigen retrieval. Antibodies used for IHC are summarized in 458 
supplementary table 1. IHC was performed using the Ventana Benchmark automated system 459 
(Ventana Medical Systems, USA) and Ventana reagents. The Optiview DAB IHC detection kit was 460 
used to stain with the antibodies against CKpanB, CK7, Pax8, CD10, CD117, Vimentin, RCC and 461 
cMet. The staining procedure for CAIX was carried out with the automated Leica BOND system 462 
using the Bond Polymer Refine Detection Kit (Leica Biosystems) and HMB45 IHC was conducted 463 
using the UltraView AP detection kit. 464 
 465 
VHL mutation analysis 466 
Sanger sequencing was employed to assess the mutation status of the VHL gene for all ccRCC 467 
primary tumors and the corresponding monolayer cell cultures. A pathologist reviewed HE-stained 468 
sections of FFPE or fresh frozen tissue for tumor cell content and the tumor area was marked. 469 
DNA was isolated from FFPE punches (3 cylinders with a diameter of 0.6 mm), sections of fresh-470 
frozen tissue (5 sections à 30 µm) or a minimum of 10000 cultured cells using the Maxwell® 16 471 
DNA Purification Kits (Promega). PCR and sequencing of VHL was performed as previously 472 
described (46). For DNA extracted from fresh-frozen tissue and cultured cells, we amplified the 473 
complete Exon 1 by using the following alternative forward primer:  474 
5’-CGAGCGCGCGCGAAGACTAC-3’.  475 
 476 
 477 
Fluorescence In Situ Hybridization (FISH) 478 
FISH analysis of chromosome 3p was carried out using the ZytoLight SPEC VHL/CEN 3 Dual-479 
color Probe (ZytoVision). HE-stained slides were examined to identify areas containing tumor 480 
cells. Consecutive unstained sections (4 μm) of FFPE tissue and cell blocks were prepared and 481 
deparaffinized. FISH probes were denatured on the tissue slides at 75 °C for 10 min followed by 482 
hybridization at 37 °C for at least 20 hrs in a ThermoBrite hybridization oven (Abbott). 483 
Subsequently, slides were washed (2X SSC, 0.3% NP40) and nuclei were counterstained with 484 
DAPI. Slides were examined on a fluorescence microscope (Leica, 63X objective and appropriate 485 
filter sets) and images were acquired. Using ImageJ (47), a minimum of fifty non-overlapping 486 
nuclei from different areas were analyzed, and the number of VHL and CEN3 signals was recorded 487 
for each nucleus. The total number of VHL and CEN3 signals as well as the percentage of cells 488 
with less VHL than CEN3 signals (3p loss) and loss of chromosome 3 (monosomy) were 489 
calculated. 490 
 491 
Next-Generation Sequencing (NGS) 492 
DNA was extracted from the primary tumor, adjacent normal tissue and from cultured cells as 493 
described above. Barcoded libraries were generated from 40 ng of total genomic DNA per sample 494 
using the Ion AmpliSeq Comprehensive Cancer Panel (Life Technologies) and the Ion Ampliseq 495 
library kit 2.0 (Life Technologies) according to the manufacturer’s instructions. Libraries were 496 
quantified by qPCR with the Ion Library Quantitation kit (Life Technologies) and amplicon 497 
distribution was analysed using the 2100 Bioanalyzer (Agilent). Subsequently, libraries were 498 
diluted to 12 pM, mixed and used for template preparation, loaded on a Proton chip and sequenced 499 
on the Proton platform (Ion Proton Sequencing 200 Kit v3 or Ion Pi Hi-Q Sequencing 200 Kit; Life 500 
Technologies) according to the manufacturer’s instructions. Signal processing, base calling, 501 
alignment, and variant calling was carried out using the AmpliSeq CCP - Proton - w1.1 - Single 502 
Sample and AmpliSeq CCP w1.1 - Tumor-Normal pair workflows to identify germline and somatic 503 
mutations in the Ion Reporter Software version 5.4 (Life Technologies). Sample concordance was 504 
determined based on a subset of Ion AmpliSeq CCP Hotspots (5.4), for which at least two different 505 
genotypes could be observed across all samples (46 diverse hotspot positions). A potential 506 
somatic variant was included in our analysis for the respective patient when the following criteria 507 
were met: (i) a minimum coverage depth of 50 reads in the normal sample, (ii) a minimum variant 508 
allele frequency of 10 % and a minimum of 10 reads supporting the variant in at least one of the 509 
non-normal samples of a patient. Non-synonymous coding variants passing these criteria were 510 
manually reviewed using the Integrative Genomics Viewer (IGV, Broad Institute, Boston, MA). For 511 
a small number of these variants, the Ion Reporter Software could not reliably determine the 512 
normal genotype, which could result in a false positive somatic variant call. We manually inspected 513 
the reported reference and alternate allele observations at these positions and found sufficient 514 
evidence to include the corresponding tumor-specific somatic calls for further analysis. 515 
 516 
Analysis of cell proliferation 517 
Cell proliferation was characterized in patient-derived monolayer cell cultures. Cells were plated 518 
in 100 μl K1n medium at a density of approximately 500 cells per well in collagen I-coated 96-well 519 
plates (Corning) and allowed to attach for 4 hrs. Subsequently, the baseline level of living cells 520 
(day 0) was determined by adding PrestoBlue® Cell Viability Reagent (Invitrogen) according to 521 
manufacturer’s instructions. Fluorescence (535/590 nm) was recorded using a plate reader 522 
(Tecan infinite 200). Measurements were taken every 48 hrs for 14 days and normalized to the 523 
baseline value on day 0. Data normalization and analysis was performed using Graph Pad Prism 524 
6 (GraphPad Software, Inc.). 525 
 526 
Drug Profiling in PDC models 527 
For 2D drug profiling, white clear-bottom 96-well plates (Corning) were coated with 0.01 % 528 
collagen (Sigma) prior to plating 1000 cells per well in K1n medium. For 3D organoid drug profiling, 529 
1000 cells per well were plated in a 10 μl cell culture media- and Matrigel-mix (v/v 1:1) in white 530 
clear-bottom 96-well plates (Corning). Plates were incubated for 30 min at 37°C to solidify the 531 
cell–matrix mix; 80 μl of 3D media was added to each well. For drug profiling of the microtissues, 532 
2000 cells were plated in the hanging drop plates and allowed to form microtissues for 72 hrs. 533 
Twenty-four hours after plating (2D and 3D organoid cultures) or upon formation of microtissues 534 
(72 hrs post cell seeding), drugs were administered in technical duplicates (3D cultures) or 535 
triplicates (2D cultures). Cell viability was measured either at 6 days (2D drug profiling), 9 days 536 
(hanging drop) or 14 days (3D matrigel) following drug treatment. A re-dosing of the drugs was 537 
undertaken on day 7 of the 3D assays. For all drug screens, viability assays were performed using 538 
CellTiter-Glo® Reagent (Promega). 2D assays were processed according to manufacturer’s 539 
guidelines. In brief, a volume of CellTiter-Glo® Reagent equal to the volume of cell culture medium 540 
present in each well was added and the content was incubated on a shaker for 30 min to induce 541 
cell lysis. Luminescence was recorded using a plate reader (Tecan infinite 200) with 1 sec of 542 
integration time. For 3 D drug organoid assays, the media was replaced with 60 µL CellTiter-Glo® 543 
Reagent and plates were incubated for 90 min in a cell culture incubator (37 °C, 5 % CO2) to 544 
ensure tumor organoid lysis. Luminescence was read as described above. To measure the cell 545 
viability of microtissues cultured in 96-well GravityTRAP™ ULA Plates, CellTiter-Glo® Reagent 546 
was added at a volume of 1:1 to the culture supernatant and the content was transferred into a 547 
white, opaque 96-well microplate (Corning). Complete lysis of the microtissues was ensured by 548 
incubating the plates on an orbital shaker for 20 min at room temperature before recording the 549 
luminescence intensity as described above. Analysis of drug sensitivity was performed Graph Pad 550 
Prism 6 (GraphPad Software, Inc.). 551 
 552 
 553 
 554 
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Table 1: Analysis of the cases of the T/CMA.  
Comparison of FFPE-primary tumor tissue (PT) and the corresponding cell culture (CC) using IHC with the indicated antibodies and sequencing of the 
VHL gene. 
Patient Subtype Pax8 CkpanB CK7 Vim CD10 CAIX RCC CD117 VHL mutation status 
  PT CC PT CC PT CC PT CC PT CC PT CC PT CC PT CC PT CC (Passage) 
1 chromophobe                                  /  / 
2 chromophobe         NA                        /  / 
3 clear cell                                 WT  / 
4 clear cell                                 WT  / 
5 clear cell                                 c.579insA/p.Asp193LysfsX63 retained (P3) 
6 clear cell                                 c.464-6_482delinsG retained (P3) 
7 clear cell                                 c.488T>C/p.Leu163Pro retained (P4) 
8 clear cell                                 c.201delC/p.Asn67AsnfsX91 retained (P7) 
9 clear cell                                 c.556G>T/p.Glu186X retained (P3) 
10 clear cell                                 c.444delT/p.Phe148LeufsX11 not retained (P5) 
11 clear cell                                 c.158_164del/p.Glu53GlyfsX12 retained (P5) 
12 Clear cell                                 c.IVS1+2T>A(c.340+2T>A) not retained (P5) 
13 clear cell           NA       NA             c.IVS1+1G>A (c.340+1G>A) retained (P3) 
14 clear cell                                 c.419_420delTC/p.Leu140GlnfsX3 not retained (P4) 
15 clear cell                                 c.194C>G/Ser65Trp not retained (P5) 
16 clear cell                                 WT  / 
17 clear cell                                 c.74C>T/p.Pro25Leu retained (P2) 
18 clear cell                                 WT  / 
19 clear cell                                 c.234insA/p.Asn78ArgfsX54 not retained (P3) 
20 clear cell                                 c.228insT/p.Phe76PhefsX55 not retained (P2) 
21 clear cell                                 c.493delG/p.Val165LeufsX5 retained (P2) 
22 clear cell                                 WT  / 
23 clear cell                                 c.390delT/p.Val130ValfsX28 retained (P2) 
24 clear cell                                 WT  / 
25 clear cell                                 c.533_537del/p.Leu178HisfsX76 retained (P3) 
26 clear cell                                 c.230insT/p.Phe77LeufsX55 retained (P3) 
27 clear cell                                 c.231C>A/p.Cys77X retained (P3) 
28 clear cell/papillary                                 
c.269A>T/p.Asn90Ile; 
c.525C>G/p.Tyr175X retained (P1) 
29 papillary                                  /   
30 papillary                         NA        /   
31 papillary                                  /   
32 papillary                                  /   
33 papillary                                  /   
34 unclassified                                 WT  / 
35 oncocytoma                                  /   
36 angiomyolipoma                                  /   
Table 2: Advantages and disadvantages of cell models used in this study 
 
 Advantages Disadvantages 
Monolayer 
cultures 
− represents the original tumor 
− can be cultured for several 
passages to facilitate biobanking 
− reasonable costs 
− simple to use, robust 
− physiological less relevant due to 
limited spatial interactions between 
cells 
− cell growth on flat plastic surface 
may influence experimental 
outcomes 
 
Microtissues 
− simple and fast gravity- based 
method to generate 3D cancer 
models 
− more accurate representation of 
cell-cell interactions within the 
original tumor 
− formation of uniform 3D models 
facilitates high-throughput assays 
 
− unsuitable for expanding primary 
cell material 
− cellular composition may be 
hampered due necessary addition 
of stromal component 
− interactions with the stromal 
compartment may influence 
experimental outcomes 
 
Organoids 
− more accurate representation of 
spatial (cell-cell and cell-matrix) 
interactions within the original 
tumor 
− can be cultured over long times to 
facilitate biobanking 
− laborious culturing procedures 
− very slow proliferation of renal 
cancer cells  
− big variation of organoid sizes 
within one sample complicates 
high-throughput assays 
− matrigel scaffold may influence 
outcomes 
 
 
 
 
 
 
 
 
 
  
Fig. 1: Workflow for collecting human tumor tissue for diagnostic purposes and biobanking 
Surgical specimens and biopsies that enter the pathology department are sectioned and 
consequently processed into formalin-fixed and paraffin-embedded tissue blocks (1) or fresh 
frozen tissue samples (2) while the remainder is used to generate PDC models (3). The repository 
of biospecimens can be further extended, e.g. by collecting matched body fluids (e.g. blood or 
urine). 
 
Fig. 2: Validation in a cohort of patient-derived monolayer cell cultures derived from neoplasms 
of the kidney 
(A) Distribution of RCC subtypes and renal neoplasms arrayed on the T/CMA for validation of 
patient-derived monolayer cell cultures in comparison to the tumor of origin.  
(B) H&E-stained section of the T/CMA. Each spot of FFPE-preserved primary tumor is followed 
by two spots from the FFPE cell pellet of the corresponding PDC culture. Primary tumor elements 
are circled and colors denote cases belonging to certain RCC subtypes as indicated in (A). Cases 
are numbered corresponding to table 1.  
(C) FISH analysis of chromosome 3 in VHL-wildtype ccRCC cases using the ZytoLight ® SPEC 
VHL/CEN 3 Dual Color probe. Losses of whole chromosome 3 or of the short arm of 
chromosome 3 (3p) were determined in a minimum of 50 non-overlapping nuclei. Numbers denote 
patient cases and correspond to Figure 2B and table 1. PT – primary tumor, CC – corresponding 
cell culture. 
 
Fig. 3: Characterization of ccRCC patient-derived monolayer cell cultures 
(A) Clinical characteristics of donors for ccRCC-derived cell models. VHL driver mutations present 
in the primary tumors are stated. 
(B) Monolayer ccRCC-derived cell culures grown on collagen I-coated dishes. Brightfield images 
(X10 objective) depict the morphology of the cultured cells at Passage 3 (Patient A) or Passage 1 
(Patient B, C and D). Scale bar denotes 50 µm. VHL driver mutations shown in (A) were verified 
by targeted sequencing confirming resemblance of cultured cells to the primary tumor.   
(C) High-confidence, non-silent somatic variants were identified by NGS. Tumor-specific mutation 
spectra were generated for FFPE-tissue (patient A and D) or dissociated primary cells of the 
original ccRCC (patients B and C) and compared to DNA extracted from cultures cells at the 
designated passage numbers (P1-8). Variant allele frequencies are indicated and correspond to 
the color scale.  
 
Fig. 4: Generation of RCC patient-derived 3D models and comparative drug profiling in 2D and 
3D cell models 
(A) HE and IHC staining with the indicated antibodies on consecutive sections of primary tumors 
(FFPE) and corresponding FFPE-microtissues generated by the hanging drop technology (X20 
objective, insets X40 objective). Cryopreserved cells from patient A (passage 9) and patient B 
(dissociated primary cancer cells) were used as input for microtissue formation. Brightfield images 
depict microtissue morphology (X10 objective), scale bar denotes 300 µm. 
(B) Histopathological features of tumor organoids generated using matrigel. Cryopreserved cells 
from patient A (passage 9) and patient B (dissociated primary cancer cells) were used as input for 
organoid formation. Brightfield images (X20 objective) of tumor organoids, scale bar denotes 
30 μm. Pap–stained smears (X40 objective) of tumor organoids showing criteria of malignancy 
(presence of multiple nuclei, large nucleoli, clear vacuoles).  
(C) In vitro testing of selected drugs in ccRCC-derived cell models generated from patient A. 
Cryopreserved patient-derived cells (passage 9) were seeded into monolayer cell culture, 3D 
microtissues and 3D organoids and exposed to the indicated drugs for 6 days (monolayer), 9 days 
(microtissues) or 14 days (organoids). Re-dosing of the drugs was undertaken on day 7 in the 3D 
assays. Cell viability was measured to determine dose-responses. The means of at least two 
technical replicates are shown. For monolayer cultures, N = 2, data are presented as mean ± S.D. 
Fig. 5: Optimal workflow for the implementation of patient-derived 2D and 3D cancer models  
Fresh RCC tissue is reviewed by pathologists before processing into single cell suspensions. 
Ideally, 2D and 3D cell models should be generated in parallel, validated and assessed for growth 
characteristics. To facilitate biobanking, cells have to be cryopreserved for later use. Each culture 
that is established from frozen stocks must be characterized before being subjected to further 
analysis, e.g. in vitro drug profiling. 
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Supplementary Materials 
Supplementary Table 1: Antibodies used for IHC. 
 
Antibody Name/Clone Dilution IHC Supplier 
CKpanB Cytokeratin AE1/AE3 1:50 DAKO A/S 
CK7 OV-TL 12/30 1:100 DAKO A/S 
Pax8 Paired box 8 1:400 Protein Tech Group, Inc. 
CA-IX Carbonic Anhydrase IX polyclonal 1:6000 Abcam 
CD10 56C6 1:25 Novocastra Laboratories Ltd 
CD117 c-Kit Oncoprotein 1:200 Cell Marque Lifescreen Ltd. 
HMB45 Melanosome 1:50 DAKO A/S 
Vimentin Vim3B4 1:800 Abcam 
RCC Renal Cell Carcinoma PN-15 1:250 Ventana-Cell Marque 
cMet c-Met (SP44) 1:100 Spring Bioscience 
 
 
Supplementary Table 2: Links to HE- and IHC-images of the T/CMA 
 
Link ZTMA alias IHC stain 
Schnitt-Link 240 cd117 c-Kit Oncoprotein CD117 
Schnitt-Link 240 ck 7 Mouse anti-Human Cytokeratin 7 
Schnitt-Link 240 ckpan b Mouse anti-Human Cytokeratin AE1/AE3 
Schnitt-Link 240 vim Mouse anti-human Vimentin 
Schnitt-Link 240 cd 10 Mouse monoclonal anti-CD10 
Schnitt-Link 240 CA IX Rabbit anti-Carbonic Anhydrase IX 
Schnitt-Link 240 pax8 Rabbit anti-Paired Box 8, Pax8 
Schnitt-Link 240 rcc Renal Cell Carcinoma 
Schnitt-Link 240 he haematoxylin and eosin 
 
 
Suppl. Fig. 1: Tissue processing within the living biobank  
(A) Schematic representation of tissue processing workflow. Surgical specimens are dissociated 
into single cell suspensions by mechanical fragmentation and enzymatic digestion. These can be 
cryopreserved, utilized for the generation of patient-derived cancer models or subjected to further 
analysis.  
(B) Representative images of surgical RCC specimens entering the living biobank workflow to 
generate RCC patient-derived tumor cell models. 
 
Suppl. Fig. 2: Validation of representative PDC monolayer cultures from RCC 
(A) IHC using a c-Met-antibody on FFPE-primary tumor tissue and the corresponding cell culture 
(X20 objective, insets X40 objective) for patient 33 (refer to table 1). 
(B) The ZytoLight ® SPEC VHL/CEN 3 Dual Color Probe was used to assess aberrations on 
chromosome 3 (X60 objective). An orange fluorochrome-labeled probe is specific for the 
centromeric region of chromosome 3 (D3Z1) and a green fluorochrome-labeled SPEC VHL probe 
spans the VHL gene at 3p25.3. Representative images are shown for patient 4 (refer to table 1). 
 
Suppl. Fig. 3: IHC characterization and concordance of representative PDC cultures from ccRCC 
(A) to (D) For each patient A-D, consecutive sections of FFPE-pellets from monolayer cell cultures 
were characterized by HE staining and IHC with the indicated antibodies and compared to the 
corresponding primary tumors (X20 objective, insets X40 objective). 
(E) Sample concordance of genomic alterations in patient tissue and corresponding ccRCC-
derived cell cultures at the indicated passage numbers. 
 
Suppl. Fig. 4: Proliferation and drug response in PDC models from patient A 
(A) Cell proliferation of patient-derived 2D culture from patient A was analyzed using a plate-based 
cell viability assay. The relative number of living cells was determined every 48 hrs and normalized 
to the value measured on the day of seeding. N = 2, data are pesented as mean ± S.D. 
(B) Bright-field images of ccRCC-derived 3D microtissues (X10 objective) from in vitro testing of 
selected drugs. Dissociated primary cancer cells were mixed with 5 % nHDFs and allowed to form 
microtissues for 72 hrs using GravityPLUS™ plates and then transferred to GravityTRAP™ ULA 
Plates. Drugs were administered 24 hrs after transfer and re-dosing was undertaken on day 7. 
Images of microtissues were taken 9 days after of drug exposure to illustrate dose-responses. 
The scale bar denotes 300 µm. Doxo – Doxorubcin (cytotoxic positive control). 
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6.3 Identifying new biomarkers for renal cancer stem cells with potential therapeutic 
implications. 
6.3.1 IL-8 and CXCR1 are associated with cancer stem cell-like properties in renal cancer and 
represent a potential therapeutic target for ccRCC patients. 
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ABSTRACT 23 
Growing evidence suggests that clear cell renal cell carcinoma (ccRCC) as other solid tumors 24 
possess a rare population of cancer stem cells (CSCs) which contribute to metastasis and 25 
therapeutic resistance. In this study, we successfully isolate CSC populations from both human 26 
derived RCC cell lines as well as primary tissues. Interestingly, RCC-derived CSCs displayed 27 
high levels of the drug transporter ABCB5, the chemokine IL-8 and its receptor CXCR1. While 28 
the addition of recombinant IL-8 could significantly increase CSC number and properties in 29 
vitro, CXCR1 inhibition (CXCR1ab or repertaxin) significantly reduced these features. In 30 
addition, when injected into NSG mice, CSCs formed primary tumors capable of metastasizing 31 
to the lung and liver which expressed high levels of IL-8 and CXCR1. Furthermore, IL-8 32 
expression correlated strongly with intratumoral lymphocytic infiltration and decreased overall 33 
survival in ccRCC patients. Taken together, these results suggest that the IL-8/CXCR1 axis is 34 
associated with cancer stem cell-like properties in renal cancer and represents a novel 35 
therapeutic target for ccRCC patients. 36 
  37 
INTRODUCTION 38 
Renal cell carcinoma (RCC), a malignant tumor affecting the adult kidney, is among the 10 39 
most common cancers worldwide, affecting approximately 64’000 people every year with 5 % 40 
mortality (1,2). Clear cell renal cell carcinoma (ccRCC) is the most common type of RCC (3) 41 
and inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene by mutation or 42 
promoter methylation has been found responsible for about 80 % of ccRCC cases (4-6). 43 
Although therapeutic interventions that specifically target the VHL-HIF-VEGF pathway are 44 
routinely used for treating ccRCC, these treatment options have only moderately improved 45 
overall patient survival while also having significant side effects for patients (7,8). 46 
There is growing evidence to suggest that renal cancer and other solid tumors possess a rare 47 
population of cancer stem cells (CSCs) that are capable of self-renewal and contribute to 48 
metastasis and resistance to therapy (9). CSCs are a small population of neoplastic cells within 49 
a tumor which present characteristics reminiscent of normal stem cells. CSCs are 50 
characterized by unlimited cell division, maintenance of the stem cell pool (self-renewal), give 51 
rise to all cell types within the tumor and contribute to metastasis in vivo (tumorigenicity), 52 
treatment resistance and recurrence (10-12). While conventional therapies, such as 53 
chemotherapy or irradiation, usually eliminate the majority of cells in the tumor bulk, the CSC 54 
pool is often unaffected (13). 55 
CSCs were first identified in 1994 when Dick and colleagues isolated CD34+/CD38- cells from 56 
acute myeloid leukemia (AML) patients and showed they could initiate AML in vivo upon re-57 
transplantation into NOD/SCID mice (14). Subsequently, several others have showed the 58 
presence of CSCs in colorectal cancer, breast cancer, glioblastoma, melanoma, lung cancer, 59 
liver and prostate cancer (15-24). In addition, numerous studies have since tried to identify the 60 
CSC population from RCC (25-29), with CD105, ALDH1, OCT4, CD133 and CXCR4 reported 61 
as markers of CSC or CSC-like cells from RCC (30-32). 62 
CD105 (endoglin) was expressed on a ccRCC subpopulation with potent capability to grow as 63 
spheres and initiate tumors and metastasis in mice (9,26). Additionally, immunohistochemistry 64 
(IHC) of tumoral CD105 has been found positively correlated to nuclear grade and tumor stage 65 
(33). On the contrary, sorted CD133+ cells  from RCC patients did not show tumorigenic 66 
capability in vivo although they expressed stem cell markers such as CD44, CD29, Vimentin, 67 
and Pax2 (34). When co-transplanted with renal carcinoma cells, CD133+ progenitors 68 
significantly enhanced tumor development and growth. The same result was obtained using 69 
CD133+ cells derived from normal kidney tissue (35). CD105+ cells did not express CD133 70 
suggesting that CD133+ cells may be renal resident adult progenitor cells. 71 
However, none of these markers were shown to embody the entire tumor resident CSC pool 72 
and contrasting results are reported in the literature (36-39). Therefore, improving the 73 
identification of a specific subpopulation of cells within a tumor that either initiate or maintain 74 
tumorigenesis is of utmost importance for understanding tumor biology and in the development 75 
of novel therapies. 76 
CXCL8 (C-X-C motif ligand 8 or IL-8), represents one of the major chemokines associated with 77 
the promotion of neutrophils and inflammatory response (40). It is induced in response to 78 
inflammatory cytokines, hypoxia and environmental stress (41,42). Previous studies have 79 
demonstrated that IL-8 is also involved in proliferation and survival of neoplastic cells. IL-8 acts 80 
through several signaling pathways associated with apoptosis, multidrug resistance, 81 
angiogenesis and metastasis-related tissue remodeling in a positive feedback loop (42-46). IL-82 
8 interacts with both CXCR1 and CXCR2 with different affinities and potencies to mediate 83 
different cellular responses. CXCR1/2 have recently been demonstrated to be associated with 84 
CSC populations as well as proliferation, migration and invasion in certain type of human 85 
cancers such as breast, prostate, colon and pancreatic cancers (47-50). 86 
In particular, a recent study on pancreatic cancer showed that positive CXCR1 expression 87 
correlates with metastasis and poor survival rate in patients (47). Furthermore, IL-8 increased 88 
sphere formation and invasion in pancreatic cancer, and these effects could be reversed by 89 
CXCR1 blockade (47). In addition, Ginestier et. al. developed a strategy to target breast cancer 90 
stem cells using either CXCR1-specific antibodies or repertaxin. Repertaxin, a small molecule 91 
blocking CXCR1/2, was able to specifically target breast cancer xenografts retarding tumor 92 
growth and reducing metastasis (49). Nevertheless, the role of the IL-8/CXCR1 axis in ccRCC 93 
is currently unknown. In this study, we identify an essential role for IL-8/CXCR1 signaling in 94 
the proliferation, migration and invasion, sphere formation and self-renewal capabilities of 95 
RCC-derived tumor cells, and highlight the therapeutic potential of blocking IL-8/CXCR1 96 
signaling during ccRCC.  97 
MATERIALS AND METHODS 98 
Ethics statement 99 
The local ethics commission (KEK-ZH-Nr. 2011-0072 and KEK-ZH-Nr. 2014-0614) approved 100 
this study and all patients gave written consent (General Consent, Institute of Pathology and 101 
Molecular Pathology, University Hospital of Zurich, Switzerland). NOD.Cg-Prkdcscid 102 
Il2rgtm1Wjl/SzJ (NSG) mice were purchased from The Jackson Laboratory (Mouse strain 103 
#005557). Housing and experimental procedures of all animals were performed at the 104 
University of Zurich in accordance with the Cantonal Veterinary Office (Zurich, Switzerland) 105 
under the license number ZH104/2015. Animals were maintained under specific pathogen free 106 
(spf) conditions with a light/dark cycle of a 12 h/12 h cycle with artificial light of approximately 107 
40 lux in the cage. The mean room temperature was 21 ± 1 °C, with a relative humidity of 50 108 
± 5 % and 15 complete changes of filtered air per hour (HEPA H14 filter); the air pressure was 109 
controlled at 50 Pa. 110 
Specimen Procurement 111 
Renal cell carcinomas (RCCs) were surgically resected and underwent routine tissue 112 
processing for diagnostic purposes. One pathologist (H.M.) evaluated all tissue specimens. 113 
Tumors were histologically classified and graded according to the World Health Organization 114 
classification (51), and tumour staging was performed according to the current TNM system. If 115 
available, additional fresh adjacent tissue samples from areas macroscopically identified as 116 
cancer were placed into sterile 50-ml conical tubes containing transport media (RPMI (Gibco, 117 
Thermo Fisher Scientific Inc., Zug, Switzerland) with 10 % vol/vol dialyzed fetal calf serum 118 
(FCS, Gibco) and Antibiotic-Antimycotic (Gibco)) and kept at 4 °C. Tissue samples were further 119 
processed within 24 h. 120 
Tissue processing and generation of 2D primary cell cultures 121 
RCC tumor specimens as well as xenograft tumors were rinsed with PBS and finely cut into 122 
small fragments using a scalpel. Consequently, samples were enzymatically digested in a 123 
TBS/Collagenase A-mix containing a surplus of Ca2+ for 2-3 h at 37 °C.  The slurry was passed 124 
through a 70 µm cell strainer to remove large fragments and centrifuged at 1’000 rpm for 5 125 
minutes. The Collagenase A digestion was stopped by incubating the pellet in 1 ml Stop 126 
solution (50 mM Tris, 150 mM NaCl, 10 mM EDTA) for 5 minutes at room temperature. Cells 127 
were washed once with PBS and erythrocytes were lysed by incubating the cells for 2 minutes 128 
in ACK buffer (150 mM NH4Cl, 10 mM KHCO3, 100 mM EDTA). After a final wash with PBS, 129 
dissociated cells were evaluated for cell viability by trypan blue dye exclusion. Appropriate 130 
amounts of cell suspension were resuspended in K1n medium to be transferred to collagen I-131 
coated cell culture dishes for culture in a humidified incubator at 37 °C with 5 % CO2. The 132 
medium was replaced no earlier than after 5 days after initial plating and consecutively every 133 
three to four days. 134 
Cell lines 135 
The RCC cell lines 769P, A498, Caki1 and ACHN together with the lung cancer cell lines A549 136 
and H460, were purchased from ATCC (Manassas, VA). These cell lines were additionally 137 
authenticated via STR-based DNA-profiling by IdentiCell (Department of Molecular Medicine, 138 
Aarhus University, Denmark). Cells were cultured using Dulbecco’s Modified Eagle Medium 139 
(DMEM, Gibco) or RMPI medium containing 10 % FCS and 2 mM glutamine (Gibco). Cells 140 
were split when reaching 80 % confluence. 141 
Immunohistochemistry (IHC) 142 
Tissue and cell culture microarrays (T/CMAs) were constructed as described previously (52). 143 
T/CMA, whole tumor and cell pellet sections (2 µm) were prepared from formalin-fixed, 144 
paraffin-embedded specimens and were stained with H&E for histological evaluation. For 145 
immunohistochemistry, sections (2 μm) were transferred to glass slides followed by antigen 146 
retrieval. IHC was performed using the Ventana Benchmark automated system (Ventana 147 
Medical Systems, United States) and Ventana reagents. The Optiview DAB IHC detection kit 148 
was used for staining with the antibodies against PanCKa, Pax8, E-cadherin, CD105, 149 
Snail/Slug, and CXCR1. The staining procedure for CA-IX, Vimentin, and CXCL8 was carried 150 
out with the automated Leica BOND system using the Bond Polymer Refine Detection Kit 151 
(Leica Biosystems). Antibodies used for immunostains are listed in the supplementary table 1. 152 
Sanger sequencing 153 
In order to obtain DNA from the primary tumor, HE-stained sections of FFPE or fresh frozen 154 
tissue were reviewed by a pathologist for tumor content and the tumor area was marked. DNA 155 
was isolated from FFPE punches (3 cylinders with a diameter of 0.6 mm) or a minimum of 156 
10’000 cultured cells using the Maxwell 16 DNA Purification Kit (Promega, Dübendorf, 157 
Switzerland). PCR and sequencing of VHL was performed as previously described (53) using 158 
primers for amplification of the VHL exons 1-3. For DNA extracted from FFPE tissue specimens 159 
only a section of Exon 1 was amplified using the primer Exon 1B forward. The same primers 160 
as described above were used for the exons 2 and 3. The RefSeq for VHL was NM198156.4. 161 
The following primers were used: 162 
Exon 1 forward: 5’-CGAGCGCGCGCGAAGACTAC-3’;  163 
Exon 1 reverse: 5`-GACCGTGCTATCGTCCCTGC-3’; 164 
Exon 1B forward: 5’-AGAGTCCGGCCCGGAGGAACT-3’; 165 
Exon 2 forward: 5’-ACCGGTGTGGCTCTTTAACA-3’;  166 
Exon 2 reverse: 5’-TCCTGTACTTACCACAACAACC TT-3’; 167 
Exon 3 forward: 5’-GAGACCCTAGTCTGT CACTGAGG-3’;  168 
Exon 3 reverse: 5’-TCATCAGTAC CATCAAAAGCTGA-3’ 169 
Western blot 170 
Cell and tissue lysates were prepared using NP‐40 buffer (10 mM Tris pH 8, 1 mM EDTA pH 171 
8, 400 nM NaCl, 0,1 % NP40, 1 mM DTT) containing complete protease and phosphatase 172 
inhibitor cocktail (Roche, Applied Science). Lysates were centrifuged for 15 minutes (16’000 173 
rcf, 4 °C). Protein concentration of the supernatant was determined by the BCA Assay (Thermo 174 
Fisher Scientific Inc.) with bovine serum albumin (BSA) as a standard. Equal amounts of 175 
protein (40 ng) in NuPAGE LDS sample buffer (Thermo Fisher Scientific Inc.) and a size 176 
marker (MagicMark XP and SeeBlue Plus2, Thermo Fisher Scientific Inc.) were loaded on a 4 177 
% to 12 % gradient Bis‐Tris gel (Thermo Fisher Scientific Inc.) and transferred to PVDF 178 
membrane. The membrane was incubated for 1 h in 5 % milk and subsequently with primary 179 
antibody over night at 4 °C. As secondary antibodies anti‐rabbit‐HRP or anti‐mouse‐HRP 180 
(Thermo Fisher Scientific Inc., California, United States) were used. Proteins were detected by 181 
using the ClarityTM Western ECL Substrate Kit (Bio‐Rad Laboratories Inc.). The following 182 
antibodies were employed: human CXCR1 ab (clone 42705, 5 µg/µl, R&D, Minneapolis, United 183 
States), human CXCL8 ab (clone 6217, 10 µg/µl, R&D), HIF1α (1:1’000, Novus Biologicals, 184 
Colorado, United States), HIF2α (1:500, Abnova, Taiwan), CAIX (clone M75, 1:1’000, J. 185 
Zavada, Prague, Czech Republic) and actin (1:2000, Chemicon International, California, 186 
United States). 187 
Quantitative real-time PCR 188 
Total RNA was purified using the Maxwell 16 RNA Purification Kit (Promega) and quantified 189 
using the Qubit Protein Assay Kit (Thermo Fisher Scientific Inc.). Total RNA (400 ng) was 190 
reverse‐transcribed using the RT2 First Strand Kit (Qiagen, Hilden, Germany). A human CSC 191 
gene expression array (RT2 Profiler PCR Array; Qiagen), which profiles 84 genes linked to 192 
CSCs, was employed. In addition, the expression of the three candidate genes was verified 193 
separately using the RT2 qPCR Primer Assay for ABCB5, NM_001163941; CXCR1, 194 
NM_000634; and IL-8, NM_000584. Analysis was performed on qPCR machine (ViiATM7 195 
Real‐Time PCR System, Applied Biosystems, Thermo Fisher Scientific Inc.) in 10 μl of total 196 
volume. 197 
Hypoxia 198 
For hypoxic treatment, cells were cultured at 0.2 % of oxygen in an INVIVO2 hypoxia 199 
workstation 300 (Ruskin Technology, Bridgend, UK) for 48 h. 200 
Cell invasion and migration 201 
Migratory/invasive potential of RCC cell lines was measured in real-time using the 202 
xCELLigence RTCA DP System (ACEA Biosciences, San Diego, United States). This 203 
technique adapts the boyden chamber principle and combines it with impedance 204 
measurements. Cells seeded in the upper chamber of a microplate containing “low 205 
chemoattractant (1 % FCS)” can migrate through the microporous membrane into the lower 206 
chamber being the “high chemoattractant (10 % FCS)” compartement. Migrated cells adhere 207 
to the gold micro-electrode sensor located at the lower side of the membrane and lead to an 208 
increase in impedance, which is measured by the RTCA DP instrument. Optimal cell seeding 209 
densities were determined in pre-experiments and 20’000 cells were found to be optimal. 210 
Impedance measurements were performed for 72-96 h. For invasion assays, the membrane 211 
was coated with Matrigel Basement Membrane Matrix (BD Biosciences, 400 µg/ml protein in 212 
1 % FCS-containing medium). 213 
Tumorsphere culture 214 
Generation of tumorspheres was performed by resuspending 5x104 cells into a special medium 215 
containing DMEM/F12 (Gibco), 2 % B27 supplement (Gibco), 20 ng/mL Human Recombinant 216 
EGF (Gibco), 10 ng/mL Recombinant Human FGF-basic (Thermo Fisher Scientific Inc.), 5 217 
µg/ml Insulin (Sigma) and 10 % FCS. Cells were then plated into ultra-low attachment 10 cm2 218 
dishes (Corning, NY, United States) and the medium was refreshed every 4 days. 219 
Tumorspheres at approximately 300 µm in size were collected by centrifugation (500 rpm, 5 220 
minutes) into 50 ml Falcon tubes. Carefully the supernant was removed and spheres were 221 
washed using PBS. Spheres were passaged by incubation with 1 ml of TrypLE Express (Gibco) 222 
for 5 minutes in incubator at 37°C. Spheres were further dissociated by slowly pipetting up and 223 
down the cell suspension.  The trypsin was then inactivated by adding at least three volumes 224 
of DMEM containing 10 % FCS and the cells were pelleted by centrifugation at 500 rpm for 5 225 
minutes. Single cell suspension was re-plated according to the procedure described above. 226 
Sphere formation assay 227 
Tumor cells growing into adherent conditions were transferred into 6 well ultra-low attachment 228 
plates containing tumorsphere medium at 5x103 cells/well. Spheres were grown for 15 days. 229 
In enrichment step, spheres were split and plate at the same initial cell density of 5x103 230 
cells/well every 15 days and counted at the end of each period. This step was repeated for at 231 
least five times. 232 
When talking about spheres in this manuscript, we always refer to CSCs enriched in the sphere 233 
formation assay for at least three passages. 234 
Limiting dilution assay 235 
Sphere formation capability was evaluated by limiting dilution assay (LDA). Adherent tumor 236 
cells and sphere-derived cells were plated in triplicates into 96 well plates at 0.5 cell/well 237 
density in the tumorsphere medium. Only wells which contained 1 cell/well were marked and 238 
observed every day. 10 µl of fresh medium was added every 2 days. After a week, tumorsphere 239 
formation was evaluated in the marked wells using the formula: (n of positive wells/n of total 240 
marked wells) x 100. 241 
Clonogenic assay 242 
Cells were harvested, counted, and diluted in sterile tubes, in order to plate 200 cells/well into 243 
6 well plates or 2’000 cells into 10 cm2 dishes. Appropriate medium was used to grow cells 244 
over two-week time period. Fresh medium was added every 3 days to avoid cell death due to 245 
senescence. In the treatment experiment, cells were pretreated for 72 h before seeding them 246 
into the clonogenic assay. After two weeks, medium was removed and cells were rinsed 247 
carefully with PBS. Methanol was used to fix the cells for 10 min following staining with 0.5 % 248 
crystal violet for 15 minutes. The excessive dye was removed by rinsing each well with tap 249 
water. Dishes and plates were left to dry in normal air at RT. Colonies containing up to 50 cells 250 
were counted under the microscope. 251 
Adipogenesis 252 
Cells plated in triplicate in 48 well plates at 2’000 cells per well. Complete medium used to 253 
differentiate contained DMEM with 10 % FCS, L-glutamine and penicillin/streptomycin. Cells 254 
were induced for 3 days with 400 µl of complete medium supplemented with dexamethasone 255 
(1 µM, D4902, Sigma), insulin (10 µg/ml), indomethacin (120 µM, I7378, Sigma) and 3-Isobutyl-256 
1-methylxanthine (IBMX, 0.5 mM, I5879, Sigma). Further, cells were maintained for 15 days in 257 
complete medium added with dexamethasone, insulin and indomethacin. Medium was 258 
changed every 3 days. 259 
Xenografts 260 
Female NSG mice were subcutaneously injected with parental or sphere-derived cells from 261 
the RCC cell lines 769P and Caki1. 106 cells, 104 cells or 102 cells were injected into the left 262 
flank of each mouse in 50 % mixture of Matrigel (growth factor reduced 35623, Corning) and 263 
PBS in triplicates. Each group of three mice received either tumor cells or only matrigel and 264 
PBS. Mice were monitored daily in the first 10 days post-injection and when the tumor started 265 
to grow, otherwise every second day. Tumor size was measured using a caliper. When the 266 
tumor size reached 1 cm3, mice were euthanized and the tumor was harvested. The tumor 267 
tissue was used for primary culture and FFPE tissue preparation. At the same time, mice were 268 
extensively inspected in order to determine the presence of macro-metastasis. Lungs, liver, 269 
heart, spleen, and kidneys were harvested and processed for paraffin embedding. These 270 
tissues were screened for micro-metastasis by IHC staining for H&E and Pax8. 271 
Flow cytometry 272 
Flow cytometry was performed on the LSR Fortessa instrument at the Flow cytometry Facility 273 
(University of Zurich, Switzerland). 106 tumor cells were resuspended into 1 ml of DMEM 274 
containing 2 % FCS and 10 mM HEPES (Thermo Fisher Scientific Inc.) together with Hoechst 275 
33342 (H3570, Thermo Fisher Scientific Inc.) at the final concentration of 5 µg/ml. Cells were 276 
then incubated at 37 °C in the water bath for 90 minutes. To confirm that the correct cells are 277 
identified as SP on the flow cytometer, an aliquot of cells was treated using 50 µM verapamil 278 
(V4629, Sigma) which blocks the efflux of Hoechst in the SP before incubation in the Hoechst 279 
staining solution. Upon verapamil treatment, SP disappears from the plot. After 90 minutes, 280 
cells were centrifuged at 500 rpm and resuspended in ice-cold HBSS containing 2 % FCS and 281 
10 mM HEPES. Samples were further stained with either CXCR1 (Alexa Fluor 700, FAB330N, 282 
R&D) or CXCR2 (PerCP, FAB3331C, R&D) antibody for 1hr at 4 °C and subsequently fixed in 283 
1.6 % PFA (Thermo Fisher Scientific Inc.) for 10 minutes. 2 µg/ml propidium iodide (PI) was 284 
added right before flow cytometry for cell dead discrimination. Hoechst was excited at 405 nm 285 
and the blue signal was collected with a 450/40 nm band-pass filter, whereas the red 286 
fluorescence with a 610/20 nm filter. Due to the high capability to extrude Hoechst dye, side 287 
population can be defined as the negative population for Hoechst blue and Hoechst red. 288 
CXCR1 was detected by using the laser 640 nm and 730/45 nm filter, whereas for CXCR2 the 289 
laser 488 nm and 710/50 nm filter were applied. 290 
cyTOF: Barcoding and Staining 291 
Formalin-fixed cell lines (Caki1 and ACHN) and the corresponding spheres were resuspended 292 
with Cell Staining Medium (CSM) with 0.3 % Saponin (CSM-S) and loaded into a 96-well plate. 293 
Samples were washed with PBS-S and barcoded with barcoding reagent (104Pd, 106Pd, 108Pd, 294 
110Pd, 113In, 115In ) at a final concentration of 100 nM for 45 minutes at RT (54). Sample were 295 
washed three times in CSM-S. Afterwards barcoded cells and spheres were combined and 296 
stained with a metal-conjugated antibody mix (Suppl. Table 2) diluted in CSM-S for 1 h at 4 297 
°C. Sample was washed three times with CSM-S and once with PBS with 0.03 % Saponin 298 
(PBS-S). Samples were intercalated and fixed using MaxPar Intercalator 500 µM (Fluidigm) 299 
diluted 1:10’000 in 1.6 % PFA in PBS over night at 4 °C. Samples were washed three times in 300 
PBS. Before analysis, the samples were washed once with ddH2O and filtered through a 35 301 
µm cell strainer. 302 
Mass cytometry analysis 303 
Samples were mixed 1:10 with EQTM Four Element Calibration Beads (Fluidigm) and then 304 
analyzed on a CyTOF2. Following the manufacturer’s standard operation procedure, samples 305 
were acquired at a rate of ~500 cells per second. After acquisition all generated fcs files were 306 
concatenated (54), then data were normalized and bead events removed (55), followed by a 307 
debarcoding step (56). The data analysis was done using Cytobank 308 
(http://www.cytobank.org/). Therefore, cells were gated using 191Ir and 193Ir to remove doublets 309 
and debris. 310 
Drug treatment 311 
Different compounds were used in the treatment of cells in this study. Repertaxin (HY15251, 312 
Hycultec) is a small molecule with potent inhibitory activity on CXCR1/2. It was used at 100 313 
nM concentration. Anti-CXCR1 antibody (clone 42705, R&D) was used at the concentration of 314 
20 µg/ml, whereas to achieve CXCR1 activation the human recombinantug IL-8 (208-IL, R&D) 315 
was exploited at the concentration of 1 µg/ml. Sunitinib (S7781, Selleck) is a small molecule 316 
targeting the receptor tyrosine kinase (RTK). It is currently used as a first line treatment in 317 
ccRCC patients. Sunitinib was used at 2 µM. 318 
Statistical and computational analyses 319 
Analysis between groups was carried out with two-way ANOVA and Bonferroni multiple 320 
comparison. Student’s t test, Kruscal-Wallis test associated with Dunn’s multiple comparison, 321 
and Wilcoxon signed rank test were also employed. Survival curves were estimated with the 322 
Kaplan–Meier method and the log-rank test. All these analysis were performed using 323 
GraphPad Prism 5 (GraphPad Software) and the p-values < 0.05 were considered statistically 324 
significant and presented as follow: * p-value < 0.05; ** p-value < 0.02; *** p-value < 0.001; 325 
**** p-value < 0.0001. 326 
 327 
  328 
RESULTS 329 
CcRCC contains CSC populations capable of self-renewal 330 
The presence of a cancer stem cell population in RCC was investigated first in nine RCC cell 331 
lines by sphere formation assay. Five out of nine RCC-derived cell lines (55 %) displayed 332 
sphere formation and self-renewal properties (Fig. 1A). Self-renewal properties were evaluated 333 
by enriching the CSC population over five passages. In particular, two metastasis-derived RCC 334 
cell lines (Caki1 and ACHN) showed significantly greater sphere formation capability and self-335 
renewal features when compared to RCC cell lines derived from primary tumors (769P and 336 
A498) (Fig. 1B). In addition, spheres derived from Caki1 and ACHN were significantly bigger 337 
in size than the spheres formed by 769P and A498, ranging between 20 and 300 µm (Fig. 1C). 338 
Increased expression of EMT markers such as Vimentin, Snail/Slug and N-cadherin, and the 339 
cancer stem cell marker CD105 was found by IHC in the spheres compared to the 340 
corresponding mono-adherent cells, whereas a decreased expression of E-cadherin was 341 
observed (Fig. 1D). 342 
The capability to revert the EMT phenotype was also investigated by seeding spheres into 343 
normal adherence tissue culture dishes. Spheres were able to attach again to the surface and 344 
propagate by dissolving the sphere structure (Suppl. Fig. 1A). The same markers where then 345 
investigated in these cells after attachment and the expression patter observed was 346 
comparable to the parental mono-adherent cells (data not shown). Additionally, sphere-derived 347 
cells were able to differentiate in vitro into adipocytes upon induction (Suppl. Fig. 1B). 348 
By limiting dilution assay, Caki1 and ACHN further exhibited an improved sphere formation 349 
capability compared to 769P and A498 (Suppl. Fig. 1C). Moreover, Caki1 and ACHN also 350 
displayed enhanced clonogenic activity compared to primary tumor-derived cultures indicating 351 
increased self-renewal properties (Suppl. Fig. 1D and E). 352 
Several recent studies have shown that hypoxic conditions enhanced stemness features 353 
(34,57,58). Therefore, sphere formation capability was investigated under hypoxia (48 h, 0.2 354 
% O2, 5 % CO2). An increased sphere production was observed in parental cells upon hypoxia 355 
incubation, whereas sphere-derived cells did not further enhance sphere formation probably 356 
due to the constitutive expression of HIFs under normoxia (Suppl. Fig. 1F). In fact, sphere-357 
derived cells showed increased level of HIF1α and its downstream target CAIX compared to 358 
the corresponding parental cells. A498 and 769P did not show HIF1α expression due to 359 
homozygous deletion of HIF1α, instead they did express high levels of HIF2α (Suppl. Fig. 1G; 360 
(59)). 361 
In accordance with the observations obtained from RCC cell lines, two metastatic primary 362 
cultures derived from ccRCC patients showed enhanced sphere formation capability compared 363 
to primary tumor-derived cultures, suggesting an increased CSC fraction in the metastatic sites 364 
compared to the primary tumors (Fig. 1A and E). 365 
 366 
Identification of potential novel cancer stem cell markers 367 
To identify potential novel CSC markers, a human cancer stem cell gene expression array (RT2 368 
Profiler PCR Array; Qiagen), which profiles 84 genes linked to cancer stem cells, was 369 
performed on 769P, A498, Caki1 and ACHN cells. Changes in the gene expression profile 370 
such as upregulation of EMT, stemness markers and genes involved in developmental 371 
pathways (e.g. NANOG, WNT and MYC), were observed in sphere-forming cells vs 372 
corresponding parental cells (Suppl. Fig. 2A). Moreover, potentially new and already described 373 
CSC markers being CD105, CD44, CXCR4, ALDH1A1 and CXCL8, were found highly 374 
expressed by the sphere population. The differentially expressed genes are summarized in the 375 
supplementary table 3.  376 
These findings were supported by CYTOF data in which differential expression of these 377 
markers was found in sphere-derived cells compared to the corresponding mono-adherent 378 
cells (Fig. 2A). Spheres showed an increased expression of EMT and putative stem cell 379 
markers (CD24, Vim, CD44, and CXCR4) as well as a decreased expression of markers of 380 
cellular differentiation (CD13, CD10) (Fig. 2A). 381 
Among all the candidates, we focused our attention on CXCL8, CXCR1, and ABCB5 since 382 
their role in ccRCC as potential CSC and chemoresistance markers is currently unknown. 383 
 384 
The IL-8/CXCR1 axis is associated with cancer stem cell properties in ccRCC 385 
In order to confirm the results obtained by the gene expression array, and to further dissect 386 
the role of IL-8/CXCR1 axis in RCC, qPCR for IL-8, CXCR1 and ABCB5 was performed. 387 
Enhanced expression of IL-8, CXCR1 and ABCB5 was observed in the sphere-derived cells 388 
compared to the parental cells in all the cell lines analyzed except for Caki1 cells (Fig. 2B). 389 
Western blot and immunohistochemical analysis showed an increased level of IL-8 and 390 
CXCR1 in the sphere-derived cells compared to the parental cells in all RCC-derived cell lines 391 
(Fig. 2C and D). Interestingly, Caki1 cells showed increased levels of IL-8 and CXCR1 on 392 
protein level which was not observed using qPCR. However, Caki1 cells had high basal IL-8 393 
expression level on qPCR making any difference hard to detect. These results indicate that 394 
cancer stem-like cells express high contents of IL-8 and its receptor CXCR1. These results 395 
were also confirmed by Flow cytometry analysis. Two lung cancer cell lines (H460 and A549) 396 
were exploited to determine the gating strategy for CXCR1. As described by Zhu and co-397 
authors, H460 cell line express CXCR1 at high levels, therefore it served as positive control 398 
(60). On the other hand, A549 showed low CXCR1 levels (Suppl. Fig. 2B). 399 
The Hoechst side population (SP) analysis is one of the several strategies used to identify 400 
stem cell populations. The ability to discriminate the SP is based on the differential efflux of 401 
Hoechst 33342 by a multi-drug resistance transporter. Stem cells possess higher activity 402 
and/or higher amount of the multi-drug transporters. Therefore, SP stands out as the portion 403 
of cells able to extrude the dye against a concentration gradient when compared to cells not 404 
having stem cell features. Therefore, SP was identified as the portion of events that 405 
disappeared upon treatment with 100 µM verapamil which blocks the efflux of Hoechst in the 406 
CSCs (Fig. 3A). All parental RCC cell lines analyzed exhibited the presence of a CSC SP (3.85 407 
% ± 1.6 %) expressing CXCR1 (6.9 % ± 1.6 %). Of note, sphere-derived SP increased by more 408 
than three times (14.6 % ± 0.7 %) compared to the parental cell lines and the total CXCR1 409 
population increased twice (17.1 % ± 8.9 %; Fig. 3C; Suppl. Fig. 3A, B and C). For instance, 410 
spheres-derived from Caki1 cell line contained 16.3 % of CXCR1+ cells, which mainly 411 
overlapped for 91.9 % with CXCR1+ cells in the side population compartment (Fig. 3A). A 412 
primary culture derived from patient primary tumor showed reduced CSC content represented 413 
by only 1.1 % SP. This population was mainly composed for 70 % of CXCR1+ cells (Fig. 3B). 414 
In line with our previous results, spheres displayed increased content of CSCs, here depicted 415 
by the SP, and CXCR1+ cells compared to parental samples. Surprisingly, SP values in the 416 
spheres and parental cells were very similar between metastasis-derived cultures and primary 417 
tumor-derived cultures suggesting that not all cells contained in the side population may have 418 
the ability to form spheres in culture. In addition, in some cases CXCR1+ cells were more 419 
frequent than SP cells indicating that also non-CSCs may express CXCR1 (Fig. 3C).  420 
As previously reported in the literature, IL-8 also interacts with CXCR2, and therefore we also 421 
investigated whether CXCR2 may play a role in promoting the cancer stem cell phenotype. 422 
Interestingly, preliminary data suggests that CXCR1 but not CXCR2 is involved in this process 423 
(Suppl. Fig. 3D). CXCR2 was found expressed by over 60 % of the cells including the CSC 424 
population by flow cytometry (Fig. 3C). Moreover, western blot analysis revealed no difference 425 
in the protein expression between sphere-derived cells and parental cells (Suppl. Fig. 3E). 426 
Therefore, from this point on we focused our attention on CXCR1. 427 
CXCR1 blockage was achieved by either using anti-CXCR1 antibody (20 µg/ml) or the small 428 
molecule repertaxin (100 nM). Whereas the human recombinant IL-8 (1 µg/ml) was employed 429 
for IL-8 stimulation. Increased cell proliferation was observed after 72 h treatment using human 430 
recombinant IL-8, whereas the opposite was observed when adding anti-CXCR1 antibody 431 
(Suppl. Fig. 4A). Additionally, IL-8 treatment was found to enhance cell invasion and migration 432 
using the real time cell analyzer XCELLigence in all the cell lines tested, most pronounced for 433 
Caki1 and ACHN (Suppl. Fig. 4B). CXCR1 blockade showed opposite or no effect, whereas 434 
the combination of treatments showed intermediate increase of invasive and migratory 435 
properties indicating that IL-8 may also act through other signaling pathways (Suppl. Fig. 4B). 436 
To test the effect of IL-8/CXCR1 on tumorsphere formation, cells were incubated for 72 h in 437 
the sphere formation assay under anti-CXCR1ab, repertaxin or IL-8 treatment. Anti-CXCR1ab 438 
slightly decreased sphere formation, whereas IL-8 treatment increased sphere content by 1.5-439 
fold in all the cell lines analyzed (Fig. 4A and B). Repertaxin alone or in combination with IL-8 440 
did not show any major effect on sphere formation except for 769P where it significantly 441 
decreased sphere formation (Fig. 4A and B). Additionally, 20 % increase in the sphere number 442 
was observed over enrichment passages upon IL-8 treatment in Caki1 and 769P (data not 443 
shown). 72 h pre-treatment of cells prior sphere formation assay did not improve the effect 444 
observed previously. 445 
Additionally, flow cytometry analysis revealed that 72 h treatment with repertaxin significantly 446 
decreased side population and CXCR1+ cells in the spheres as well as in the parental samples 447 
(Supplementary Table 4; Suppl. Fig. 5 A, B, C and D). For instance, in Caki1 spheres, the 448 
CXCR1+ side population decreased of about 50 % upon repertaxin treatment going from 84.8 449 
% to 44.5 % CXCR1+ cells (Fig. 4C and D). Surprisingly, repertaxin treatment alone as well as 450 
combined with sunitinib (standard of care in ccRCC patients) did not show any effect in the 451 
clonogenic assay (Suppl. Fig. 4C and D). 452 
Taken together these results indicate that IL-8 stimulates cell proliferation and invasion as well 453 
as cancer stem cell formation and self-renewal. On the contrary, CXCR1 blockade decreases 454 
cell proliferation, cell invasion and cancer stem cell properties. 455 
 456 
The IL-8/CXCR1 axis is essential for tumor development and metastasis formation in 457 
vivo 458 
Sphere-derived cells as well as parental cells isolated from Caki1 were capable to give rise to 459 
tumors when injected into NSG mice at three different cell densities (106, 104, 102). However, 460 
in each case tumor formation and growth was enhanced when tumor cells derived from the 461 
spheres were injected compared to parental cells. For instance, Caki1 spheres injected at 106 462 
cells reached the tumor size of 1 cm3 after only 19 days, whereas mice injected with parental 463 
cells harbored less than half of the tumor size (358.1 ± 187.4 mm) after the same time period 464 
(Fig. 5A and B). 465 
Mice injected with 102 parental cells did eventually develop tumors at the site of injection after 466 
70 days post-injection, time point in which tumors derived from spheres were already 467 
harvested. Caki1 cell line is derived from a metastatic tumor; therefore, these cells are more 468 
aggressive and prone to tumor formation. In fact, metastasis-derived cultures contained more 469 
stem cells than primary tumor-derived cell lines. In support of this, sphere-derived cells from 470 
769P developed tumors when injected into NSG mice as low as 102 cells (Suppl. Fig. 6A and 471 
B). Whereas, no tumor formation was observed after over 130 days post-injection when 472 
parental cells were injected into NSG mice at the cell density of 106, 104, or 102. 473 
Xenografted tumors histologically resembled the ccRCC subtype and were positive for the 474 
kidney marker Pax8 and the epithelial marker PanCKa (Fig. 5C; Suppl. Fig. 6C). Interestingly, 475 
tumors derived from spheres showed higher CXCR1 and IL-8 expression in IHC compared to 476 
tumors derived from parental cells (Fig. 5C; Suppl. Fig. 6C). 477 
Mice injected with sphere-derived cells did harbor micrometastasis preferentially in lung and 478 
liver, whereas mice injected with parental cells did not show the presence of micrometastasis 479 
(Fig. 5D; Suppl. Fig. 6D and E). Interestingly, macrometastasis were identified when mice 480 
received sphere-derived cells at a density of 104 but not 106. This is most likely due to the much 481 
shorter time-span required for primary tumor to reach 1 cm3 in mice which received 106 cells, 482 
at which point the mice were sacrificed (Suppl. Fig. 6F; Suppl. Table 5). 483 
Xenografted primary tumors isolated from mice as soon as they had grown to 1 cm3, were 484 
dissociated and re-injected into new NSG mice at a cell density of 104 cells. Xenografted 485 
primary tumors were re-transplanted for a further two generations. Strikingly, enhanced tumor 486 
growth was observed upon each re-transplantation (Fig. 5F). Each time the primary xenograft 487 
was harvested and dissociated, part of the single cell suspension generated was used to 488 
analyze the CXCR1+ population by flow cytometry. Interestingly, CXCR1+ cells also increased 489 
in number upon each re-transplantation. For instance, dissociated tumor cells derived from 490 
Caki1 sphere xenografts included 19.3 % of CXCR1+ cells in the first round of transplants that 491 
increased to 23.4 % in the second round, and finally reached 34.4 % in the third round of 492 
transplantations (Fig. 5G). Unexpectedly, side populations used to identify CSCs in vitro were 493 
not found within the primary xenografted tumors. At the same time, another portion of the 494 
dissociated tumor tissue was plated into the sphere formation assay. As expected, tumor cells 495 
were capable to reform spheres in culture indicating that they retain stem cell features (Fig. 496 
5E; Suppl. Fig. 6G). 497 
 498 
IL-8/CXCR1 expression correlates negatively with clinical prognosis in ccRCC patients 499 
In order to investigated the translational relevance of the IL-8/CXCR1 axis to the clinic, IL-8 500 
and CXCR1 protein expression was evaluated in 255 ccRCC patients using tissue microarrays 501 
and staining intensities were classified in absent, moderate and strong (Fig. 6A and C, Suppl. 502 
Fig. 7A). We found a striking negative correlation between IL-8 and CXCR1 with overall 503 
survival of ccRCC patients with a p-value of 0.004 and 0.027, respectively (Fig. 6B and D). In 504 
particular, the median survival for ccRCC patients expressing high IL-8 levels was 48 months, 505 
whereas patients expressing low IL-8 levels showed an improved median survival to 84 506 
months. High CXCR1 levels showed a median survival of 57 months, whereas low CXCR1 507 
showed an extension of the medium survival to 93 months. 508 
Additionally, the RNA expression of IL-8 was investigated in 90 patients affected by ccRCC 509 
(61). The RNA expression was compared to normal kidney tissue (n = 5). Significantly higher 510 
IL-8 expression was found in metastatic ccRCC (n = 32; p-value: 0.0001; Fig. 6E) compared 511 
to normal tissue, and a positive trend was observed in relation to tumor grade and stage in 512 
ccRCC patients (Suppl. Fig. 7B). In addition, IL-8 was found positively correlated with tumor 513 
lymphocytes infiltration (p-value: 0.0125; Fig. 6F), and decreased overall survival (p-value: 514 
0.009; Suppl. Fig. 7C and D). 515 
Taken together, the IL-8/CXCR1 axis represents a prognostic factor as well as a novel 516 
therapeutic target for ccRCC patients. 517 
  518 
DISCUSSION 519 
Characterized by high intra- and inter-tumor heterogeneity renal cell carcinoma is resistant to 520 
chemo- and radiotherapy in metastatic stage. Growing evidence suggests that ccRCCs as 521 
other solid tumors possess a rare population of cells contributing to metastasis and resistance 522 
to therapy namely CSCs (9). Therefore, identifying CSCs and understanding the mechanism 523 
underlying self-renewal properties is essential for dissecting tumor heterogeneity and drug 524 
treatment efficiency. In our study, we isolated CSCs derived from RCC cell lines as well as 525 
primary tissues expressing high levels of the chemokine IL-8 and its receptor CXCR1. 526 
Interestingly, we found that IL-8/CXCR1 axis was associated with CSC-like properties in vitro 527 
and in vivo. Further, IL-8 expression correlated with intratumoral lymphocytic infiltration and 528 
decreased overall survival in ccRCC patients, indicating its prognostic and therapeutic 529 
implications for ccRCC patients. 530 
 531 
Several markers were found specifically expressed in cancer stem cells and cancer-like stem 532 
cells derived from RCC such as CD105, ALDH1, OCT4, CD133 and CXCR4 (25-32). However, 533 
contrasting results on these markers are reported in the literature (36-39), increasing the need 534 
of new biomarkers. On the contrary to the majority of the studies whereby cancer stem cells 535 
were isolated by antigen-based techniques, in the present work, functional studies and in vivo 536 
models were used to identify a potential new biomarker for targeting renal CSCs. The sphere 537 
formation assay allowed us to isolate cancer stem cells from RCC cell lines and primary 538 
cultures. Interestingly, metastasis-derived cultures showed pronounced sphere formation 539 
efficiency and self-renewal properties compared to the primary tumor-derived cultures 540 
indicating an increased CSC fraction in the metastatic sites compared to primary tumors. For 541 
instance, the metastatic RCC cell line Caki1 showed 2 % sphere formation efficiency and 6 % 542 
of CSCs embodied by SP. Whereas primary culture derived RCC cell line 769P only 0.5 % 543 
sphere formation efficiency and 3.8 % CSCs by analysis of the SP in flow cytometry. Cancer 544 
cells isolated by the sphere formation assay displayed self-renewal properties, upregulation of 545 
EMT markers (Vimentin, Snail/Slug and N-cadherin), stemness and developmental genes 546 
(CD105, CD44, CXCR4, ALDH1A1, Nanog, MYC and WNT). Spheres expressed low levels of 547 
E-cadherin and differentiation markers such as CD10 and CD13. Additionally, they were able 548 
to differentiate into adipocytes upon induction. 549 
It has been previously reported that hypoxia and enhanced expression and activity of HIF1 and 550 
HIF2 in cancer stem/progenitor cells and their progeny frequently occur during disease 551 
progression and metastases, and may induce the expression of several genes involved in self-552 
renewal, survival, metabolism, angiogenesis, invasion, migration and resistance to therapy 553 
(62,63). In our study, CSC properties were enhanced upon hypoxia incubation and higher 554 
expression of HIFs was observed in the spheres compared to parental cells. Moreover, higher 555 
levels of the drug transporter ABCB5 as well as the chemokine IL-8 and its receptor CXCR1 556 
but not CXCR2 were found on RNA and protein level by Western blot, IHC and flow cytometry. 557 
Interestingly, the drug efflux transporter ABCB5 is functionally involved in the regulation of IL-558 
8/CXCR1 signaling through IL1β in melanoma cells and has therefore been associated with 559 
cancer stem-like cells, clinical disease progression and tumor recurrence (40,45). Additionally, 560 
IL-8 and CXCR1/2 have recently been demonstrated to be associated with cancer stem cell 561 
populations in many tumor types such as breast, prostate, colon and pancreatic cancers (47-562 
50). However, CXCR1 and CXCR2 were found expressed independently or together in 563 
different tumor types, indicating they may have different influence on CSC activity (47,50,64). 564 
In line with previous studies in HCC, breast and pancreatic cancers where anti-IL-8/CXCR1 565 
impaired CSC features (40,47,49), ccRCC cultures treated with CXCR1 blocking agents (anti-566 
CXCR1ab and repertaxin) showed reduced proliferation, migration and invasion, sphere 567 
formation and self-renewal properties, whereas IL-8 stimulation enhanced CSC properties. 568 
Moreover, flow cytometry analysis revealed that repertaxin treatment significantly decreased 569 
side population and CXCR1+ cells in the spheres as well in the parental samples. Surprisingly, 570 
no effect in the clonogenic assay was observed after repertaxin treatment compared to the 571 
standard of care sunitinib. When injected subcutaneously into NSG mice, sphere-derived cells 572 
gave rise to tumors and metastasis in only 20 days. Whereas, parental cells derived exclusively 573 
from the metastatic ccRCC culture Caki1 were only able to form tumors after over 100 days. 574 
This data also support the idea that metastasis-derived cultures possess an increased CSC 575 
content. Interestingly, high IL-8 and CXCR1 levels were found in the xenograft tumor tissue 576 
derived from spheres. In addition, CXCR1 expression as well as tumor development were 577 
enhanced upon tumor transplantation. These results suggest that transplantation fosters the 578 
expansion of CSCs, thus, CXCR1+ populations may play a key role in tumor progression. 579 
IL-8 represents one of the major chemokines associated with the promotion of neutrophils and 580 
inflammatory response (40). Increased expression of IL-8 is potentially an independent 581 
adverse prognostic biomarker for CSS and RFS in patients with ccRCC after nephrectomy 582 
(65). 583 
In our study, significantly higher IL-8 levels were found in metastatic ccRCCs compared to 584 
normal tissue, and a positive trend was observed in relation to tumor grade and stage in ccRCC 585 
patients. Moreover, IL-8 was found to be positively correlated with tumor lymphocytes 586 
infiltration, poor prognosis and decreased overall survival. Interestingly, in ccRCC increased 587 
IL-8 expression were associated with sunitinib resistance in vitro and in vivo (66). Taken 588 
together, these results suggest that the IL-8/CXCR1 axis is associated with cancer stem cell-589 
like properties in renal cancer and represents a potential therapeutic target for ccRCC patients. 590 
Targeting IL-8 in combination with conventional chemotherapy agents and/or immunotherapy 591 
would be the next step towards overcoming tumor recurrence. 592 
  593 
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FIGURE LEGEND 797 
Figure 1. A) Nine RCC cell lines named A498, 769P, 786O, RCC4wt, RCC4VHL, SLR21, 798 
SLR23, Caki1, and ACHN, were tested in the sphere formation assay. A498, 769P, 786O, 799 
Caki1 and ACHN were capable to form spheres, whereas RCC4wt, RCC4VHL, SLR21 and 800 
SLR23 did not harbor any sphere. Spheres formed at the first seeding step by primary tumor-801 
derived cultures ranged between 10.2 and 12.4, whereas metastasis-derived cultures showed 802 
a more pronounced sphere formation capability, which ranged between 23.4 to 69.8 spheres 803 
formed. B) 769P, A498, Caki1 and ACHN displayed self-renewal properties by enriching CSCs 804 
in over five passages. Again, metastasis-derived RCC cultures (Caki1 and ACHN) showed 805 
improved sphere formation compared to primary tumor derived culture (769P and A498). C) 806 
Representative pictures of the spheres derived from ccRCC cell lines. D) 807 
Immunohistochemical stains showing enhanced protein expression of the mesenchymal 808 
markers Vimentin, N-cadherin and Snail/slug, and decreased expression of E-cadherin 809 
indicating EMT in the spheres from Caki1 (upper panel) compared to parental cells (lower 810 
panel). Moreover, the cancer stem cell marker CD105 was highly expressed in the spheres. 811 
Interestingly, a gel-based shell was found covering the spheres upon formation (arrow head). 812 
E) Representative pictures of primary culture-derived spheres. 813 
 814 
Figure 2. A) CyTOF analysis revealed high expression of CD24, CD44 and CXCR4 in the 815 
spheres compared to parental cells where on the contrary CD13, CD10 and E-cadherin were 816 
found highly expressed. B) Gene expression data showing significantly enhanced expression 817 
of IL-8, ABCB5 and CXCR1 in spheres derived from 769P, A498 and ACHN. C) Spheres 818 
displayed high protein levels of CXCR1 and IL-8 in Western blot. D) Representative pictures 819 
of IL-8 and CXCR1 upregulation in Caki1 spheres compared to parental cells. 820 
 821 
Figure 3. A) 13.1 % of CSCs represented here by the side population were found in Caki1 822 
spheres. Moreover, SP was composed by 91.9 % of CXCR1+ cells. SP as well as CXCR1+ 823 
cells disappeared upon treatment with 100 µM verapamil (0.99 % and 4.55 %, respectively). 824 
We can better appreciate the difference between before and after treatment in the overlaid 825 
panel, where the population of interest is highlighted in red and verapamil treatment in blue. 826 
B) One representative example of primary culture showing low CSC content. Nevertheless, 827 
SP was composed for 68.4 % of CXCR1+ cells. Blue: verapamil treatment. Red: population of 828 
interest. C) High levels of CSCs and CXCR1+ cells were found in the spheres compared to 829 
parental cells. CXCR2+ was extremely abundant and not specifically expressed by SP. 830 
Therefore, it was not considered as potential CSC marker. 831 
 832 
Figure 4. A) Caki1 cells treated in the sphere formation assay with anti-CXCR1ab slightly 833 
decreased sphere formation. The opposite effect was observed upon IL-8 treatment. 834 
Treatment with repertaxin did not show any significant effect. Combination of treatment using 835 
CXCR1 blocking agents together with IL-8 did not show any significant effect. B) 769P cells 836 
treated in the sphere formation assay with anti-CXCR1ab or repertaxin slightly decreased 837 
sphere formation. The opposite effect was observed upon IL-8 treatment. Combination of 838 
treatment using CXCR1 blocking agents together with IL-8 did not show any effect compared 839 
with anti-CXCR1 treatment alone. C) A 3% reduction in the CSC content was observed upon 840 
repertaxin treatment by flow cytometry in Caki1 cell line (11.4 % - 7.4 %). Moreover, the whole 841 
CXCR1+ population as well as CXCR1+ SP was impaired. D) Histograms showing decreased 842 
SP and CXCR1+ cells upon repertaxin treatment. The yellow area indicates the number of 843 
events for the two specific populations upon verapamil treatment. As expected, no SP and 844 
CXCR1+ cells were found after verapamil treatment (internal control). The red area shows the 845 
CSC and CXCR1+ populations in the sample. Whereas, the blue area displays the remainder 846 
number of events after repertaxin treatment. In this example, we can clearly appreciate the 847 
reduction in the CSC population expressing CXCR1 before (red) and after (blue) repertaxin 848 
treatment. 849 
 850 
Figure 5. A) Tumor growth over time for Caki1 cell line. 106 sphere-derived cells injected 851 
subcutaneously into NSG mice formed tumors in less than 20 days, whereas parental cells 852 
took around 30 days. B) Representative pictures of NSG mice at 19 days post-injection with 853 
either parental or sphere cells. Mice that received 106 parental cells displayed half of the tumor 854 
size compared to mice injected with spheres. C) Immunohistochemical stains of the 855 
xenografted tumors derived from Caki1 showing the histological subtype by H&E, and the 856 
epithelial and kidney nature by PanCKa and Pax8 positivity. CXCR1 and IL-8 were found highly 857 
expressed by tumors derived from the spheres compared to tumors derived from parental cells. 858 
D) Metastasis in lungs and liver were found in mice injected with sphere-derived cells. In this 859 
figure micrometastasis derived from Caki1 spheres are depicted. In the H&E images we can 860 
appreciate the normal histological structure of the tissue interrupted by clusters of larger cells. 861 
Moreover, these cells expressed Pax8 which is a specific kidney marker indicating the renal 862 
origin of the cells. E) Xenografted tumors were dissociated into single cell suspension and cells 863 
were plated into sphere formation assay. Tumor cells derived from both Caki1 xenografts, 864 
parental cells and spheres, retained the capability to form spheres in vitro. F) Three 865 
transplantation rounds were performed for those tumors where 104 cells were initially injected. 866 
The same cell density was used over the passages. Enhanced tumor progression was 867 
observed upon transplantation reaching the size of 1 cm3 after 50 days in the first round, 40 868 
days during the second, and less than 30 days in the third. G) CXCR1+ cells increased in 869 
number upon transplantation. In yellow are depicted CXCR1+ cells in the first round (19.3 %), 870 
in blue the second round (23.4 %), whereas CXCR1+ cells from the third round are shown 871 
here in red (34.4 %). 872 
 873 
Figure 6. A) IL-8 protein expression on tissue microarrays. Strong IL-8 expression was 874 
observed in ccRCC and met. ccRCC compared to normal kidney tissue. B) Kaplan-Meier 875 
survival curve developed according to the mean IL-8 expression from tissue microarrays 876 
showing poor prognosis for patients expressing high IL-8 levels. C) CXCR1 protein expression 877 
on tissue microarrays. Strong CXCR1 expression was observed in ccRCC and met. ccRCC 878 
compared to normal kidney tissue. D) Kaplan-Meier survival curve developed according to the 879 
mean CXCR1 expression from tissue microarrays showing poor prognosis for patients 880 
expressing high CXCR1 levels. E) Elevated IL-8 expression on RNA level correlated with the 881 
presence of metastasis in ccRCC. F) High I-L8 expression on RNA level correlated with tumor 882 
lymphocyte infiltration. 883 
  884 
   
  



  
  
SUPPLEMENTARY MATERIAL 885 
Supplementary Table 1. 886 
Antibody Name/ 
clone 
Dilution Supplier IHC system Reagents Protocol/ 
detection 
PanCKa LU-5 1:50 DAKO A/S Ventana 
Benchmark 
Ultra 
OptiViewKit Pretreatment: 
Protease1 
4min 
CK7 OV-TL 
12/30 
1:100 DAKO A/S Ventana 
Benchmark 
Ultra 
OptiViewKit Pretreatment: 
Protease1 
4min 
Pax8 Paired box 
8 
1:400 Protein Tech 
Group, Inc. 
Ventana 
Benchmark 
Ultra 
OptiViewKit Pretreatment: 
Tris-EDTA-
Borat Buffer 
80min 
CAIX Carbonic 
Anhydrase 
IX 
polyclonal 
1:6000 Abcam  
Leica Bond 
Bond Polymer 
Refine Kit 
Pretreatment: 
Tris-EDTA-
Borat Buffer 
30min 
Vimentin Vim3B4 1:800 Abcam  
Leica Bond 
Bond Polymer 
Refine Kit 
Pretreatment: 
Tris-EDTA-
Borat Buffer 
60min 
E-cadherin EP700Y 1:200 CellMarque Ventana 
Benchmark 
Ultra 
OptiViewKit Pretreatment: 
Tris-EDTA-
Borat Buffer 
40min 
Snail/Slug  1:200 Abcam Ventana 
DiscoveryUltra 
ChromoMapKi
t 
Pretreatment: 
Tris-EDTA-
Borat Buffer 
30min 
CXCR1 42705 1:2000 R&D Ventana 
DiscoveryUltra 
ChromoMapKi
t 
Pretreatment: 
Protease1 
4min 
CXCL8 6217 1:100 R&D Leica Bond Bond Polymer 
Refine Kit 
Pretreatment: 
Tris-EDTA-
Borat Buffer 
90min 
CD105 3A9 1:400 Novus 
Biologicals 
Ventana 
Benchmark 
Ultra 
OptiViewKit Pretreatment: 
Tris-EDTA-
Borat Buffer 
60min 
 887 
 888 
 889 
Supplementary Table 2. 890 
Antibody Clone Concentration Supplier 
CD13 WM15 2µg/ml Biolegend 
CD24 32D12 2µg/ml Miltenyi 
CD44 IM7 0.5µg/ml BectionDickinson 
CD10 HI10a 2µg/ml Biolegend 
CXCR4 12G5 4µg/ml Biolegend 
Vimentin RV202 0.1µg/ml BectionDickinson 
E-Cadherin 36/E-Cadherin 2µg/ml BectionDickinson 
 891 
Supplementary Table 3. 892 
CSC Markers Others Stemness/Developmental 
pathways 
Marker of 
interest 
CD105 CD29 SNAIL CXCL8 
CD44 CD20 STAT3 
 
CD24 CD38 ZEB1/2 
 
ALDH1A1 BMP7 NANOG 
 
CXCR4 NOS2 WNT1 
 
 
 
MYCN 
 
  
TWIST1/2 
 
 893 
Supplementary Table 4. 894 
 895 
  
  
769P   A498   Caki1   ACHN   
parental spheres parental spheres parental spheres parental spheres 
SP 8.45 4.64 3.91 4.06 10.6 11.4 19 4.98 
CXCR1 31.6 20.5 4.19 6.06 23.2 27 16.9 18.2 
SP CXCR1 1.6 19.6 20.2 13.9 29.3 85 24.9 64.4 
+ Repertaxin 
SP 3.03 3.04 3.25 4.11 3.06 7.3 5.8 5.43 
CXCR1 26.5 8.9 3.26 5.15 20 15.5 31.5 26.2 
SP CXCR1 6.32 2.75 21.7 3.7 6.03 44 79.4 64 
 896 
 897 
Supplementary Table 5. 898 
 899 
Caki1 Parental Caki1 Spheres 
Cell 
number 
Tumor 
(1 cm3) 
Micro-
metastasis 
Macro-
metastasis 
Cell 
number 
Tumor 
(1 cm3) 
Micro-
metastasis 
Macro-
metastasis 
106 cells 27 days - - 106 cells 19 days + - 
104 cells 63 days + - 104 cells 53 days + + 
102 cells 101days - - 102 cells 83 days + - 
769P Parental 769P Spheres 
Cell 
number 
Tumor 
(1 cm3) 
Micro-
metastasis 
Macro-
metastasis 
Cell 
number 
Tumor 
(1 cm3) 
Micro-
metastasis 
Macro-
metastasis 
106 cells - n.a. n.a. 106 cells 28 days + - 
104 cells - n.a. n.a. 104 cells 46 days + + 
102 cells - n.a. n.a. 102 cells 69 days + - 
  900 
 901 
Supplementary Figure 1. A) Mesenchymal-epithelial transition (MET) of Caki1 spheres 902 
attached to the bottom of a plastic plate. B) Sphere-derived cells showing lipid islets due to 903 
differentiation into adipocytes upon induction. C) Caki1 and ACHN further proved a better 904 
sphere formation efficiency compared to 769P and A498 in the limiting dilution assay. D) Self-905 
renewal properties were investigated by clonogenic assay. Again, metastasis-derived cultures 906 
showed pronounced CSC properties compared to primary-tumor derived cultures. E) 907 
Representative pictures of the colony formation assay. F) Incubation under hypoxia conditions 908 
improved sphere formation in parental cells compared to spheres. G) Spheres derived from 909 
Caki1 and ACHN showed high HIF1α levels, whereas 769P and A498 displayed HIF2α 910 
upregulation. 911 
 912 
Supplementary Figure 2. A) Gene expression data of 84 genes linked to stemness for ACHN 913 
cell line. Significantly high IL-8 expression is highlighted. B) High CXCR4 expression was 914 
found correlated to ccRCC and met. ccRCC. C) ccRCC showed high MMP9 expression 915 
compared to normal kidney tissue. D) The lung cancer cell line H460 showing 28.2 % CXCR1+ 916 
cells compared to A549 where only 2.6 % CXCR1+ cells were found. 917 
 918 
Supplementary Figure 3. A) Side population and corresponding CXCR1+ cells in 769P 919 
spheres. Blue: verapamil treatment. Red: population of interest. B) Side population and 920 
corresponding CXCR1+ cells in ACHN parental cells and spheres. Blue: verapamil treatment. 921 
Red: population of interest. C) Side population and corresponding CXCR1+ cells in A498 922 
parental cells and spheres. Blue: verapamil treatment. Red: population of interest. D) CXCR2+ 923 
population (64.6 %) in Caki1 spheres. E) Western blot showing no differential expression in 924 
the spheres compared to parental cells for CXCR2. 925 
 926 
Supplementary Figure 4. A) Decreased cell proliferation was observed after 72h treatment 927 
using anti-CXCR1ab, whereas the opposite was observed when adding human recombinant 928 
IL-8. 769P cell line showed a more pronounced effect compare to Caki1. B) Caki1 showing 929 
enhanced cell invasion and migration upon IL-8 treatment. Whereas, CXCR1 blockade showed 930 
opposite effect. Interestingly, combination of treatments showed intermediate increase of 931 
invasive and migratory properties. C) No effect was observed after repertaxin treatment in the 932 
clonogenic assay. D) Representative picture of the colony formation assay for Caki1. 933 
 934 
Supplementary Figure 5. A) Histograms showing decreased SP and CXCR1+ cells upon 935 
repertaxin treatment for Caki1 parental cells. The yellow area indicates the number of events 936 
upon verapamil treatment. Whereas, the red and blue areas represent the population before 937 
and after treatment, respectively. B) Histograms showing decreased SP and CXCR1+ cells 938 
upon repertaxin treatment for 769P parental cells and spheres. C) Histograms showing 939 
decreased SP and CXCR1+ cells upon repertaxin treatment for A498 parental cells and 940 
spheres. D) Histograms showing decreased SP and CXCR1+ cells upon repertaxin treatment 941 
for ACHN parental cells and spheres. 942 
 943 
Supplementary Figure 6. A) Tumor growth over time for 769P cell line. Sphere-derived cells 944 
gave rise to tumors when injected subcutaneously into NSG mice at three different cell 945 
densities (106, 104, 102). Whereas, parental cells did not. B) Representative pictures of NSG 946 
mice injected with matrigel only (control), with 106 parental cells after 132 days, and with 106 947 
sphere-derived cells after 28 days post-injection. Only spheres were capable to form tumors. 948 
C) Immunohistochemical stains of the xenografted tumors derived from 769P spheres showing 949 
the histological subtype by H&E, and the epithelial and kidney nature by PanCK and Pax8 950 
positivity. CXCR1 and IL-8 were also found highly expressed. D) Metastasis in lungs and liver 951 
were found in mice injected with sphere-derived cells. No positive staining for metastasis was 952 
observed in the control mice and mice that received parental cells. E) This figure shows a 953 
common process for tumor spreading and distal organ colonization which is the tumor cell 954 
extravasation. Tumor cells are here leaving the blood vessel and extravasating into the lung 955 
tissue to metastasize. F) Spheres were also capable to form macrometstasis when few tumor 956 
cells were injected, meaning they had enough time to grow bigger metastasis before the 957 
primary tumor could reach 1 cm3 in size. Arrow heads and dashed lines indicate single tumor 958 
cells or clusters of cells in lung, liver, brain and lymph nodes for 769P spheres.  G) Xenografted 959 
tumors were dissociated into single cell suspension and cells were plated into sphere formation 960 
assay. Tumor cells derived from 769P spheres retained the capability to form spheres in vitro. 961 
 962 
Supplementary Figure 7. A) IL-8 and CXCR1 expression on tissue microarrays classified in 963 
absent, moderate and strong according to the staining intensity. B) Elevated IL-8 expression 964 
on RNA level correlated with the tumor grade in ccRCC. C) Kaplan-Meier survival curve 965 
developed according to the mean IL-8 expression on RNA showing poor prognosis for patients 966 
expressing high IL-8 levels. D) Enhanced IL-8 expression was found correlated with poor 967 
prognosis (five-year survival) in ccRCC patients. 968 
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DISCUSSION 
7. Discussion and future perspectives 
Clear cell renal cell carcinoma is a very heterogeneous tumor, characterized by asymptomatic manifestation 
in early stage and a poor response to radiotherapy and chemotherapy in metastatic stage, making this tumor 
type very difficult to diagnose and treat (256,257). Therefore, new prognostic and predictive markers are 
needed. The possibility to dissect tumor heterogeneity and follow the evolution of tumor subpopulations 
during cancer progression and treatment is essential to overcome tumor recurrence. 
The majority of biomarkers require invasive procedures such as biopsies and surgical intervention resulting 
in a static and rather simple modeling of the tumor disease, besides being an inadequate practice for the 
patient. 
Blood and urine represent two valuable sources of cancer-derived molecules such as proteins, nucleic acids, 
extracellular vesicles and circulating tumor cells. Detection of changes in the level of these molecules in the 
body fluids have been associated with tumor load and malignant progression, proposing these liquid biopsies 
as a novel prognostic, diagnostic and predictive tool for cancer patients (63-65). Nevertheless, the 
development of non-invasive methods to detect de novo or to monitor already known tumor specific 
signatures continue to be a major challenge in renal cancer (75). 
Detection of circulating tumor DNA in blood of cancer patients is regarded as an important step towards 
personalized medicine and treatment monitoring. Therefore, we investigated the clinical applicability of 
ctDNA as liquid biopsy in renal cancer. In our study, we confirmed the presence of specific VHL mutations in 
ctDNA derived from RCC xenografts indicating the capability of renal tumors to release DNA into the blood 
circulation. However, we could not detect any VHL mutation in plasma or serum samples derived from nine 
ccRCC patients, whereas a specific VHL mutation was successfully detected when using a highly sensitive 
Taqman assay. These data suggest a reduced tumor DNA shedding and an increased clearance of the tumor 
DNA from the circulation in renal cancer patients.
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Therefore, highly sensitive detection methods and prior knowledge of the mutation are required for liquid 
biopsies in renal cancer, limiting their applicability in the clinics to tumor recurrence tracking. 
Recently, the discovery of the presence of dsDNA in exosomes in different cell lines of pancreatic, breast and 
lung cancer has opened a new perspective in the cancer biomarkers field proposing exosomes as a novel 
biomarker in cancer detection (258).  
Considering that not only wild-type DNA is packed in exosomes but tumor DNA as well, the mutational profile 
of the tumor might be assessed by isolating DNA contained in exosomes. Tumor cells can release EVs which 
may remain in close proximity to the place of origin or enter biological fluids and reach distant sites (208). 
Therefore, exoDNA derived from body fluids could be utilize as liquid biopsy to detect tumor-specific genetic 
mutations next to ctDNA improving the clinical applicability of ctDNA alone. 
Moreover, an increased number of exosomes was detected in patients with poor prognosis and resistance 
to chemotherapy in many tumor types (208). Exosome secretion is promoted by different environmental 
stress signals (i.e. inflammation, hypoxia). Chemotherapy itself may trigger the release of EVs. Therefore, we 
could potentially take advantage of the enrichment of the exosome pool in the body fluids due to therapeutic 
intervention in order to successfully detect new mutations harboring in the context of a personalized 
medicine approach. In our study, we could identify the presence of dsDNA in the exosomes released by seven 
RCC cell lines. Our isolation technique provides a high quality samples which can be directly processed by 
NGS without further handling.  
Interestingly, exosomes are involved in many different signaling processes related to intercellular 
communication, protein secretion pathways, immune system function, cancer progression (201,209). 
Growing evidence suggests that renal cancer as other solid tumors possess a rare population of cells capable 
of self-renewal that contribute to metastasis and resistance to therapy namely cancer stem cells. CSCs have 
been found secreting higher amount of exosomes and CSC-derived exosomes have been found involved in 
promoting angiogenesis in xenograft mice with renal cancer (124), metastatic niche formation in lung 
carcinoma (221) as well as invasion, migration and tumor growth in many other tumor types (212,222-225). 
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In our study, we observed that hypoxia enhanced exosome secretion suggesting that environmental stress 
and stemness properties induce exosome release by cancer cells in order to communicate with neighboring 
cells and create a favorable niche to drive tumor progression. 
Due to high tumor heterogeneity which tumor subpopulation, driver mutation, or stem cell like 
subpopulation, regulates tumor spreading and resistance to therapy in ccRCC remains unresolved. Therefore, 
besides the genomic investigation of exoDNA in blood of RCC patients as a potential diagnostic and prognostic 
biomarker, transcriptomic and proteomic analysis of the exosome content derived from in vitro cultures of 
RCC tumor cells and CSC subpopulations, as well as, in vivo tumor xenografts during tumor progression and 
upon therapeutic intervention, will help us understanding tumor heterogeneity and RCC pathogenesis. 
In order to address these open questions, primary cultures derived from RCC patients were established, and 
in vitro 2D and 3D models were applied in the context of a personalized medicine approach. It has become 
increasingly clear that drug discovery screen and applied cancer studies often fail to translate into new cancer 
therapies because they largely relied on monolayer cultures of immortalized cell lines, which often fail to 
recapitulate fundamental biological features of human tumors such as, phenotypic and genetic 
heterogeneity, as well as, cell-cell interactions with the tumor microenvironment and in the spatial dimension 
(259). 
Here, we proved that patient-derived cultures are more accurate in retaining patient-specific molecular 
features and, therefore, are a promising tool for translational cancer research studies. Indeed, primary 
cultures need validation and our study revealed that Pax8 and PanCK, together with VHL-targeted sequencing 
and fluorescence in situ hybridization are valuable in the characterization of ccRCC primary cultures. 
Mutational landscape analysis by next-generation sequencing of our primary cultures over several passages 
compared to the primary tumor they derived from, revealed that genetically distinct subpopulations are 
retained in the corresponding cell culture but that are subjected to clonal selection. Nevertheless, the genetic 
adaptation of the primary cultures was limited and often concerned variants considered of poor confidence 
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by the analysis. Therefore, primary cultures highly preserve the intra-tumor heterogeneity present in the 
corresponding primary tumor. 
2D and 3D models were used to examine drug responses to a panel of agents used to treat locally advanced 
and metastatic RCCs. Taken together, our results indicate that drug profiling in patient-derived cell models 
can be a useful tool to direct ccRCC treatment decisions. Moreover, our drug profiling highlighted the intra-
tumor heterogeneity inherent in ccRCCs. Analyzing a larger panel of approved and experimental drugs 
including combination therapy in a larger cohort of patient-derived cell models should be employed. In 
addition, single cell analysis of tumor heterogeneity with and within RCC patients, together with immune cell 
profiling of the tumor microenvironment (260) will be essential in order to discover more effective treatment 
strategies for ccRCC. 
Importantly, one should consider that CSCs are recognized being the major cause of tumor recurrence and 
resistance to therapy. They are characterized by unlimited cell division, maintenance of the stem cell pool 
(self-renewal), capability to differentiate into several cell types and tumorigenicity (107-109). In our study, a 
subpopulation of cells retaining all these features was isolated from RCC cell lines and primary cultures. 
Interestingly, metastasis-derived cultures showed an increased CSC content and tumorigenic potential 
compared to primary tumor-derived cultures, indicating that, indeed, these cells were responsible for tumor 
progression and therapy failure in ccRCC. It is becoming increasingly clear that tumor microenvironment, 
stroma cells, soluble molecules and extracellular vesicles (i.e. exosomes) play an important role in modulating 
metastatic properties and sensitivity of tumor cells to therapy (192,260). Stemness traits can be acquired via 
genetic, epigenetic modification and interaction with tumor microenvironment. Processes like inflammation, 
hypoxia, angiogenesis and EMT contribute to maintenance of the CSC fate by acting on the most known 
pathways regulating CSCs and by maintaining the stem cell niche. Stem cell niches are often localized in 
hypoxic region where low O2 levels induce slow cycle proliferation and minimize DNA damage due to ROS. 
Interestingly, Varna and co-authors showed that CD133+/CXCR4+ cells coexpressed HIF1α and were located 
in perinecrotic areas in RCCs (127,136). In our study, CSC properties were enhanced upon hypoxia incubation 
and high expression of HIFs and HIF-target genes were observed in renal CSCs.
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Interestingly, our study also demonstrated that the IL-8/CXCR1 axis is associated with CSC-like properties in 
vitro and in vivo in renal cancer, and correlated with tumor lymphocytes infiltration, poor prognosis and 
decreased overall survival in ccRCC patients. CSCs derived from RCC cultures displayed self-renewal 
properties, enhanced expression of EMT and stemness markers, upregulation of genes involved in 
developmental pathways, capability differentiate into adipocytes and to give rise to tumors when injected 
into NSG mice. All these features were impaired when cells were treated with CXCR1 blocking agents such as 
anti-CXCR1 ab or repertaxin. 
Additionally, CSCs expressed high levels of the multidrug ABC transporter. ABCB5 has been found functionally 
involved in the regulation of IL-8/CXCR1 signaling through IL1β in melanoma cells and has therefore been 
associated with cancer stem-like cells, clinical disease progression, tumor recurrence and therapy failure 
(176,228). An increased IL-8 expression was found associated with sunitinib resistance in vitro and in vivo in 
ccRCC (61). Conventional chemo- and radio-therapy usually eliminates the majority of cells present in the 
tumor bulk while sparing the CSC pool. Therefore, it is necessary to develop new approaches aimed to 
targeting CSCs. To date, several therapeutic agents targeting IL-8/CXCR1-2 are currently being tested in colon, 
bladder, ovarian and breast cancers (230,238,251,253). However, none of these treatments have been 
proposed for renal cancer. Investigating the effect of CXCR1 blockade on tumor progression and 
aggressiveness in vivo would further prove that targeting IL-8/CXCR1 axis is paramount to overcome therapy 
failure. 
The management of ccRCC patients has dramatically changed in the last years (38). Poor response is observed 
upon chemotherapy and radiotherapy, whereas targeted therapies such as TKI are only palliative. 
Nevertheless, novel immunotherapies (i.e. checkpoint inhibitors) are demonstrating impressive activity 
across an increasing number of tumor types, including ccRCC patients (38,254,260). To date, nivolumab 
(monoclonal antibody against PD-1) has been approved in the second line setting for RCC patients (261,262). 
Moreover, increased levels of the chemokine CXCL9 and CXCL10 in peripheral blood was found predicting 
immunotherapy response (263). Of note, IL-8 represents one of the major chemokines associated with the 
DISCUSSION 
169 
 
promotion of neutrophils and inflammatory response (228). IL-8 promotes the recruitment of bone marrow-
derived MSCs to the tumor region, which support angiogenesis and tumor aggressiveness (231). Serum IL-8 
levels correlated tumor burden and clinical stage in patients with melanoma, RCC, NSCLC and HCC (234,264). 
In a recent investigation, it was shown that treatment with anti-CXCR2 antibody along with anti-PD-1 
antibody improved survival and delay in tumor growth in vivo in rhabdomyosarcoma (234,265). For this 
reason, targeting CSCs through IL-8/CXCR1 in combination with conventional chemotherapy agents and/or 
immunotherapy would be the next step towards overcoming tumor recurrence. 
In conclusion, understanding the mechanisms underlying tumor heterogeneity and cancer stem cell 
contribution to tumor progression, metastasis formation and therapy failure, together with the use of 
primary cell cultures, may ultimately promote the discovery of more accurate and reliable diagnostic and 
prognostic tools as well as provide the instruments for precise and patient-oriented therapeutic intervention. 
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Abstract: 
Characterized by high intra- and inter-tumor heterogeneity renal cell 
carcinoma is resistant to chemo- and radiotherapy in metastatic stage. 
Therefore, development of new prognostic and diagnostic markers for RCC 
patients are needed. Cancer stem cells are a small population of neoplastic 
cells within a tumor presenting characteristics reminiscent of normal stem 
cells. In particular, they are capable to give rise to all the cell types present 
in the tumor tissue which they derive from (differentiation). They are 
characterized by unlimited cell division, maintenance of the stem cell pool 
(self-renewal), give rise to tumor and metastasis in vivo (tumorigenicity), 
and they are responsible for resistance to therapies and tumor recurrence. 
So far, many studies tried to establish unique biomarkers to identify cancer 
stem cell populations in RCC. At the same time, different approaches were 
developed with the aim to isolate cancer stem cells. Several markers were 
found specifically expressed in cancer stem cells and cancer-like stem cells 
derived from RCC such as CD105, ALDH1, OCT4, CD133, CXCR4 and 
Rh123. However, genetic and epigenetic mechanisms and tumor 
microenvironment contributing to cellular plasticity make the discovery of 
unique biomarkers a very difficult task. Therefore, a better understanding 
of the mechanism underlying CSC may help dissecting tumor heterogeneity 
and drug treatment efficiency. 
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Abstract 21 
22 
Characterized by high intra- and inter-tumor heterogeneity, renal cell carcinoma (RCC) is resistant 23 
to chemo- and radiotherapy in metastatic stage. Therefore, the development of new prognostic 24 
and diagnostic markers for RCC patients is needed. Cancer stem cells (CSCs) are a small population 25 
of neoplastic cells within a tumor which present characteristics reminiscent of normal stem cells 26 
(NSCs). CSCs are characterized by unlimited cell division, maintenance of the stem cell pool (self-27 
renewal), capability to give rise to all cell types within a tumor and contribute to metastasis in vivo 28 
(tumorigenicity), treatment resistance and recurrence. So far, many studies have tried to establish 29 
unique biomarkers to identify CSC populations in RCC. At the same time, different approaches 30 
were developed with the aim to isolate CSCs. Consequently, several markers were found 31 
specifically expressed in CSCs and cancer stem-like cells derived from RCC such as CD105, ALDH1, 32 
OCT4, CD133, and CXCR4. However, genetic and epigenetic mechanisms and tumor 33 
microenvironment contributing to cellular plasticity made the discovery of unique biomarkers a 34 
very difficult task. In fact, contrasting results regarding the applicability of such markers in the 35 
isolation of renal CSCs have been reported in the literature. Therefore, a better understanding of 36 
the mechanism underlying CSC may help dissecting tumor heterogeneity and drug treatment 37 
efficiency. 38 
39 
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Introduction 42 
Renal cell carcinoma (RCC), a malignant tumor affecting the adult kidney, accounts for 2 % of all 43 
cancers. Affecting 64’000 people every year with 20 % death incidence, RCC is among the 10 most 44 
common cancer worldwide [1]. Arising from the renal tubular epithelial cell, RCC is the most 45 
frequent malignancy affecting the adult kidney (87 %) [2]. 46 
RCCs are a very heterogeneous class of tumors [3]. According to the classification proposed by the 47 
World Health Organization in 2016, which combines histological and genetic characteristics and 48 
clinical implications, RCC can be subdivided into three different entities [3,4]. Clear cell renal cell 49 
carcinoma (ccRCC) is the most common subtype of RCC and represents up to 80 % of all RCCs [5,6], 50 
papillary renal cell carcinoma (pRCC) accounts for 10-15 % of all RCCs [7-9], whereas chromophobe 51 
RCC (chRCC) embodies only the remainder 5 % [10]. 52 
RCC is characterized by asymptomatic manifestation in early stage and a poor response to 53 
radiotherapy and chemotherapy in metastatic stage, making this tumor type very difficult to 54 
diagnose and treat [11]. Due to the much higher prevalence of ccRCCs, very few clinical trials have 55 
been carried out considering other histological RCC subtypes. Therefore, most of the drugs have 56 
been developed based on ccRCC, and they are currently applied to all RCC patients. Treatment of 57 
advanced or metastatic RCC patients is achieved primarily by targeted therapies (TKIs) and five-58 
year survival for these patients is 12 % [12]. Despite all the progress made in the development of 59 
novel anti-cancer compounds, the management and treatment of RCC patients still remains a 60 
crucial aspect in the clinics. 61 
In particular, intra-tumor and inter-tumor heterogeneity is one of the major limitation in the 62 
treatment of epithelial tumors [13]. Two different tumor models were proposed playing a role in 63 
tumor development, progression and tumor heterogeneity. The clonal evolution model or 64 
stochastic model implies the presence of a tumor cell population carrying different mutations 65 
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which were accumulated during time and then selected under different selective pressure [14]. 66 
Every cell within a tumor has potentially the same likelihood to facilitate tumor formation and 67 
progression. Selection, clonal expansion and genetic instability are the key elements driving the 68 
stochastic approach [15]. The cancer stem cell (CSC) model or hierarchical model, instead, 69 
proposes that tumor growth and propagation is driven by a small phenotypically distinct subset of 70 
cells within the total cancer cell population with pluriproliferative features [16,17]. According to 71 
this model, the tumor bulk is established by a pool of CSCs that have both stem cell potential and 72 
the ability to give rise to progeny with self-limited proliferative capacity [18]. As result of this 73 
model the elimination of the entire CSC population will result in the tumor eradication, whereas 74 
leaving even only one cell behind will end up in tumor recurrence [15,19].  75 
Nevertheless, it is becoming increasingly clear that genetic and epigenetic factors are not just the 76 
only two factors contributing to tumor heterogeneity. The tumor microenvironment (TME), 77 
stroma cells, soluble molecules and extracellular vesicles (i.e. exosomes) play an important role in 78 
modulating metastatic properties and sensitivity of tumor cells to therapy [20,21]. Therapy itself 79 
may act as selection mechanism that shapes tumor evolution. More recently, a unifying model of 80 
clonal evolution applied to CSCs was proposed by Kreso et al., whereby CSCs can acquire 81 
mutations and generate new stem cell branches, and at the same time, tumor cells in the non-CSC 82 
subpopulation can undergo epithelial-mesenchymal transition (EMT) and acquire CSC-like features 83 
contributing to tumor heterogeneity [17] (Fig. 1). Processes like inflammation, hypoxia, 84 
angiogenesis and EMT undergoing in the TME contribute to maintenance of the CSC fate. Due to 85 
cellular plasticity, it is important to note that the cell of origin -the normal cell that acquires the 86 
first genetic hit(s) that culminate in the initiation of cancer- is not necessarily referred to the CSC 87 
population as the hierarchical model would suggest instead. CSCs are the cellular subset within the 88 
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tumor that uniquely sustains malignant growth. Cells-of-origin and CSCs refer to tumor-initiating 89 
cells (TICs) and cancer-propagating cells, respectively [22]. 90 
CSCs are a small population of neoplastic cells within a tumor presenting characteristics 91 
reminiscent of normal stem cells. In particular, they are capable to give rise to all the cell types 92 
present in the tumor tissue which they derive from (differentiation). They are characterized by 93 
unlimited cell division and maintenance of the stem cell pool (self-renewal). They can give rise to 94 
tumor and contribute to metastasis formation in vivo (tumorigenicity). Moreover, CSCs are 95 
recognized being the major cause of tumor recurrence and resistance to therapy. 96 
Dick and co-authors performed the first experimental study on CSCs in 1994. They isolated 97 
CD34
+
/CD38
- 
cells from acute myeloid leukemia (AML) patients and showed they could initiate 98 
AML in vivo upon transplantation into NOD/SCID mice [23,24]. Subsequently, several others have 99 
showed the presence of CSCs in colorectal cancer, breast cancer, glioblastoma, melanoma, lung 100 
cancer, liver and prostate cancer [25-34]. Growing evidence suggests that renal cancer, as many 101 
other solid tumors, possesses a rare population of cells capable of self-renewal that contribute to 102 
metastasis and resistance to therapy [35]. Therefore, the identification of a specific subpopulation 103 
of cells within a tumor that either initiate or maintain tumorigenesis is of utmost importance for 104 
understanding tumor biology and in the development of novel therapies. In this review, we outline 105 
potential CSC markers in RCC as well as advantages and pitfalls in the identification of these 106 
tumor-propagating cells. 107 
Cancer stem cell biomarkers 108 
To date, several markers were found specifically expressed in CSCs and cancer stem-like cells 109 
derived from RCC. A summary of these putative CSC markers is listed in table 1. 110 
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CD105 111 
Among those, CD105 (endoglin) is a transmembrane glycoprotein encoded by the endoglin gene 112 
located on chromosome 9q34. This protein is composed of two constitutively phosphorylated 113 
subunits of 95 KDa each, forming a 180 KDa homodimeric mature protein [36]. CD105 is an 114 
accessory protein of the TGFβ complex. Upon activation of the TGFβ complex, the binding of 115 
endoglin results in the activation of Smad proteins leading to the regulation of various cellular 116 
processes such as cell proliferation, migration, differentiation and angiogenesis [37]. Endoglin is 117 
predominantly expressed in endothelial cells where it is activated by hypoxia and TGFβ 118 
stimulation, whereas it is decreased by tumor necrosis factor α (TNFα) [38]. 119 
Interestingly, in breast, prostate and gastric cancer, CD105 was found present in endothelial cells 120 
forming immature tumor vasculature. In ccRCC, a subpopulation of cells representing <10 % of the 121 
tumor mass showed CD105 upregulation. CD105
+
 cells isolated by magnetic sorting displayed122 
potent capability to grow as spheres and initiate tumors and metastasis recapitulating the clear 123 
cell histological pattern in mice [39,40]. These cells also expressed mesenchymal markers CD44, 124 
CD90, CD29, CD73 and Vimentin; embryonic stem cell markers Oct3/4, Nanog and Nestin and the 125 
embryonic renal marker Pax2 [39]. However, they did not express CD133 also known as human 126 
tubular progenitor cell marker [41]. CD105
+
 CSCs were able to differentiate into epithelial and 127 
endothelial cells and generate CD105
-
 cells. Additionally, immunohistochemical analysis of tumoral 128 
CD105 was found positively correlated to nuclear grade and tumor stage, whereas endothelial 129 
expression negatively correlates with clinicopathological features [42]. Thus, CD105 has been 130 
proposed as the main marker for CSC identification in RCC. 131 
CSCs have been found secreting higher amount of exosomes and CSC-derived exosomes have 132 
been found involved in promoting angiogenesis in xenograft mice with renal cancer [40], 133 
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metastatic niche formation in lung carcinoma [43] as well as invasion, migration and tumor growth 134 
in many other tumor types [44-48]. Interestingly, CD105
+
 CSCs can release microvesicles and 135 
exosomes containing pro-angiogenic mRNAs (VEGF, FGF, MMP2 and 9) that trigger angiogenesis 136 
and promote the formation of a premetastatic niche in vivo [40]. Extracellular vesicles (EVs) 137 
derived from renal CSCs impaired T cell activation and dendritic cell differentiation by HLA-G 138 
promoting escape from the immune system [49]. 139 
Nevertheless, the use of CD105 as a renal CSCs marker was questioned in many studies where 140 
CD105
- 
cells also showed CSC-like features [50]. 141 
CD133 142 
143 
144 
145 
146 
147 
148 
149 
150 
151 
152 
153 
154 
155 
Prominin-1 (CD133) is a transmembrane glycoprotein of 865 amino acids (120 KDa) encoded by 
the gene PROM1 on chromosome 4p15 [51]. This protein exists in different isoforms and its 
regulation is quite complex [52,53]. Expressed by almost all cell types, CD133 localizes in the 
plasma membrane suggesting its involvement in membrane remodeling and signal transduction 
[52]. Phosphorylation of CD133 results in the activation of PI3K/AKT signaling pathway [54,55]. 
Hypoxia, mTOR inhibition, TGFβ1 increased CD133 expression in lung cancer, pancreatic cancer 
and hepatocellular carcinoma (HCC). Oct4 and Sox2 have been found binding the promoter region 
of CD133 inducing its activation in lung cancer cell lines. Along with its expression in stem and 
progenitor cells within normal tissues, CD133 has been proposed as putative CSC marker across 
different tumor types [52]. 
CD133
+
 cancer cells were able to form spheres, give rise to tumors in vivo and exhibit 
chemoresistance properties in colorectal carcinoma (CRC), HCC, lung cancer, glioblastoma, 
pancreatic cancer and ovarian cancer. On the contrary, sorted CD133
+
 cells  from RCC patients did 
not show tumorigenic capability in vivo although they expressed stem cell markers such as CD44,  156 
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CD29, Vimentin, and Pax2 [41]. When co-transplanted with renal carcinoma cells, CD133
+
 157 
progenitors significantly enhanced tumor development and growth. The same result was obtain 158 
using CD133
+
 cells derived from normal kidney tissue [56]. Of note, CD105
+
 cells did not express159 
CD133, suggesting that CD133
+
 cells may represent renal resident adult progenitor cells rather 160 
than CSCs. 161 
Interestingly, CD133
+
/CD24
+
 cells derived from RCC cell lines ACHN and Caki1 displayed sphere162 
formation capability, enhanced invasion and migration properties, high colony formation 163 
efficiency in soft agar, and resistance to sorafenib and cisplatin [57]. 164 
Another interesting publication identified CD133 and CXCR4 coexpressing CSCs in spheres derived 165 
from RCC xenografts and tumor tissues. Increased expression of these markers was found in RCC 166 
patients after sunitinib treatment [58]. Nevertheless, whether the CD133 and CXCR4 positive or 167 
negative cells had detectable levels of CD105 was not assessed. Additionally, the gene expression 168 
profile as well as the tumorigenic potential of the spheres was not deciphered. Moreover, CD133
-
 169 
cells were also able to give riese to tumors in immunodeficient mice in glioblastoma and CRC 170 
[59,60]. 171 
Lastly, CD133 expression was found strongly correlated with nuclear HIF1α in RCC patients [61,62]. 172 
CD133 mRNA levels in blood can be useful for identifying metastasis, predicting recurrence, and 173 
stratifying the patients into different risk groups for possible adjuvant treatment [63]. However, 174 
CD133 expression analyzed by IHC in RCC patients was inconsistent and varied among different 175 
studies [37,64]. Because of the complex epigenetic and microenvironmental modulation together 176 
with higher protein processing and post-translation modifications, the applicability of CD133 as a 177 
CSC marker is limited [52]. 178 
CD44 179 
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CD44 is a transmembrane glycoprotein of 85 KDa (742 aa) encoded by the CD44 gene located on 180 
chromosome 11. CD44 exists in more than 20 isoforms due to RNA alternative splicing, giving rise 181 
to different proteins in different cancer tissue subtypes. Due to the wide variety of isoforms, CD44 182 
is involved in diverse biological processes such as cell-cell interaction, cell adhesion, migration, 183 
proliferation, differentiation and angiogenesis [65].  184 
Although other extracellular matrix (ECM) components such as collagen, growth factors and 185 
metalloproteinases can interact with CD44, the extracellular glycosaminoglycan hyaluronan (HA) 186 
represent its primary ligand [66]. Binding of CD44 to HA promotes multiple signaling pathways 187 
including activation of receptor tyrosine kinases (RTK), TGFβ, MAPK, PI3K/AKT supporting cell 188 
proliferation, survival, invasion, and ultimately homing of CSCs in many tumor types [65,67]. In 189 
addition, CD44 has been found involved in the regulation of stem cell features via the Wnt/β-190 
catenin signaling pathway and protein kinase C (PKC) [68]. Because of its tight interaction with the 191 
ECM, CD44 plays an essential role in the modulation of CSC niche. CSCs can synthetize HA to 192 
attract tumor-associated macrophages (TAMs) in the CSC niche. On the other hand, stromal cells 193 
will produce growth factors that regulate stem cell activity [65]. Enhanced CD44 expression was 194 
observed in RCC cell lines after co-culture with macrophages. This effect was the result of the 195 
activation of NFkβ pathway by the TNFα derived from TAMs [69]. TNF-α enhanced migration and 196 
invasion of ccRCC cells together with down-regulation of E-cadherin expression and up-regulation 197 
of matrix metalloproteinase 9 (MMP9) and CD44 expression [70]. Interestingly, spheres derived 198 
from HEK293T, ACHN, Caki-1 and 786O renal cancer cell lines as well as CD105
+
 cells isolated from199 
RCC specimens showed the presence of a CD44
+
 population having self-renewal properties, sphere 200 
formation capability and resistance to therapy [71-73]. Moreover, CD44 expression was found 201 
associated with Fuhrman grade, primary tumor stage, histological subtype, and poor prognosis in 202 
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RCC patients [37,70,74]. Therefore, CD44 expression may serve as a prognostic and predictive as 203 
well as potential CSC marker for RCC [64]. 204 
Considering the involvement of CD44 in enhancing stem cell features in cancer cells and mediating 205 
the crosstalk with the TME, CD44-based therapeutic strategies have been developed [68]. 206 
Monoclonal antibodies against CD44 are now in clinical trial for patients affected by AML, whereas 207 
knockdown of CD44 has been shown to increase sensitivity to chemotherapy in cell cultures 208 
derived from HCC, lung, breast and pancreatic cancers [66,75]. 209 
CD24 210 
CD24 is a small cell surface protein molecule composed by only 27 amino acids resulting in a 211 
molecular weight ranging between 20 and 70 KDa depending on the glycosylation status. It is 212 
encoded by the CD24 gene located in the chromosome 6q21. CD24 is expressed in a wide variety 213 
of cell types, including hematopoietic cells [76]. Nevertheless, it is preferentially expressed in 214 
progenitor and stem cells. CD24 was shown to be an important maker for cancer diagnosis and 215 
prognosis in breast, non-small cell lung, colon, ovarian, and prostate cancer [76-78]. CD24 216 
upregulation has been also found associated with CSCs and CSC features in many solid tumors, on 217 
the contrary breast cancer stem cells showed low CD24 levels, suggesting that the role of CD24 in 218 
stem cells may be tissue dependent [79-81]. Interestingly, high CD24 expression was observed in 219 
CSCs derived from the  RCC cell line Caki2 [82], although contrasting results were reported when 220 
analyzing the expression of CD24 together with the CSC marker CD44. Nevertheless, CD24 221 
expression was found correlated with tumor grade, overall survival and disease-free survival in 222 
RCCs suggesting its prognostic significance [77]. Lazzeri et al. identified a subpopulation of cells 223 
exhibiting self-renewal properties, expression of stem cell transcription factors, and the ability of 224 
regenerate kidney tissue upon injury. These cells derived from the human embryonic kidney 225 
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expressed both CD24 and CD133 indicating they may represent putative normal kidney stem cells 226 
[83]. 227 
Because of the very limited research studies conducted on CD24 in RCC, we can conclude that, to 228 
date, no clear observation that CD24 can be used as CSC marker in RCC has been made. 229 
CXCR4 230 
The CXC-chemokine receptor 4 (CXCR4 or CD184) is a seven transmembrane G protein-coupled 231 
receptor (GPCR) on the cell membrane. It is encoded by the CXCR4 gene located on chromosome 232 
2q22. CXCR4 selectively binds to the CXC chemokine stromal cell-derived factor 1 (SDF1 or CXCL12) 233 
leading to the activation of a variety of biological processes such as proliferation, survival, 234 
migration, stemness and angiogenesis [84]. A number of signaling pathways are involved in the 235 
signal transduction. For instance, PLC/MAPK, PI3K/AKT, JAK/STAT and the Ras/Raf pathway. 236 
CXCR4 was found expressed in many different tumor tissues. It has been shown in breast, small 237 
cell lung cancer (SCLC), neuroblastoma and renal cancer that CXCR4
+
 cells migrate towards tissues 238 
expressing high levels of SDF1 to metastasize [57,85,86]. Therefore, CXCR4/SDF1 is involved in cell-239 
stroma interactions creating a permissive niche for metastasis [37]. Further, SDF1 stimulates 240 
adhesion of bone marrow progenitor/stem cells through CD44, demonstrating again a link 241 
between CD44 and CXCR4 signaling and TME [68]. 242 
Recent studies showed that CXCR4
+
 cells derived from several RCC cell lines (RCC26 and RCC53; 243 
Caki1, Caki2, 786O and 769P) express high levels of stem cell-associated genes and exhibit 244 
resistance to therapy (TKIs) and enhanced capability to form spheres in vitro and tumors in vivo 245 
compared to CXCR4
-
 cells [87,88]. Whereas, inhibition of CXCR4 by ADM3100 or small interfering 246 
RNA (siRNA) impaired tumor formation [87,88]. Interestingly, loss of pVHL in ccRCCs as well as 247 
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hypoxia showed increased CXCR4 and MMPs expression indicating HIF1α may be responsible for 248 
expansion of the CXCR4 population [89]. Supporting evidence showed that CD133
+
/CXCR4
+
 cells 249 
coexpressed HIF1α and were located in perinecrotic areas in RCCs [58]. Moreover, hypoxia 250 
promoted CD133
+
/CXCR4
+
 cells tumorigenicity, whereas HIF2α was shown to be involved in the 251 
expansion of CXCR4
+
 CSCs in four RCC cell lines [88]. The translational relevance of CXCR4 252 
expression in the clinic was investigated in 2’673 RCC patients by meta-analysis revealing a 253 
negative correlation with between CXCR4 expression and overall survival (OS), cancer free survival 254 
(CFS) and disease free survival (DFS) [90]. Taken together these results indicate that CXCR4 may be 255 
explored as a potential CSC marker in RCC perhaps in combination with a second marker. 256 
Nevertheless, care should be taken when choosing the appropriate marker for CSC isolation since 257 
a too restrictive selection may lead to a failure in targeting all the stem-like cells present in the 258 
tumor population. 259 
ALDH1 260 
Aldehyde dehydrogenase 1 (ALDH1) is a cytosolic enzyme involved in the dehydrogenation of 261 
aldehydes to their corresponding carboxylic acids [91]. It is encoded by the ALDH1 gene located in 262 
the chromosome 9q21.  ALDH1 plays an important role in cellular differentiation, proliferation, 263 
mobility, embryonic development and organ homeostasis [92]. 264 
ALDH1 has been initially proposed and used as a marker to isolate stem cells from normal tissues 265 
such as brain and bone marrow with potential applications in the area of regenerative medicine 266 
[93,94]. More recently, the activity of cytosolic ALDH1 has also been shown to be a reliable marker 267 
of CSCs in several types of solid tumors, including breast, colon, pancreas, lung, liver, prostate and 268 
bladder [95 {Resetkova, 2010 #204,96]. Nevertheless, its prognostic significance in RCC is still 269 
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unclear [97], although ALDH1 was found correlated with tumor grade in RCC by Ozbek and co-270 
authors [98]. 271 
High expression of ALDH1 was found in the side population (SP) derived from the RCC cell line 272 
ACHN compared to the non-SP. Analysis of the ALDH1
+
 cells revealed enhanced sphere formation 273 
capability, self-renewal properties, tumorigenicity and high expression of stemness genes in the 274 
ALDH1
+
 cells compared to ALDH1
-
 cells. Moreover, drug treatment and hypoxia conditions were275 
showed to increase the ALDH1
+
 cell population in vitro [92]. 276 
Interestingly, a recent study investigated ALDH1 expression patterns in 24 types of normal human 277 
tissues as well as primary epithelial tumor specimens and epithelial cancer cell lines showing that 278 
ALDH1 may not be a suitable CSC marker for all tumor types especially in tissues where ALDH1 is 279 
constitutively highly expressed such as in liver and pancreas [99]. Therefore, growing evidence 280 
suggests that ALDH1 is not only a putative stem cell marker, but may actually play multiple 281 
functional roles in regulating stem cell function [91]. 282 
ABCB5 283 
The drug efflux transporter ABCB5 (ATP-binding cassette, sub-family B, member number 5), is an 284 
integral membrane glycoprotein encoded by the ABCB5 gene located in the chromosome 7p21. It 285 
is composed of 812 amino acids for an overall molecular weight of 90 KDa. This protein is involved 286 
in the transport of small ions, sugar, peptides and organic molecules across the plasma membrane 287 
against a concentration gradient by hydrolysis of ATP [100]. Because of its function, ABCB5 has 288 
been considered responsible for mediating therapeutic resistance [101]. 289 
ABCB5 has been found overexpressed in CSCs derived from melanoma, liver and colorectal 290 
cancers. Moreover, it was found associated with tumor progression, chemotherapy resistance and 291 
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recurrence in many other tumor types [102]. For instance in renal cell cancer, ABCB1 was found 292 
expressed in all cells and these tumors rarely respond to primary chemotherapy treatment [103]. 293 
Therefore, ABCB5 is exploited for distinguishing between stem cells (side population) and non-294 
stem cells using flow cytometry. 295 
Others 296 
297 
298 
299 
300 
301 
302 
303 
304 
305 
306 
307 
308 
309 
310 
311 
312 
313 
DNAJB8 is part of the heat shock family proteins (HSP40) that regulate chaperone activity. It is 
encoded by the DNAJB8 gene located in chromosome 3q21. DNAJB8 is commonly expressed in the 
testis. Recently, Nishizawa et al., showed that DNAJB8 is expressed in different cancer cells 
including RCCs. In particular, the expression of DNAJB8 correlated with the SP compartment, and 
overexpression of the protein increased SP cells. Interestingly, DNAJB8 immunization completely 
abolished tumor formation in mice, indicating that DNAJB8 can be a target for immunotherapy 
[104]. 
MicroRNAs (miRNAs) are non-coding small RNA molecules (22 nucleotides) involved in regulation 
of gene expression by translational repression, mRNA cleavage, and deadenylation. The role of 
miRNAs in CSCs has been described for different tumor types [105]. Six miRNAs involved in TGFβ 
and Wnt signaling pathways showed the most significant variations in expression by RT-PCR 
between spheres and parental cells derived from two metastatic RCC cell lines, ACHN and Caki1. 
Among those, miR17 was significantly downregulated in Caki1 and ACHN spheres. Inhibition of 
miR17 resulted in  enhanced sphere formation indicating that TGFβ signaling plays an important 
role in renal CSCs and that miR17 impair the signaling cascade by targeting TGFB signaling pathway 
[72]. 
Galleggiante et al. isolated a subpopulation of cancer cells expressing CD133 and CD24 from 40 
RCC samples. This population showed stem cell properties such as self-renewal, differentiation,  314 
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tumorigenicity and expression of stemness-related transcription factors. CD133
+
/CD24
+
 cells 315 
appeared to be more undifferentiated compared to the corresponding tubular adult renal 316 
progenitor cells. Interestingly, these cells also expressed on the cell membrane the amino acid 317 
transporter CTR2 which was found involved in resistance to cisplatin [106]. 318 
Rhodamine 123 (Rh123) is a fluorescent dye that permeates the cell membrane and accumulates 319 
in the mitochondria proportionally to the mitochondrial membrane potential [107]. 786O cells 320 
were stained with Rh123 and sorted by flow cytometry into two population: Rh123
high
 and 321 
Rh123
low
. Rh123
high
 exhibited high proliferative activity, differentiation, resistance to radiation, 322 
tumorigenic potential and spheroid formation in soft agar, indicating Rh123 as an alternative 323 
method to isolate CSCs [73]. 324 
Finally, high CD73 expression was observed in spheres derived from the 786O RCC cell line. 325 
Moreover, CD73
+
 cells displayed high levels of stemness-related transcription factors, resistance to326 
radiotherapy and tumorigenicity in vivo [50]. 327 
Isolation techniques 328 
Different approaches for CSC isolation have been developed over the past years (Fig. 2). 329 
Antigen-based methods require labelling of the cells based on the expression of specific markers. 330 
These include magnetic beads-conjugated antibodies (MACS) [108,109], fluorescent-activated cell 331 
sorting (FACS) [110,111], and in some extent side population (SP) analysis [112,113]. Antigen 332 
selection often relays on markers which have been found relevant in developmental biology, 333 
embryonic and hematopoietic stem cell studies. Nevertheless, dissociation of the tumor tissue into 334 
a single cell suspension may damage surface antigens limiting the efficiency of isolating CSCs using 335 
cellular marker-based methods [112]. Further, cells can lose viability upon enzyme treatment and 336 
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sorting procedure [114]. Cell sorting itself has proven to be imprecise with 1 - 3 % of tumorigenic 337 
cells that can contaminate the non-tumorigenic population [19]. In addition, no generally 338 
applicable markers are known so far, and excessively permissive or restrictive labelling may have 339 
meaningful implications when developing therapeutic strategies targeting CSCs based on the 340 
marker expression [19]. Thus, identification and characterization of putative CSC markers may also 341 
be achieved using functional assays [41]. In order to recreate the in vivo CSC niche using in vitro 342 
culture conditions, three-dimensional cell culture models were developed. Two different methods 343 
can be adopted for culturing CSCs in 3D: anchorage-independent and anchorage-dependent. 344 
While the anchorage-independent system takes advantage of the ability of CSCs to grow in 345 
suspension, the anchorage-dependent system uses scaffolds in order to enable cells to mimic their 346 
interaction with the ECM microenvironment and promote stemness features. These methods 347 
comprehend spheroid [115,116] and organoid cultures [117-119], and sphere formation assay 348 
[111,116,120] and hanging drops [121,122], respectively. 349 
ECM plays crucial roles in establishing the CSC niche and in mediating tumor drug resistance. It is 350 
composed of collagens, laminins, fibronectin, proteoglycans and all the non-cellular components 351 
present in the tissues [123]. Different scaffolds can be used in these 3D CSC culture assays in order 352 
to mimic ECM. Natural scaffolds include collagen, gelatin, elastin, fibrinogen, agarose and alginate. 353 
Combinations of materials are also possible. Synthetic scaffolds can overcome the risk of 354 
contamination, degradation and batch-to-batch variations compared to natural scaffolds. These 355 
are mainly polymeric microparticles (i.e. hydrogels, PLGA and PLC) [124]. 356 
Antigen-based methods 357 
Magnetic beads conjugated antibodies (MACS) 358 
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MACS allows the isolation and the enrichment of stem cells without further staining. Cells are 359 
labelled using antibodies conjugated to magnetic nanoparticles. Labelled cells are then transferred 360 
into a column placed in a strong magnetic field. During this step, cells expressing the antigen will 361 
end up being conjugated to the magnetic beads and will stay in the column, whereas all the other 362 
cells that are negative for the antigen will flow through [108,109]. The population of interest can 363 
be subsequently eluted from the column. 364 
Fluorescent-activated cell sorting (FACS) 365 
FACS is an alternative isolation method capable of sorting cells using fluorescently-labeled 366 
antibodies targeting selected surface proteins or intracellular markers  via direct or indirect 367 
immune fluorescence staining. Flow cytometry allows a sample of cells or particles in suspension 368 
to be separated through a narrow liquid stream. As the sample pass through a laser it allows for 369 
detection of size, granularity, and fluorescent properties of individual cells/particles in the sample 370 
[125]. Generally, FACS separation uses fluorochromes directly conjugated with either primary or 371 
secondary antibodies with different emission wavelengths. Although MACS is simpler and requires 372 
less complicated equipment than FACS, it is monoparametric and cannot isolate cells via multiple 373 
markers simultaneously [110,111]. 374 
Side population (SP) 375 
376 
377 
378 
379 
380 
The Hoechst SP analysis is one of the several strategies used in the stem cell studies [126].  SP is 
defined as a small fraction of cancer cells within a tumor exhibiting stem-like properties. The 
ability to discriminate the SP is based on the differential efflux of Hoechst 33342 by the multi-drug 
resistance ABC transporters [127]. CSCs possess higher activity and/or higher amount of the ABC 
pumps, which are also responsible for the efflux of chemotherapeutic agents resulting in 
chemotherapy resistance of CSCs [101]. Therefore, SP stands out as the portion of cells able to  381 
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extrude the dye against a concentration gradient when compared to cells not having stem cell 382 
features [113]. 383 
Identification of CSCs is achieved by specifically inhibiting ABC pumps by verapamil (100 μM) or 384 
reserpine (5 μM). Hoechst is excited at 405 nm and the blue signal is collected with a 450/40 nm 385 
band-pass filter, whereas the red fluorescence with a 610/20 nm filter. Due to the high capability 386 
to extrude Hoechst dye, side population can be defined as the negative population for Hoechst 387 
blue and Hoechst red [112]. Nevertheless, analysis of the SP has risen many concerns due to the 388 
dynamic nature of the dye efflux property as well as toxicity of the Hoechst dye making this 389 
technique highly variable [114,126]. 390 
SP isolation can also be achieved by using rhodamine 123 (Rh123) [73,128,129]. Rh123 is a 391 
mitochondrial dye that stains mitochondria with increasing intensity as cells become activated 392 
[73]. Rh123 fluorescence intensity is an index of mitochondrial mass, number and activation state, 393 
and multidrug efflux pump activity [130]. Decreased intracellular accumulations of Rh123 result 394 
from the efflux of the dye. Because also non-stem cells may express some of the ABC transporters, 395 
the isolation of CSCs through SP analysis results imperfect. SP may contain some non-stem cells, as 396 
well as some stem cells may not be located in the SP fraction [101]. 397 
Functional assays 398 
Sphere formation assay 399 
The sphere formation assay exploits the capability of CSCs to grow in vitro in an anchorage-400 
independent manner as spheroids due to the mesenchymal phenotype. Cells are plated onto ultra-401 
low attachment plates under serum-free medium conditions. Recent studies demonstrated that 402 
CSC expansion requires medium lacking serum, which is believed to stimulated cellular 403 
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differentiation [111,116,120]. The medium composition may vary but it is generally composed of 404 
DMEM/F12 medium supplemented with stem cell growth factors and/or hormones (i.e. bFGF, 405 
EGF, HGF, insulin, androgen and progesterone). Therefore, cancer cells with stem cell-like features 406 
are capable to proliferate and form spherical structures, whereas all the others will die. Due to the 407 
asymmetrical cell division, each CSC is capable to form a sphere composed of both, cells that have 408 
stem cell features as well as more differentiated cells. By passaging the spheres, CSCs can be 409 
enriched [111,116,120]. This results in an increased sphere number from one passage to the 410 
other. Compared to MACS and FACS, the sphere formation assay may retain clonal variations 411 
within the CSC pool by avoiding marker selection. Nevertheless, several critical parameters can 412 
impair CSC isolation and investigation using the sphere formation assay. These are inappropriate 413 
seeding cell densities which can impact sphere formation and sphere clonality; presence of 414 
quiescent CSCs which cannot be expanded using this method; and finally, possible overestimation 415 
of the stem cell frequency [131]. 416 
Hanging drops 417 
In the hanging drop system, droplets of cell suspension are deposited on a dish or into special 418 
plates (i.e. GravityPLUS™ Hanging Drop System and Perfecta3D® hanging drop plates). Upon 419 
inversion of the tray, cells accumulates and aggregates by gravity on the surface of the liquid drop. 420 
This method is mainly used in the study of embryonic stem cells [121,122]. The Hanging Drop 421 
system allows efficient formation of uniform-size spheroids in a relative short time proving to be a 422 
very useful tool for high-throughput screening studies. 423 
Tumor spheroids 424 
425 Incorporation of ECM proteins in serum-free medium may challenge CSC-ECM interactions, 
normoxic/hypoxic conditions, metabolic gradients, and cooperation with stromal cell components  426 
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by co-cultures [124]. In the tumor spheroid model, a defined amount of tumor cells are 427 
encapsulated into macro-beads derived from natural or synthetic scaffolds, and let them float into 428 
the medium until spheroids are formed. Another interesting version is based on plating tumor cell 429 
into soft agar [115,116]. An initial layer of agar composed of 0.6 % agarose is disposed on the 430 
bottom of the plate. Once it has settled, a second layer of 0.3 % agarose containing a tumor single 431 
cell suspension is placed onto the 0.6 % agarose. An additional feeder layer of 0.3 % agarose is 432 
added at the end. Agarose concentration may be adapted depending on the cancer type. 433 
Tumor organoids 434 
Organoids are formed by distributing dissociated tumor cells into Matrigel drops. Matrigel is a gel-435 
based natural compound that consists of laminin, collagen IV and enactin. Matrigel drops 436 
containing tumor cells are disperse into normal tissue culture plates, and the cell-matrix mixture is 437 
incubated at 37 °C before adding the medium. Different ratio of cell suspension/matrigel can be 438 
used depending on tumor type. Organoid medium is composed of adDMEM/F12 supplemented 439 
with stem cell growth factors promoting Wnt signaling pathway (B27 supplement, N-acetyl-L-440 
cysteine, EGF, A-83, Noggin and R-spondin 1)[117-119]. 441 
Transplantation assay 442 
443 
444 
445 
446 
447 
448 
To finally evaluate the tumorigenic potential of a tumor cell population expressing CSC features, 
cancer cells are serially transplanted into immunocompromised mice (serial tumor 
transplantations) at low cell density (limiting dilution assay, LDA). Cancer cells capable to develop 
tumors repeatedly and to recapitulate the histological features and heterogeneity of the parental 
tumor are defined as TICs [13]. TICs and CSCs are often used interchangeably, although TIC more 
specifically refers to the cell-of-origin. Nevertheless, the capability of a cancer cell to form tumors 
in vivo and to recapitulate the tumor heterogeneity of the corresponding parental tumor is one of 449 
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the most known features of a CSC. Cancer cells capable to grow as 3D cultures but that do not 450 
have tumorigenic potential cannot be considered CSCs. Importantly, immune-deficient mice are 451 
not completely devoid of an immune system, and reactions involving host cytokines and immune 452 
cells may still take place when CSCs are transplanted into immunocompromised mice 453 
[19,132,133]. Additionally, cells need to adapt to the mouse milieu shaping CSC survival and 454 
properties. Therefore, optimization of the transplantation assay as well as critical interpretation of 455 
the results should be adopted when studying CSC properties in vivo. 456 
Lineage tracing 457 
To determine the cell(s) of origin of cancer, normal cells are labeled under cell-specific promoters 458 
followed by induction of genetic modifications. In this way, a single cell or a population of cells is 459 
marked and their signature is transmitted to all the progeny [134]. Investigation of the cellular 460 
source of a tumor can be achieved by identifying and tracing over time these transformed cells 461 
responsible for forming the tumor.  In parallel, this technique can be adopted to resolve the cell 462 
fate of tumor subpopulations in established tumors or to determine how cells behave in the 463 
context of the intact tissue or organism [13]. More importantly, genetic lineage tracing allows in 464 
vivo visualization of stem cells [124]. 465 
466 
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Normal kidney stem cells 467 
At the top of the cellular organization, normal adult stem cells matain tissues homeostasis and 468 
facilitate regeneration [135]. Kidneys carry out many different functions in the human body, 469 
including secreting hormones, absorbing minerals, filtering blood and producing urine. Hence, 470 
impaired kidney functions can ultimately lead to life threatening complications [136]. Tissue 471 
homeostasis in the kidney is limited and further diminished by age or disease [137]. This results in 472 
20 million people worldwide suffering for chronic kidney disease (CKD) [138]. Therefore, 473 
identifying stem cell populations in the fetal and adult kidney is important for developing effective 474 
therapeutic applications and understanding stem cell biology within the kidney tissue. 475 
Here, we briefly describe embryonic and adult renal stem cell markers with the aim to translate 476 
this knowledge to cancer stem cell biomarker discovery. 477 
Wilms’ tumors proved to be the best model system for studying embryonic renal stem cells. These 478 
tumors result from differentiation arrest of embryonic progenitor cells committed to the nephric 479 
lineage [139]. Comparative gene expression profiling of WT and fetal human kidneys showed high 480 
concordance in the expression of the following markers: Pax2, Six1/2, NCAM, Fzd7 and Fzd2 481 
[140,141]. Nevertheless, embryonic renal stem cells are entirely exhausted during nephrogenesis 482 
and the expression of these genes is rapidly lost during differentiation [142], limiting their utility to 483 
uncover merely embryonic-specific renal stem cell markers. 484 
Adult renal stem cells are investigated using BrdU staining [143]. BrdU is incorporated into dividing 485 
cells during the pulse phase, but further cell divisions will quickly dilute the stain leaving cells that 486 
divide infrequently like stem cells alone labeled with BrdU [144]. Nevertheless, some limitations 487 
must be considered such as adult stem cells divide infrequently and may not be labelled, and on 488 
the other hand, kidney has normally a limited mitotic index resulting in impaired signal dilution. 489 
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Following BrdU staining, a subset of cells expressing CD133 and CD24 were isolated from the 490 
urinary pole of the Bowman’s capsule and from the proximal tubules, in particular in the S3 491 
segment. These cells also expressed stemness markers (i.e. Sox2, CD44, Oct4 and Vimentin), and 492 
could be discriminated by CD106 differential expression [145,146]. Stem cells derived from the 493 
Bowman’s capsule were shown to move and differentiate from the urinary pole to the vascular 494 
pole acquiring podocyte traits (PDX marker) and losing stem cell markers (CD133 and CD24), 495 
whereas stem cells from the distal end of the proximal tubules were able to migrate within this 496 
segment [145-147]. Renal papilla offers a perfect niche for stem cells due to its hypoxic and 497 
hyperosmotic microenvironment [148]. Interestingly, Nestin and CD133 have been found 498 
expressed in stem cells derived from papilla [149].  499 
Several studies have demonstrated that resident adult kidney stem cells are not the major player 500 
involved in tissue repair in the proximal tubule [150]. While differentiated cells undergo EMT and 501 
proliferate to repopulate the damaged area, some investigators proposed that other non-resident 502 
stem cells such as bone marrow-derived stem cells or MSCs may be also involved in the process 503 
[142]. Nevertheless, these cells are defined as renal progenitor cells rather than renal stem cells 504 
due to their limited differentiation capability and lack of self-renewal properties. 505 
506 
507 
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Conclusions 508 
Tumor relapse and metastasis are the primary causes of poor survival in ccRCC patients. CSCs are 509 
thought to be responsible for tumor propagation, metastasis formation and treatment failure in 510 
many solid tumors, including renal cancer [25-35]. According to the CSC hypothesis, conventional 511 
therapies (i.e. radiation and chemotherapy) usually eliminates the majority of cells present in the 512 
tumor bulk while sparing the CSC pool [18]. This results in tumor recurrence. Therefore, 513 
understanding of the mechanisms underlying metastasis and drug-resistance associated with CSCs 514 
may help identifying new therapeutic options. 515 
Various approaches were developed with the aim to successfully isolate and characterize CSCs, 516 
leading to the identification of a variety of CSC markers [151]. However, contrasting results have 517 
been reported in the literature on the use of these biomarkers [50,59,60,99]. Several studies have 518 
shown that CSC markers are not unique across tumor types; therefore, knowledge on relevant 519 
markers for normal stem cells (NSCs) or CSCs from other tumor types may not be useful in renal 520 
cancer. Growing evidence suggests that distinct CSC subpopulations may coexist within a 521 
heterogeneous tumor and new CSC (sub-)clones can be generated, selected and compete with 522 
each other similarly to the stochastic model during tumor progression and treatment resulting in 523 
greater intra- and inter- CSC clone variability [135]. Therefore, some biomarkers can be relevant 524 
and applicable in certain phases during tumor development and progression, whereas they 525 
become obsolete in others. 526 
Many scientists have raised their concerns about the stem cell hypothesis. In particular, the fact 527 
that CSCs are considered as a rare slow-cycling subpopulation of cells questioned the possibility of 528 
their involvement in treatment failure in support of mechanisms of acquired or intrinsic resistance 529 
[19]. Many studies demonstrate a higher CSC content than what one could expect under the 530 
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hypothesis of CSCs being a small subset, which can be explained by inefficient isolation methods 
affecting functional assays as well as xenograft rates [114]. Finally, if CSCs are slowly proliferating 
one could argue that CSCs are lost during in vitro manipulation, whereas these cells remain a 
constant fraction of the total population [101]. All these concerns finds their explanation in the 
plastic nature of CSCs as well as technical issues. 
CSC traits are sustained by the interaction with the TME (niche) [21]. The CSC niche is an 
anatomical and distinct TME present within one tumor that support and sustain CSC properties 
[152,153]. It is composed of ECM, cancer-associated fibroblasts (CAFs), mesenchymal stem cells, 
endothelial and immune cells [132]. Stem cell niches are often localized in hypoxic region where 
low O2 levels induce slow cycle proliferation and minimize DNA damage due to ROS [58,88]. 
Processes such as inflammation, hypoxia, angiogenesis and EMT taking place within the TME 
contribute to maintenance of the CSC fate by acting on the most known pathways regulating CSCs: 
Wnt, SHH, Notch, TGFβ, and growth factor-receptor tyrosine kinase (RTK) [112,132,153,154]. 
Interestingly, tumor cells in the non-CSC compartment can spontaneously undergo EMT changes 
and acquire CSC-like phenotype and surface marker expression [155]. At the same time, CSCs 
display different stemness features depending on the microenvironment, and these features may 
be transient [133,152]. The entire process has to be considered reversible, plastic and dynamic. 
Therefore, understanding the mechanisms underlying CSC properties and the integration of 
genomic and functional assays exploiting such features may advance CSCs studies as well as 
promote the identification of new biomarkers for renal CSCs. CSC assays should take into 
consideration the niche contribution. Moreover, optimization of the transplantation assay using 
highly immune-deficient mice humanized with human TME and growth factors together with 
complementary lineage tracing analysis is of outmost importance for advancing CSC studies [132]. 
Lastly, combination of therapies specifically targeting CSCs by acting not only on CSC surface  
For Review Only
markers but also inhibiting CSC-related signaling pathways, delivering CSC-specific therapeutics as 555 
well as targeting the CSC niche together with conventional chemotherapy and radiotherapy may 556 
ultimately lead to improving RCC patient survival [37,132]. 557 
558 
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Table 1. Summary of putative CSC markers. 888 
Sample Assay Putative 
marker of the 
study 
Positive 
markers 
Negative 
markers 
CSC features Reference 
769P side population ABCB1 ABCC1, 
ABCG2 
clonogenic, 
tumorigenicity, resistance 
to chemo and 
radiotherapy 
Huang et al. 
[156] 
786O sphere formation assay CD73 tumorigenicity, resistance 
to radiotherapy 
Song et al. 
[50] 
786O flow 
cytometry 
Rh123 spheroids in soft agar, 
proliferation, 
differentiation, 
tumorigenicity, resistance 
to radiotherapy 
Lu et al. [73] 
786O, 
769P, 
A704, 
Caki1, 
Caki2 
Flow 
cytometry 
USP21 ALDH sphere formation, 
clonogenic, proliferation, 
invasion 
Peng et al. 
[157] 
ACHN  side population ALDH1 CD105, 
CD133 
sphere formation, self-
renewal, tumorigenicity 
Ueda et al. 
[92] 
ACHN, 
Caki1 
sphere formation assay Oct4, Nanog, 
LIN28, KL4, 
Zeb1, Zeb2, N-
cadherin, 
Vimentin, CD44, 
CD24 
miR17 sphere formation, self-
renewal, differentiation, 
tumorigenicity 
Lichner et 
al. [72] 
ACHN, 
Caki1 
flow 
cytometry 
CD105 CD105, Oct4, 
Nanog, CD90, 
CD73 
CD24, 
CD34, 
CD11, 
CD19, 
CD45 
spheroids in soft agar, 
hanging drops 
Khan et al. 
[158] 
ACHN, 
Caki1 
MACS CD133+/CD24+, 
Oct4, Notch1, 
Notch2, 
Jagged1, 
Jagged2, DLL1, 
DLL 4 
self-renewal, invasion and 
migration, tumorigenicity, 
resistance to 
chemotherapy (sorafenib 
and cisplatin) 
Xiao et al. 
[57] 
ACHN, 
Caki1, 
SMKTR2, 
SMKTR3, 
side population DNAJB8 tumorigenicity Nishizawa et 
al. [104] 
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RenCa 
ACHN, 
Caki2 
flow 
cytometry 
ALDH1 Oct4, Nanog, Pax2 self-renewal, clonogenic, tumorigenicity 
Caki1, 
Caki2, 
786O, 
769P 
sphere formation assay CXCR4 sphere formation, 
tumorigenicity 
Micucci et 
al. [88] 
HEK293T sphere formation assay ALDH+, CD44, 
β-catenin, 
Notch1, 
Survivin, 
Vimentin, N-
cadherin, Zeb1, 
Snail, Slug 
CD24 sphere formation, 
resistance to radiotherapy 
Debeb et al. 
[71] 
RCC 
xenograft 
sphere formation assay CD133/CXCR4 sphere formation, 
tumorigenicity, resistance 
to chemotherapy 
Varna et al. 
[58] 
RCC26, 
RCC53 
flow 
cytometry 
CXCR4 CXCR4, CD24, 
CD29, CD44, 
CD73, Nanog, 
Oct4, Sox2 
CD90, 
CD105, 
CD133, 
CXCR1, 
Vimentin, 
β-catenin 
sphere formation, 
tumorigenicity, resistance 
to chemotherapy 
Gassenmeier 
et al. [87] 
RCCs flow 
cytometry 
CD105 CD105, CD44, 
CD90, CD73, 
CD29, Nanog, 
Oct4, Vimentin, 
Nestin 
CD133 sphere formation, 
clonogenic, 
differentiation, 
tumorigenicity 
Bussolati et 
al. [39] 
RCCs flow 
cytometry 
CD133+/ 
CD34- 
CD73, CD44, 
CD29, 
Vimentin 
non tumorigenic Bruno et al. 
[159] 
RCCs flow 
cytometry 
CD133+/ 
CD24+ 
CTR2, Nanog, 
Oct4, Sox2 
CD105, 
CD90 
resistance to 
chemotherapy 
Galleggiante 
et al. [106] 
RCCs side population CD133 spheroids in soft agar, 
differentiation 
Addla et al. 
[160] 
RenCa DNAJB8 side population, sphere 
formation, tumorigenicity 
Yamashita 
et al. [161] 
SK-RC-42 sphere formation assay Oct4, Nanog, 
BMI, β-catenin 
MHC-II, 
CD80 
sphere formation, 
tumorigenicity, resistance 
to radio and 
chemotherapy 
Zhong et al. 
[120] 
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Figure Legend 892 
Figure 1. Model of tumorigenesis. 893 
This figure illustrates three models of tumorigenesis. The clonal evolution model or stochastic model which 894 
implies the presence of a tumor cell population carrying multiple mutations which is transformed over time 895 
by selective pressure resulting in tumor heterogeneity and progression. The cancer stem cell model or 896 
hierarchical model which proposes that tumor growth and propagation is driven by a small subpopulation 897 
of cells with pluriproliferative features namely CSCs. More recently, a unifying model characterized by high 898 
tumor heterogeneity, plasticity and complexity has bene proposed. According to this model CSCs can 899 
acquire mutations and generate new stem cell branches, on the other hand, tumor cells in the non-CSC 900 
subpopulation can undergo EMT and acquire CSC-like features contributing to tumor heterogeneity. 901 
Moreover, tumor microenvironment and therapy add another layer of complexity. 902 
903 
Figure 2. Identification and isolation of cancer stem cells. 904 
Several potential CSC markers are here depicted. CD105, TβR, CD133, CD44, CD24, CXCR4 and ABCB5 are 905 
some of the most studied membranous CSC markers. Whereas, miRNAs, DNAJB8, ALDH1 stand out among 906 
the intracellular CSC markers. Based on these markers, FACS and MACS have been adopted as isolation 907 
methods for the separation of CSCs from other tumor cells. More recently, other techniques exploiting CSC 908 
properties have been developed with the aim to discover potentially new biomarkers such as sphere assay, 909 
spheroid and organoid formation and hanging drops. 910 
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